
<html lang="en"     class="pb-page"  data-request-id="13882943-3d97-449c-95e5-9b9fa1a53c07"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01754"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies" /></meta><meta name="dc.Creator" content="Bernard  Barlaam" /></meta><meta name="dc.Creator" content="Robert  Casella" /></meta><meta name="dc.Creator" content="Justin  Cidado" /></meta><meta name="dc.Creator" content="Calum  Cook" /></meta><meta name="dc.Creator" content="Chris  De Savi" /></meta><meta name="dc.Creator" content="Allan  Dishington" /></meta><meta name="dc.Creator" content="Craig S.  Donald" /></meta><meta name="dc.Creator" content="Lisa  Drew" /></meta><meta name="dc.Creator" content="Andrew D.  Ferguson" /></meta><meta name="dc.Creator" content="Douglas  Ferguson" /></meta><meta name="dc.Creator" content="Steve  Glossop" /></meta><meta name="dc.Creator" content="Tyler  Grebe" /></meta><meta name="dc.Creator" content="Chungang  Gu" /></meta><meta name="dc.Creator" content="Sudhir  Hande" /></meta><meta name="dc.Creator" content="Janet  Hawkins" /></meta><meta name="dc.Creator" content="Alexander W.  Hird" /></meta><meta name="dc.Creator" content="Jane  Holmes" /></meta><meta name="dc.Creator" content="James  Horstick" /></meta><meta name="dc.Creator" content="Yun  Jiang" /></meta><meta name="dc.Creator" content="Michelle L.  Lamb" /></meta><meta name="dc.Creator" content="Thomas M.  McGuire" /></meta><meta name="dc.Creator" content="Jane E.  Moore" /></meta><meta name="dc.Creator" content="Nichole  O’Connell" /></meta><meta name="dc.Creator" content="Andy  Pike" /></meta><meta name="dc.Creator" content="Kurt G.  Pike" /></meta><meta name="dc.Creator" content="Theresa  Proia" /></meta><meta name="dc.Creator" content="Bryan  Roberts" /></meta><meta name="dc.Creator" content="Maryann  San Martin" /></meta><meta name="dc.Creator" content="Ujjal  Sarkar" /></meta><meta name="dc.Creator" content="Wenlin  Shao" /></meta><meta name="dc.Creator" content="Darren  Stead" /></meta><meta name="dc.Creator" content="Neil  Sumner" /></meta><meta name="dc.Creator" content="Kumar  Thakur" /></meta><meta name="dc.Creator" content="Melissa M.  Vasbinder" /></meta><meta name="dc.Creator" content="Jeffrey G.  Varnes" /></meta><meta name="dc.Creator" content="Jianyan  Wang" /></meta><meta name="dc.Creator" content="Lei  Wang" /></meta><meta name="dc.Creator" content="Dedong  Wu" /></meta><meta name="dc.Creator" content="Liangwei  Wu" /></meta><meta name="dc.Creator" content="Bin  Yang" /></meta><meta name="dc.Creator" content="Tieguang  Yao" /></meta><meta name="dc.Description" content="A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a s..." /></meta><meta name="Description" content="A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a s..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 11, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01754" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01754" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01754" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01754" /></link>
        
    
    

<title>Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01754" /></meta><meta property="og:title" content="Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0020.jpeg" /></meta><meta property="og:description" content="A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01754"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01754">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01754&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01754&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01754&amp;href=/doi/10.1021/acs.jmedchem.0c01754" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15564-15590</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01346" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c00171" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Bernard Barlaam</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernard Barlaam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#6d0f081f030c1f09430f0c1f010c0c005f2d0c1e191f0c170803080e0c430e0200"><span class="__cf_email__" data-cfemail="f89a9d8a96998a9cd69a998a94999995cab8998b8c8a99829d969d9b99d69b9795">[email protected]</span></a>. Phone: +44(0)1625 237335.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernard++Barlaam">Bernard Barlaam</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0904-7556" title="Orcid link">http://orcid.org/0000-0002-0904-7556</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert Casella</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert Casella</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Casella">Robert Casella</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Justin Cidado</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Justin Cidado</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Justin++Cidado">Justin Cidado</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Calum Cook</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Calum Cook</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Calum++Cook">Calum Cook</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chris De Savi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chris De Savi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chris++De+Savi">Chris De Savi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Allan Dishington</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Allan Dishington</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Allan++Dishington">Allan Dishington</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Craig S. Donald</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Craig S. Donald</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Craig+S.++Donald">Craig S. Donald</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisa Drew</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa Drew</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Drew">Lisa Drew</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew D. Ferguson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew D. Ferguson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+D.++Ferguson">Andrew D. Ferguson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1018-9631" title="Orcid link">http://orcid.org/0000-0002-1018-9631</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas Ferguson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas Ferguson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas++Ferguson">Douglas Ferguson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steve Glossop</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steve Glossop</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Glossop">Steve Glossop</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tyler Grebe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tyler Grebe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tyler++Grebe">Tyler Grebe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chungang Gu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chungang Gu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chungang++Gu">Chungang Gu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sudhir Hande</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sudhir Hande</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sudhir++Hande">Sudhir Hande</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Janet Hawkins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Janet Hawkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Janet++Hawkins">Janet Hawkins</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexander W. Hird</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexander W. Hird</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+W.++Hird">Alexander W. Hird</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jane Holmes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jane Holmes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jane++Holmes">Jane Holmes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Horstick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Horstick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Horstick">James Horstick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yun Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yun Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yun++Jiang">Yun Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle L. Lamb</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle L. Lamb</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+L.++Lamb">Michelle L. Lamb</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3005-8065" title="Orcid link">http://orcid.org/0000-0002-3005-8065</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas M. McGuire</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas M. McGuire</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+M.++McGuire">Thomas M. McGuire</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jane E. Moore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jane E. Moore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jane+E.++Moore">Jane E. Moore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nichole O’Connell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nichole O’Connell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nichole++O%E2%80%99Connell">Nichole O’Connell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andy Pike</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andy Pike</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andy++Pike">Andy Pike</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kurt G. Pike</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kurt G. Pike</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kurt+G.++Pike">Kurt G. Pike</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9731-7500" title="Orcid link">http://orcid.org/0000-0002-9731-7500</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Theresa Proia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Theresa Proia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Theresa++Proia">Theresa Proia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bryan Roberts</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bryan Roberts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bryan++Roberts">Bryan Roberts</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maryann San Martin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maryann San Martin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maryann++San+Martin">Maryann San Martin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ujjal Sarkar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ujjal Sarkar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ujjal++Sarkar">Ujjal Sarkar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenlin Shao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenlin Shao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenlin++Shao">Wenlin Shao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Darren Stead</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darren Stead</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darren++Stead">Darren Stead</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil Sumner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil Sumner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Sumner">Neil Sumner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kumar Thakur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kumar Thakur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kumar++Thakur">Kumar Thakur</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa M. Vasbinder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa M. Vasbinder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+M.++Vasbinder">Melissa M. Vasbinder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey G. Varnes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey G. Varnes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+G.++Varnes">Jeffrey G. Varnes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianyan Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianyan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianyan++Wang">Jianyan Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Wang">Lei Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dedong Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dedong Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dedong++Wu">Dedong Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liangwei Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liangwei Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liangwei++Wu">Liangwei Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bin Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bin Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Yang">Bin Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1499-5569" title="Orcid link">http://orcid.org/0000-0002-1499-5569</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Tieguang Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tieguang Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tieguang++Yao">Tieguang Yao</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01754&amp;href=/doi/10.1021%2Facs.jmedchem.0c01754" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15564–15590</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 11, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 October 2020</li><li><span class="item_label"><b>Published</b> online</span>11 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01754" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01754</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15564%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBernard%2BBarlaam%252C%2BRobert%2BCasella%252C%2BJustin%2BCidado%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01754%26title%3DDiscovery%2Bof%2BAZD4573%252C%2Ba%2BPotent%2Band%2BSelective%2BInhibitor%2Bof%2BCDK9%2BThat%2BEnables%2BShort%2BDuration%2Bof%2BTarget%2BEngagement%2Bfor%2Bthe%2BTreatment%2Bof%2BHematological%2BMalignancies%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15590%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01754"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2783</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01754" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bernard&quot;,&quot;last_name&quot;:&quot;Barlaam&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Casella&quot;},{&quot;first_name&quot;:&quot;Justin&quot;,&quot;last_name&quot;:&quot;Cidado&quot;},{&quot;first_name&quot;:&quot;Calum&quot;,&quot;last_name&quot;:&quot;Cook&quot;},{&quot;first_name&quot;:&quot;Chris&quot;,&quot;last_name&quot;:&quot;De Savi&quot;},{&quot;first_name&quot;:&quot;Allan&quot;,&quot;last_name&quot;:&quot;Dishington&quot;},{&quot;first_name&quot;:&quot;Craig&quot;,&quot;last_name&quot;:&quot;S. Donald&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Drew&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;D. Ferguson&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;Ferguson&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Glossop&quot;},{&quot;first_name&quot;:&quot;Tyler&quot;,&quot;last_name&quot;:&quot;Grebe&quot;},{&quot;first_name&quot;:&quot;Chungang&quot;,&quot;last_name&quot;:&quot;Gu&quot;},{&quot;first_name&quot;:&quot;Sudhir&quot;,&quot;last_name&quot;:&quot;Hande&quot;},{&quot;first_name&quot;:&quot;Janet&quot;,&quot;last_name&quot;:&quot;Hawkins&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;W. Hird&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;Holmes&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Horstick&quot;},{&quot;first_name&quot;:&quot;Yun&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;L. Lamb&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;M. McGuire&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;E. Moore&quot;},{&quot;first_name&quot;:&quot;Nichole&quot;,&quot;last_name&quot;:&quot;O’Connell&quot;},{&quot;first_name&quot;:&quot;Andy&quot;,&quot;last_name&quot;:&quot;Pike&quot;},{&quot;first_name&quot;:&quot;Kurt&quot;,&quot;last_name&quot;:&quot;G. Pike&quot;},{&quot;first_name&quot;:&quot;Theresa&quot;,&quot;last_name&quot;:&quot;Proia&quot;},{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;Roberts&quot;},{&quot;first_name&quot;:&quot;Maryann&quot;,&quot;last_name&quot;:&quot;San Martin&quot;},{&quot;first_name&quot;:&quot;Ujjal&quot;,&quot;last_name&quot;:&quot;Sarkar&quot;},{&quot;first_name&quot;:&quot;Wenlin&quot;,&quot;last_name&quot;:&quot;Shao&quot;},{&quot;first_name&quot;:&quot;Darren&quot;,&quot;last_name&quot;:&quot;Stead&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Sumner&quot;},{&quot;first_name&quot;:&quot;Kumar&quot;,&quot;last_name&quot;:&quot;Thakur&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;M. Vasbinder&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;G. Varnes&quot;},{&quot;first_name&quot;:&quot;Jianyan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Dedong&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Liangwei&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Tieguang&quot;,&quot;last_name&quot;:&quot;Yao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15564-15590&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01754&quot;},&quot;abstract&quot;:&quot;A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical t&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01754&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01754" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01754&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01754" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01754&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01754" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01754&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01754&amp;href=/doi/10.1021/acs.jmedchem.0c01754" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01754" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01754" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01754%26sid%3Dliteratum%253Aachs%26pmid%3D33306391%26genre%3Darticle%26aulast%3DBarlaam%26date%3D2020%26atitle%3DDiscovery%2Bof%2BAZD4573%252C%2Ba%2BPotent%2Band%2BSelective%2BInhibitor%2Bof%2BCDK9%2BThat%2BEnables%2BShort%2BDuration%2Bof%2BTarget%2BEngagement%2Bfor%2Bthe%2BTreatment%2Bof%2BHematological%2BMalignancies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15564%26epage%3D15590%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound <b>2</b>), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound <b>24</b>, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of <b>24</b> was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound <b>24</b> led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound <b>24</b> demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound <b>24</b> is currently in clinical trials for the treatment of hematological malignancies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Evasion of programmed cell death (apoptosis) is one of the hallmarks of cancer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Apoptosis is a critical process for normal development and tissue homeostasis and is therefore tightly controlled by the balance of proteins that promote cell survival and cell death. In many cancers, this balance is disrupted in favor of cell survival, conferring a growth advantage. Myeloid cell leukemia 1 (Mcl-1) is an antiapoptotic member of the Bcl2 family and a key survival factor in a wide range of human cancers.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> Mcl-1 binds and sequesters pro-apoptotic proteins Bak and Bax at the mitochondrial outer membrane, thereby preventing activation of intrinsic apoptosis. Mcl-1 also binds and neutralizes a subset of BH3-only proteins, such as Bim, Noxa and Puma, preventing the activation of pro-apoptotic proteins.<a onclick="showRef(event, 'ref3 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref5">(3,5)</a> Furthermore, overexpression of Mcl-1 has been linked to chemotherapy resistance and relapse in cancer patients.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6−9)</a> Given the pivotal role in tumor cell survival played by Mcl-1, it is unsurprising that depletion of Mcl-1 leads to rapid cell death in cancer cells and tumor regression in several models of hematological cancers.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> As a result, many medicinal chemistry programs have attempted to develop Mcl-1 inhibitors. However, Mcl-1 has been proven difficult to target pharmacologically, due to the long, shallow hydrophobic protein–protein interaction interface.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> Only very recently have small molecule Mcl-1 inhibitors (e.g., AZD5991,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> AMG176,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> MIK665<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>) entered early clinical development.</div><div class="NLM_p">An alternative approach would be to target Mcl-1 activity indirectly by inhibiting the cyclin-dependent-kinase 9. Cyclin-dependent-kinases (CDKs) are members of the serine/threonine kinase family and are highly regulated by cyclins, a family of regulatory subunits that bind to CDKs. The human genome encodes for more than 20 CDKs and over 30 cyclins.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> CDKs are classified into two groups: CDKs involved in cell cycle control,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> such as CDK1, 2, 4, and 6 and their associated cyclins A, B, D, and E; and CDKs involved in transcription regulation/RNA processing, such as CDK7, 8, and 9 and their associated cyclins C, H and T.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Dinaciclib, one of multiple nonselective CDK small molecule inhibitors with potent CDK9 activity has been shown to reduce expression of Mcl-1 and ultimately lead to cancer cell death.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> The underlying hypothesis for this observation was that transient inhibition of transcription driven by CDK9 inhibition would result in the selective reduction of protein levels for genes that have short-lived transcripts and proteins, such as Mcl-1. However, because of the lack of selectivity of dinaciclib, it was unclear whether the observed effects are related to CDK9 inhibition alone.</div><div class="NLM_p">Regulation of transcription is a complex process governed in part through the activity of CDK9.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Following successful transcription initiation, RNA polymerase II (RNAP2) pauses just downstream of the transcription start site, serving as a checkpoint.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> To release RNAP2 from this pause, multiple CDK9-mediated phosphorylation events are required, which include phosphorylation of the serine 2 (Ser2) position in the 52 heptapeptide repeats (YSPTSPS) comprising the carboxyl-terminal domain (CTD) of RNAP2.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> As an integral node of the transcription regulatory network, CDK9 is the most studied transcriptional CDK and has garnered considerable interest as a potential target for cancer therapy,<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> one working hypothesis being that transient inhibition of transcription by CDK9 inhibition may provide a therapeutic opportunity to target Mcl-1 activity indirectly.</div><div class="NLM_p">Pan-CDK inhibitors, which have activity against CDK9 (e.g., <b>1</b>, also known as AZD5438,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), have been known for some time and have been previously evaluated in clinical trials but with mixed outcomes, many of them showing complex and challenging tolerability profiles.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> More selective CDK9 inhibitors have since emerged. We<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and others<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> reported the characterization of the in vitro and in vivo CDK9 pharmacology using a preclinical tool <b>2</b> (AZ5576) identified as a reasonably potent and highly selective CDK9 inhibitor from a series of amidopyridines.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In vitro treatment of the acute myeloid leukemia (AML) cell line MV-4-11 with <b>2</b> resulted in a dose- and time-dependent decrease in pSer2-RNAP2 and Mcl-1 expression with subsequent activation of caspase 3/7, leading to rapid induction of cell death. This result was extended to additional hematological cancer cell lines. In vivo, a similar pharmacodynamic response was observed in MV-4-11 tumor xenografts following a single oral dose of <b>2</b> (60 mg/kg), which translated to significant antitumor efficacy after intermittent oral administration.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Other groups also have reported the identification of more selective CDK9 inhibitors (e.g., LDC000067,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> LY2857785<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>) and characterized the pharmacology of these compounds in vitro and/or in in vivo preclinical hematological tumor models. However, at the start of this project, no selective CDK9 inhibitor had entered clinical trials.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> More recently, two selective CDK9 inhibitors (BAY 1143572<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> and BAY 1251152<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a>) have been reported as entering clinical trials.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected CDK9 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of our understanding of the pharmacology of <b>2</b>, we set our objective to identify a highly potent and selective CDK9 inhibitor having a predicted short half-life in humans (<i>t</i><sub>1/2</sub> < 2 h), and suitable physical properties (e.g., aqueous solubility) for intravenous (i.v.) administration, to enable controlled duration of target engagement in the clinic through modulation of the infusion duration. This profile would allow maximal flexibility in the dosing schedule to maximize the efficacy/toxicity balance of such an agent. Compound <b>2</b> is a potent CDK9 inhibitor (CDK9 enzyme assay 5 mM [ATP], IC<sub>50</sub> 0.029 μM; inhibition of pSer2-RNAP2 in MCF-7 cell line, IC<sub>50</sub> 0.13 μM; induction of caspase in MV-4-11 cell line, EC<sub>50</sub> 0.22 μM) with excellent kinase selectivity and a short half-life in rodents, making it a suitable probe compound for characterizing short target engagement of CDK9 in vitro and in vivo.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> However, its low solubility (7.5 μM in 1× PBS buffer pH 7.4 (phosphate buffered saline, phosphate final concentration of 0.01 M, pH 7.4); 24 μM in 0.1 M acetate buffer pH 4; both solubilities from crystalline material) was seen as a significant limitation for i.v. formulation, especially when considering the likely requirement of a high therapeutic dose. Furthermore, it was thought that the relatively low rate of metabolism, observed in human microsomes and hepatocytes in vitro, could result in the human <i>t</i><sub>1/2</sub> being too long to provide an optimal duration of target engagement in the clinical setting. Details of the methodology for predicting human pharmacokinetic parameters and clinical dose are available in the section entitled “Protocol for human PK predictions and clinical dose projections” in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>. Predictions of human pharmacokinetic parameters from in vitro scaled clearance and scaled volume from preclinical species suggested a mean half-life of 4.3 h for compound <b>2</b> (Cl 2.3 mL/min/kg, <i>V</i><sub>ss</sub> 0.88 L/kg, mean <i>t</i><sub>1/2</sub> 4.3 h, see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Those two risks were considered significant, which drove our decision not to progress <b>2</b> to the clinic.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Pharmacokinetic Properties of Compound <b>2</b> in Preclinical Species and Predicted Human Parameters</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocytes Cl<sub>int</sub> (μL/min/10<sup>6</sup> cells)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">5.9</td><td class="colsep0 rowsep0" align="left">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma Cl (mL/min/kg)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left"><i>2.3</i><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">0.62</td><td class="colsep0 rowsep0" align="left"><i>0.88</i><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.26</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left"><i>4.3</i><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Intrinsic clearance measured from hepatocytes, Cl<sub>int</sub>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">For mouse and Han Wistar rat studies (<i>n</i> ≥ 2), the compound was administered respectively at a dose of 5.2 μmol/kg and 1.3 μmol/kg i.v. as a solution formulation. For Beagle dogs (<i>n</i> = 2), the compound was administered by intravenous infusion over 0.25 h at a dose of 5.2 μmol/kg as a solution in 15% captisol (<sup>w</sup>/<sub>v</sub>) solution adjusted to pH 4.0.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Italicized text indicates human PK predictions (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a> for methods).</p></div></div></div><div class="NLM_p last">Here we report further optimization of this amidopyridine series as highly selective CDK9 inhibitors, with a focus on potency, pharmacokinetic, and physicochemical properties suitable for an intravenous agent with a short duration of target engagement. This work led to the discovery of the clinical candidate compound <b>24</b> (also known as AZD4573) for the treatment of hematological malignancies.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthetic Chemistry</h3><div class="NLM_p">The synthesis of compounds <b>3</b>–<b>34</b> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch6" aria-label="6">6</a> of the text and Schemes 7 and 8 of the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>. In general terms, the C-4 headgroup on the pyridine central core was introduced, in most cases, by a Suzuki coupling reaction. Alternatively, the C-4 headgroup was introduced by a Heck reaction. The C-2 amido group on the pyridine central core was installed by a palladium-catalyzed reaction between the 2-halopyridine and the corresponding primary amide side chain. Alternatively, still starting from the 2-halopyridine, the C-2 amido group on the pyridine central core was installed in two steps: nucleophilic substitution of the 2-halo substituent by ammonia, followed by amide coupling with the corresponding carboxylic acid side chain. Depending on the specific compound, the C-4 headgroup was introduced first on the pyridine core, followed by the C-2 amido group, or vice versa.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) <b>36</b>, second generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 110 °C; (b) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C to rt, then <b>37</b>, pyridine, THF, rt; (c) HCl, dioxane–MeOH, rt then AcCl, DIPEA, DCM, rt.</p></p></figure><div class="NLM_p">Compound <b>3</b> was made as follows: Suzuki reaction of boronic ester <b>35</b> with <b>36</b> gave <b>37</b>, which was then coupled with carboxylic acid <b>38</b>. Amine deprotection and subsequent acetylation afforded compound <b>3</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_p">Intermediate <b>40</b> was obtained by amide coupling of <b>39</b> with carboxylic acid <b>38</b>. Suzuki coupling of <b>40</b> with boronic ester <b>41</b>, followed by a two-step sequence of amine deprotection and acetylation, gave compound <b>4</b>. Alternatively, <b>40</b> was converted to boronic ester <b>43</b>. Suzuki coupling of <b>43</b> with the corresponding halo-heterocycles followed by deprotection and acetylation afforded compounds <b>20</b> and <b>22</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C, then <b>39</b>, pyridine, DCM, THF, 0 °C to rt; (b) <b>41</b>, second generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 100 °C; (c) HCl, dioxane–DCM, rt; (d) Ac<sub>2</sub>O, NEt<sub>3</sub>, DCM, DMAP (optional), rt; (e) (BPin)<sub>2</sub>, PdCl<sub>2</sub>(dppf), KOAc, dioxane, 90 °C; (f) Het-Br or Het-I, PdCl<sub>2</sub>(dppf), K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 90 °C; (g) TFA, DCM, rt or HCl, dioxane–DCM, rt.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>5</b>, <b>8</b>, <b>10</b>, and <b>21</b> is described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Compounds <b>5</b> and <b>21</b> were synthesized from compound <b>45</b>. Suzuki coupling of <b>45</b> with boronic esters <b>41</b> and <b>49</b> gave chloro-pyridines <b>46</b> and <b>50</b> respectively. Palladium-mediated coupling of <b>46</b> and <b>50</b> with amide <b>47</b> gave <b>48</b> and <b>51</b> respectively, which were converted to <b>5</b> and <b>21</b> after amine deprotection and acetylation. Similarly starting from <b>52</b>, Suzuki coupling with the corresponding boronic ester (for <b>53a</b>) or Heck reaction with the corresponding imidazole (for <b>53b</b>) gave respectively <b>53a</b> and <b>53b</b>. The same three-step sequence of palladium-mediated coupling with amide <b>47</b> followed by amine deprotection and acetylation afforded compounds <b>8</b> and <b>10</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) Het-BPin, second generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 90 °C; (b) <b>47</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 120 °C; (c) TFA, DCM, rt; (d) Ac<sub>2</sub>O, NEt<sub>3</sub>, DMAP (optional), DCM, rt; (e) Het-BPin, Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane–water, 100 °C (for <b>53a</b>); (f) 1,2-dimethylimidazole, Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 120 °C (for <b>53b</b>).</p></p></figure><div class="NLM_p">Compound <b>6</b> was made starting from <b>55</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Conversion of 2-fluoropyridine <b>55</b> to corresponding 2-aminopyridine <b>56</b>, followed by Suzuki coupling with <b>41</b> gave intermediate <b>57</b>. Amide coupling of <b>57</b> with carboxylic acid <b>38</b>, followed by amine deprotection and acetylation gave <b>6</b>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) conc. aq. ammonia, NMP, 100 °C (microwave); (b) <b>41</b>, PdCl<sub>2</sub>(dppf), Cs<sub>2</sub>CO<sub>3</sub>, dioxane–water, 95 °C; (c) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C, then <b>57</b>, pyridine, DCM, 0 °C to rt; (d) HCl, dioxane–DCM–MeOH, 0 °C; (e) AcCl, pyridine, DCM, rt, 0 °C.</p></p></figure><div class="NLM_p">The route used for compounds <b>7</b>, <b>9</b>, <b>11</b>–<b>19</b>. and <b>27</b>–<b>29</b> where the C-2 amido group was installed first, is described in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. 2-Amino-5-chloro-pyridine <b>59</b>, obtained by chlorination of compound <b>39</b>, was coupled with carboxylic acid <b>38</b> to give key intermediate <b>61</b> after an amine deprotection/acetylation sequence. Suzuki coupling of <b>61</b> with the corresponding boronic esters or Heck coupling of <b>61</b> with the corresponding imidazoles respectively gave compounds <b>7</b>, <b>19</b> and <b>9</b>, <b>11</b>. Compounds <b>12</b>–<b>18</b> and <b>27</b>–<b>29</b> were made starting from <b>56</b> using a similar sequence (all using a Suzuki coupling, except for <b>29</b> where a Heck reaction between <b>63</b> and the corresponding imidazole was used).</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) NCS, DMF, −78 °C to rt; (b) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C, then <b>57</b>, pyridine, DCM, THF, 0 °C to rt; (c) HCl, dioxane-MeOH, 0 °C; (d) Ac<sub>2</sub>O, DMAP, NEt<sub>3</sub>, DCM, rt; (e) Het-BPin, second-generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, rt (for <b>7</b> and <b>19</b>) or Het-H, Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, NEt<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C (for <b>9</b> and <b>11</b>); (f) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C, then <b>56</b>, pyridine, rt; (g) HCl, dioxane-DCM, rt; (h) Ac<sub>2</sub>O, DMAP (optional), NEt<sub>3</sub>, DCM, rt; (i) Het-BPin, second generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 60 °C (for <b>12</b> from <b>63</b>) or Het-B(OH)<sub>2</sub>, PdCl<sub>2</sub>(dppf), Ba(OH)<sub>2</sub>, dioxane–water, 75 °C (for <b>14</b> from <b>63</b>) or Pd(OAc)<sub>2</sub>, KOAc, DMA, 150 °C (microwave) (for <b>29</b> from <b>63</b>); (j) Het-BPin, second generation XPhos precatalyst, K<sub>2</sub>HPO<sub>4</sub> or K<sub>3</sub>PO<sub>4</sub>, dioxane-water, rt to 50–80 °C (for <b>13, 15–18, 27–28</b> from <b>62</b>); (k) chiral purification (for <b>27</b>–<b>28</b> only).</p></p></figure><div class="NLM_p">Compounds <b>23</b> and <b>24</b> were made according to <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Key boronic ester intermediate <b>69</b> in the synthesis of <b>23</b> and <b>24</b> was made as follows: intermediate <b>65</b> made by alkylation of pyrazole was cyclized using the procedure developed by Larsen<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> to afford <b>66</b>. Reduction of ketone <b>66</b> under Wolff–Kishner conditions afforded previously described <b>67</b>,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> which was submitted to bromination conditions followed by palladium-catalyzed borylation to afford <b>69</b>. Compound <b>70</b>, which was obtained by Suzuki coupling of <b>45</b> with <b>69</b>, was subjected to palladium-catalyzed amidation with <b>47</b> to afford <b>71</b>. Final amine deprotection/acetylation sequence of <b>71</b> gave <b>23</b>. Suzuki coupling of <b>62</b> with <b>69</b>, followed by a final amine deprotection/acetylation sequence, gave <b>24</b>.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0015.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) BrCH<sub>2</sub>C(Me)<sub>2</sub>CO<sub>2</sub>Et, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 80 °C; aq. NaOH, MeOH, rt; (b) <i>n</i>-BuLi, 2-MeTHF, −78 °C to rt; (c) hydrazine hydrate, 2,2′-oxidiethanol, 180 °C, then NaOH, 150 °C; (d) NBS, DCM, rt; (e) Pd(P(Cy)<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, (BPin)<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf), DMA, 85 °C; (f) <b>69</b>, second generation XPhos precatalyst, K<sub>2</sub>HPO<sub>4</sub>, dioxane–water, 80 °C; (g) <b>47</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 120 °C; (h) HCl, dioxane–DCM–MeOH, rt; (i) Ac<sub>2</sub>O, pyridine or NEt<sub>3</sub>, DMAP (optional), DCM, rt ; (j) <b>69</b>, second generation XPhos precatalyst, K<sub>2</sub>HPO<sub>4</sub>, dioxane-water, 50 °C.</p></p></figure><div class="NLM_p last">The synthesis of compounds <b>25</b>, <b>26</b>, and <b>30</b>–<b>34</b> are described in Scheme 7 and 8 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Discovery of Clinical Candidate <b>24</b></h3><div class="NLM_p">Docking of <b>2</b> into a published structure of CDK9 in complex with cyclin T1 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> provided some understanding of the key interactions leading to the potency and selectivity achieved with this compound. According to this model, compound <b>2</b> interacts with the kinase hinge via a bidentate interaction through the pyridine and the amidic NH with the backbone atoms of Cys106 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The cyclohexyl amide gives access to the solvent channel. The 2-methoxy-4-fluoro phenyl motif is twisted with respect to the pyridine ring (positioned 24° out of plane), bringing the methoxy group in closer proximity to Ala153 and Leu156, which follow the catalytic HRD-motif. From our understanding of the SAR from published literature around <b>2</b><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and our docking model, our initial hypothesis was that the 4-fluoro-2-methoxyphenyl at the C-4 position of the pyridine was a key element for the potency and selectivity against CDK9.</div><figure id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>2</b> (green) docked into the ATP binding site of a publicly available crystal structure of CDK9–cyclinT1 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>), with CDK9 shown as a blue ribbon and CyclinT1 as a gray surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Conversely, the lipophilic nature of this group was considered as a key contributor to the poor solubility of <b>2</b>. We decided to investigate alternative groups at the C-4 position of the pyridine, in particular, five-membered heterocycles which are present in some CDK inhibitors (e.g., imidazole in <b>1</b>) with the thought that they might improve the physical properties of this series. Indeed, compound <b>3</b>, a hybrid of compounds <b>1</b> and <b>2</b>, retained some activity against CDK9. It is worth noting that compound <b>3</b> has a similar ligand-lipophilicity efficiency (LLE) compared to <b>2</b>, its potency being reduced ca. 10-fold compared to <b>2</b>, while its lipophilicity is reduced by 1.1 units (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In addition, <b>3</b> showed increased solubility compared to <b>2</b>. With this encouraging result in hand, we explored other five-membered heterocycles (e.g., pyrazoles, imidazoles) and other [5,6] bicyclic heterocycles from available boronic acids or esters. Among the compounds from this initial exploration, compound <b>4</b> caught our attention, having slightly improved potency against CDK9 (CDK9 enzyme assay 5 mM [ATP], IC<sub>50</sub>: 0.23 μM; CDK9 cellular assay using pSer2-RNAP2 end-point, IC<sub>50</sub>: 0.52 μM) while keeping high solubility. Previous work at AstraZeneca had shown that halogen substitution, such as fluorine or chlorine, at the C-5 position of the pyrimidine core of compound <b>1</b> increased potency against some CDKs (e.g., CDK2<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>). From <b>4</b>, substitution of the 5-position of the pyridine with a fluorine (compound <b>5</b>) or a chlorine (compound <b>6</b>) significantly increased potency against CDK9. Compound <b>6</b> was especially interesting in that it had similar potency against CDK9 and higher solubility when compared to <b>2</b>. Therefore, compound <b>6</b> was profiled further. Kinase selectivity of <b>6</b> was evaluated at 1 μM in the “Eurofins kinase panel”. It showed significant inhibition (>80% inhibition) on only 7 kinases out of 125 kinases: CDK9 (98%), GSK3α (101%), GSK3β (100%), CDK1 (96%), CDK2 (93%), DYRK2 (87%), and CK1γ1 (87%). The selectivity among the CDK family was further assessed in assays recapitulating the typical ATP concentration in cells ([ATP] of 5 mM). The overall profile is summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, supporting that <b>6</b> is a potent CDK9 inhibitor with >10-fold selectivity against CDK1–7 and CDK12, except CDK3 (2-fold).<named-content content-type="anchor" rid="tbl2" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure, CDK9 Enzyme and Cell Inhibitory Potencies, and Other Properties of Compounds <b>2</b>–<b>34</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0016.gif" alt="" id="gr16" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0017.gif" alt="" id="GRAPHIC-d7e1886-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0018.gif" alt="" id="GRAPHIC-d7e1887-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Geometric means of at least two IC<sub>50</sub> determinations per compound.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Measured using shake-flask methodology with a buffer/octanol volume ratio of 100:1.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Solubility from phosphate buffer (pH: 7.4); sample from dried DMSO solution.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Intrinsic clearance measured from fresh rat hepatocytes and cryopreserved human hepatocytes, Cl<sub>int</sub>; μL·min<sup>–1</sup>·10<sup>6</sup> cells<sup>–1</sup>.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Human liver microsome intrinsic clearance (HLM Cl<sub>int</sub>); μL·min<sup>–1</sup>·mg<sup>–1</sup>.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Selectivity of Compounds <b>6</b> and <b>23</b> against Kinases within the CDK Family</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">compound <b>6</b> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> [ATP] 5 mM</th><th class="colsep0 rowsep0" align="center">compound <b>23</b> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> [ATP] 5 mM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK9</td><td class="colsep0 rowsep0" align="left">0.039</td><td class="colsep0 rowsep0" align="left">0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK1</td><td class="colsep0 rowsep0" align="left">0.44</td><td class="colsep0 rowsep0" align="left">0.095</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">0.61</td><td class="colsep0 rowsep0" align="left">0.066</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK3</td><td class="colsep0 rowsep0" align="left">0.084</td><td class="colsep0 rowsep0" align="left">0.020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">0.334</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK5</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">2.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK6</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">0.532</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK7</td><td class="colsep0 rowsep0" align="left">5.9</td><td class="colsep0 rowsep0" align="left">0.548</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK12</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">9.85</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">[ATP] 5 mM: concentration of ATP used in the kinase assay 5 mM.</p></div></div></div><div class="NLM_p">The binding kinetics of <b>6</b> to CDK9 were determined by surface plasmon resonance. Compound <b>6</b> showed a dissociation rate constant (<i>k</i><sub>d</sub>) of 3.64 × 10<sup>–3</sup> s<sup>–1</sup>, which resulted in a dissociation half-life (<i>t</i><sub>1/2</sub>) of 6.3 min (see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) and was classified as “fast-off” binding kinetics. The reversibility of pSer2-RNAP2 inhibition was also investigated in the MCF-7 cell line by incubation of <b>6</b> followed by cell washout and measurement of pSer2-RNAP2 inhibition at 30 min and 2 h after washout of the inhibitor. Compound <b>6</b> showed reversible inhibition with an increased IC<sub>50</sub> at both time points following washout (IC<sub>50</sub> > 3 μM at both time points vs IC<sub>50</sub> 0.11 μM without cell washout). The reversibility of pSer2-RNAP2 inhibition (in line with the “fast-off” binding kinetics of <b>6</b> to CDK9) was seen as a desirable feature for a CDK9 inhibitor to deliver short target engagement.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Binding Kinetics of <b>6</b>, <b>23</b>, and <b>24</b> to CDK9 Determined by Surface Plasmon Resonance</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">compound <b>6</b></th><th class="colsep0 rowsep0" align="center">compound <b>23</b></th><th class="colsep0 rowsep0" align="center">compound <b>24</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">equilibrium dissociation constant <i>K</i><sub>D</sub> (nM)</td><td class="colsep0 rowsep0" align="left">0.295</td><td class="colsep0 rowsep0" align="left">0.123</td><td class="colsep0 rowsep0" align="left">0.0894</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">association rate constant <i>k</i><sub>a</sub> (μM<sup>–1</sup>·s<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">8.93</td><td class="colsep0 rowsep0" align="left">4.62</td><td class="colsep0 rowsep0" align="left">7.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dissociation rate constant <i>k</i><sub>d</sub> (10<sup>–6</sup>·s<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">3640</td><td class="colsep0 rowsep0" align="left">569</td><td class="colsep0 rowsep0" align="left">711</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dissociation half-life <i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left">20.3</td><td class="colsep0 rowsep0" align="left">16.2</td></tr></tbody></table></div></div><div class="NLM_p">The solubility of compound <b>6</b> was further assessed from a crystalline batch: 94 mg/L in 1× PBS buffer pH 7.4 and 210 mg/L in 0.1 M acetate buffer pH 4 (from crystalline Form B<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a>). The pharmacokinetics of compound <b>6</b> were subsequently evaluated in multiple species to facilitate prediction of its human pharmacokinetics. In mouse, rat, and dog, compound <b>6</b> showed a moderate volume of distribution typical of its neutral ionic state.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Clearance was high in rats and moderate in dogs with the observed plasma clearance values in both species being accurately predicted by scaling the intrinsic clearance derived from isolated hepatocyte incubations. Overall, this resulted in short half-lives of less than 1 h in all three species. Compound <b>6</b> was, however, metabolized much more slowly in human microsomes and hepatocytes, resulting a predicted human clearance of <2.8 mL/min/kg. The predicted human pharmacokinetic parameters, when integrated into a PBPK model, resulted in a predicted <i>t</i><sub>1/2</sub> in humans of >2.8 h (see <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), which was longer than we were seeking to achieve.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Properties of Compound <b>6</b> in Preclinical Species and Predicted Human Parameters</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocytes Cl<sub>int</sub> (μL/min/10<sup>6</sup> cells)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left"><1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma Cl (mL/min/kg)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left"><i><2.8</i><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.65</td><td class="colsep0 rowsep0" align="left">0.75</td><td class="colsep0 rowsep0" align="left">0.90</td><td class="colsep0 rowsep0" align="left"><i>0.68</i><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.45</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.50</td><td class="colsep0 rowsep0" align="left"><i>>2.8</i><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Intrinsic clearance measured from hepatocytes, Cl<sub>int</sub>.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">For mouse and Han Wistar rat studies (<i>n</i> ≥ 2), the compound was administered respectively at a dose of 4.8 μmol/kg and 1.2 μmol/kg i.v. as a solution formulation. For Beagle dogs (<i>n</i> = 2), the compound was administered by intravenous infusion over 0.25 h at a dose of 5.2 μmol/kg as a solution in 5% DMSO and made to volume with 0.9% sodium chloride.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Italicized text indicated human PK predictions (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a> for methods).</p></div></div></div><div class="NLM_p">Despite concerns that the human pharmacokinetic properties of compound <b>6</b> might not be optimal for a short target engagement CDK9 inhibitor, compound <b>6</b> was a promising lead. Another hypothetical concern with the series was the potential for pharmacologically active metabolites with longer human half-lives that would result in more sustained target engagement. Therefore, metabolite identification studies were conducted with compound <b>6</b> in HLM (and human hepatocytes) resulting in the identification of three oxidative metabolites: <b>6-M1</b>, <b>6-M2</b>, and <b>6-M3</b>. <b>6-M1</b> was identified as the major metabolite. Open chain primary alcohol <b>6-M2</b> was detected as a trace metabolite, and <b>6-M3</b> as a minor carboxylic acid metabolite (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Metabolites of <b>6</b> after incubation in HLM. Metabolites shown were considered to have the potential to retain pharmacological activity and do not represent a complete metabolic scheme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The structures of <b>6-M1</b> and <b>6-M2</b> were subsequently confirmed by chemical synthesis of authentic standards (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>). Pharmacological evaluation of <b>6-M1</b> and <b>6-M2</b> showed that they were significantly less potent (6.5-fold for <b>6-M1</b> and >18-fold for <b>6-M2</b> in the pSer2-RNAP2 cellular assay) than compound <b>6</b> (see <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In addition, <b>6-M1</b> also showed a high rate of metabolism in human hepatocytes, and <b>6-M2</b> was present only as a trace metabolite in HLM. Therefore, it was considered unlikely that either would have sufficient exposure to significantly contribute to CDK9 inhibition in the clinic.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. CDK9 Enzymatic and Cellular Potencies and in Vitro Intrinsic Clearance of <b>6</b> and Its Metabolites <b>6-M1</b> and <b>6-M2</b> in HLM and Human Hepatocytes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center" char=".">CDK9 enz. [ATP] 5 mM IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">pSer2 cell IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM Cl<sub>lint</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Hu. heps Cl<sub>lint</sub><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">0.039</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left"><1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6-M1</b></td><td class="colsep0 rowsep0" align="char" char=".">0.060</td><td class="colsep0 rowsep0" align="left">0.72</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="left">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6-M2</b></td><td class="colsep0 rowsep0" align="char" char=".">0.085</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="left">2.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Geometric means of at least two IC<sub>50</sub> determinations per compound.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsome intrinsic clearance (HLM Cl<sub>int</sub>); μL·min<sup>–1</sup>·mg<sup>–1</sup>.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Intrinsic clearance measured from human hepatocytes, Cl<sub>int</sub>; μL·min<sup>–1</sup>·10<sup>6</sup> cells<sup>–1</sup>.</p></div></div></div><div class="NLM_p">Having established the potential for five-membered and [5,6]-bicyclic systems at the C-4 position of the pyridine to balance CDK9 potency with aqueous solubility, and the potential to further improve potency through C-5 substitution of the pyridine, we decided to further mine this SAR by again varying the C-4 position. From the initial exploration of the C-4 substituent, the pyrazolopiperidine headgroup (compound <b>6</b>) combined acceptable CDK9 potency and high solubility. 1,5-Dimethyl-3-pyrazole <b>7</b> was significantly less potent against CDK9, whereas pyrazolopyridine <b>8</b> kept comparable potency to <b>6</b>, but was much less soluble. Initial compounds comparing an imidazole group to the pyrazole group (e.g., imidazopiperidine <b>9</b> vs pyrazolopiperidine <b>6</b>, 1,2-dimethyl-5-imidazole <b>10</b> vs 1,5-dimethyl-3-pyrazole <b>7</b>, and imidazopyridine <b>11</b> vs pyrazolopyridine <b>8</b>) showed reduced CDK9 potency by about 10-fold, but provided some evidence of increased solubility (probably related to the lower lipophilicity). Finally, triazolopiperidine <b>12</b> gave much reduced potency (ca. 100-fold) against CDK9 vs pyrazolopiperidine <b>6</b>.</div><div class="NLM_p">We then explored modifications of the piperidine portion of the pyrazolopiperidine headgroup in compound <b>6</b>. Pyrrolidine <b>13</b> showed slightly reduced potency (ca. 5-fold) when compared to piperidine <b>6</b>, but surprisingly, imidazopyrrolidine <b>14</b> was nearly equipotent compared vs pyrazolopyrrolidine <b>13</b> (potency reduced by only ca. 2-fold). Azepane <b>15</b> showed comparable potency (CDK9 5 mM [ATP], IC<sub>50</sub>: 0.023 μM; pSer2-RNAP2, IC<sub>50</sub>: 0.092 μM) to piperidine <b>6</b>. In addition, <b>15</b> exhibited an increased rate of metabolism in HLM and human hepatocytes, although its solubility was slightly lower. Introduction of heteroatoms to the piperidine ring of compound <b>6</b> (e.g., compounds <b>16</b>–<b>19</b>) showed reduced potency against CDK9 (range of 3–30-fold) compared to compound <b>6</b>. It is noteworthy that only a very small number of basic compounds (e.g., compound <b>17</b>) were investigated. Despite the good solubility observed with them, we were concerned by the potential higher volume of distribution associated with this ion class and the consequence on the pharmacokinetic half-life. We then looked at adding substituents on the piperidine in an attempt to further interact with the P-loop. Indeed, <i>gem</i>-dimethylpiperidine <b>20</b> showed significantly increased potency (about 10–20-fold, CDK9 5 mM [ATP], IC<sub>50</sub>: 0.008 μM; pSer2-RNAP2, IC<sub>50</sub>: 0.048 μM) versus the unsubstituted piperidine <b>4</b>. In addition, <b>20</b> was highly soluble and showed an increased rate of metabolism in HLM and human hepatocytes. Introduction of a 5-fluoro on the pyridine led to a further increase in potency (compound <b>21</b>: CDK9 5 mM [ATP], IC<sub>50</sub>: < 0.003 μM; pSer2-RNAP2, IC<sub>50</sub>: 0.010 μM) while showing an increased rate of metabolism in HLM and human hepatocytes with only a modest reduction in solubility. Similarly, substitution of the pyrrolidine with <i>gem</i>-dimethyl (compounds <b>22</b>–<b>24</b>) was very fruitful. Compound <b>22</b> was significantly more potent than <b>4</b>. Again, introduction of a 5-fluoro or a 5-chloro on the pyridine further improved potency (respectively compound <b>23</b>: CDK9 5 mM [ATP], IC<sub>50</sub>: 0.004 μM; pSer2-RNAP2, IC<sub>50</sub>: 0.025 μM and <b>24</b>: CDK9 5 mM [ATP], IC<sub>50</sub> < 0.004 μM; pSer2-RNAP2, IC<sub>50</sub>: 0.0134 μM), while introduction of a 5-cyano (compound <b>25</b>) or a 5-methyl (compound <b>26</b>) was less favorable. In addition, <b>23</b> and <b>24</b> were highly soluble (550 and 150 μM, solubility at pH 7.4 phosphate buffer, data obtained from dried DMSO sample method) and showed a higher rate of metabolism in HLM and human hepatocytes than compound <b>22</b>. <i>Gem</i>-dimethyl substitution provided more CDK9 potency than a single methyl substituent (see compound <b>24</b> vs compounds <b>27</b> and <b>28</b>). The imidazopyrrolidine analogue of <b>24</b> (compound <b>29</b>) also displayed high potency against CDK9 (CDK9 5 mM [ATP], IC<sub>50</sub> 0.011 μM; pSer2-RNAP2, IC<sub>50</sub>: 0.036 μM) and showed high solubility and a similar rate of metabolism in HLM to compound <b>24</b>.</div><div class="NLM_p">The C-2 position of the pyridine had been previously optimized, following a library on a less optimized scaffold (data not shown), but we were keen to explore the subtleties of the SAR in this position, following the extensive optimization in other areas of the molecule. The different stereoisomers of the 3-acetamido-cyclohexane-1-carboxamide substituent were evaluated (compounds <b>30</b>–<b>32</b> vs <b>24</b>), confirming the initial observation on related compounds that the (<i>R,R</i>)-diastereoisomer was the most potent. Finally, further modification of this region (e.g., compounds <b>33</b> and <b>34</b>) did not improve activity versus the 3-acetamido-cyclohexane-1-carboxamide group (compound <b>24</b>).</div><div class="NLM_p">The cocrystallographic structure of <b>24</b> bound to CDK9 in complex with cyclin T1 confirmed the ligand binding mode (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The cyclin is bound as expected near the αC-helix of CDK9, with no direct interaction with the ATP binding site or the ligand. Consistent with the predicted binding mode of <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), Cys106 makes two hydrogen-bonds with the pyridyl amide core, and the cyclohexyl ring of solvent channel group is orthogonal to this motif. The pyrazole–pyridine biaryl system is twisted out of plane by 37 deg, such that one of the gem-dimethyl substituents of <b>24</b> fills a small pocket formed near Asp167 of the activation loop, in close proximity to the aliphatic portion Cβ of its side chain, the Cα of Asn154 and the side chain of Ala166.</div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>24</b> bound to the complex of CDK9 (blue) and cyclin T1 (gray) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Z45">6Z45</a>). The ligand carbon atoms are shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Selected compounds (e.g., compounds <b>23</b> and <b>24</b>) were further profiled. Kinase selectivity of <b>23</b> was evaluated at 1 μM in the “Eurofins kinase panel”. It showed significant inhibition (>80% inhibition) on 8 kinases out of 125 kinases in the “Eurofins kinase panel”: CDK9 (100%), GSK3α (101%), GSK3β (101%), CDK1 (100%), CDK2 (100%), CDK7 (92%), CK1γ1 (91%), and DYRK2 (89%). The selectivity of <b>23</b> among the CDK family was further assessed in assays recapitulating the typical ATP concentration in cells ([ATP] of 5 mM), supporting that <b>23</b> is a potent CDK9 inhibitor with at least 16-fold selectivity against CDK1-7 and CDK12, except CDK3 (5-fold); see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Kinase selectivity of <b>24</b> was evaluated at 1 μM in the “Eurofins kinase panel” and at 0.1 μM in the “Thermofisher kinase panel”. It showed significant inhibition (>80% inhibition) on 8 kinases outside the CDK family out of 125 kinases in the “Eurofins kinase panel”: GSK3β (104%), DYRK2 (100%), GSK3α (100%), CK1γ1 (94%), Jnk1 (90%), MAP2K7 (85%), INSR (83%), and MAP3K9 (82%). In the “Thermofisher kinase panel”, only 7 kinases outside the CDK family out of 362 kinases tested were significantly inhibited (>80% inhibition): GSK3β (100%), GSK3α (96%), DYRK2 (85%), MAP4K4 (85%), Jnk1 (84%), ERK7 (83%), and DYRK1A (80%). The selectivity among the CDK family and other kinase hits was further assessed in assays recapitulating the typical ATP concentration in cells ([ATP] of 5 mM). The overall profile is summarized in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, supporting that <b>24</b> is a potent CDK9 inhibitor with >10-fold selectivity against CDK1-7 and CDK12, except CDK3 (>5.8-fold) and >47-fold selectivity for other non-CDK kinases. This selectivity profile among the CDK family was confirmed in cells, showing that <b>24</b> exhibited >25-fold cellular selectivity for CDK9 over CDK1, CDK2, CDK4, CDK6, and CDK7 upon short-term treatment.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Selectivity of Compound <b>24</b> against Selected Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> [ATP] 5 mM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK9</td><td class="colsep0 rowsep0" align="char" char="."><0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK1</td><td class="colsep0 rowsep0" align="char" char=".">0.117</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="char" char=".">0.052</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK3</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4</td><td class="colsep0 rowsep0" align="char" char=".">0.499</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK5</td><td class="colsep0 rowsep0" align="char" char=".">1.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK6</td><td class="colsep0 rowsep0" align="char" char=".">0.363</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK7</td><td class="colsep0 rowsep0" align="char" char=".">1.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK12</td><td class="colsep0 rowsep0" align="char" char=".">8.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CK1γ1</td><td class="colsep0 rowsep0" align="char" char=".">5.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CK1γ2</td><td class="colsep0 rowsep0" align="char" char=".">6.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DYRK2</td><td class="colsep0 rowsep0" align="char" char=".">8.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK3α</td><td class="colsep0 rowsep0" align="char" char=".">0.187</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK3β</td><td class="colsep0 rowsep0" align="char" char=".">0.247</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNK1</td><td class="colsep0 rowsep0" align="char" char=".">2.80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">[ATP] 5 mM: concentration of ATP used in the kinase assay 5 mM.</p></div></div></div><div class="NLM_p">The binding kinetics of <b>23</b> and <b>24</b> to CDK9 was determined by surface plasmon resonance (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Both compounds showed a short dissociation half-life: 20.3 min for compound <b>23</b> and 16.2 min for compound <b>24</b>. The reversibility of pSer2-RNAP2 inhibition in the MCF-7 cell line was investigated by incubation of <b>23</b> and <b>24</b> followed by cell washout and measurement of pSer2-RNAP2 inhibition at 30 min and 2 h after wash-out. Compounds <b>23</b> and <b>24</b> showed reversibility, where inhibition was very significantly reduced at 30 min (IC<sub>50</sub> reduced by 19-fold for <b>23</b> and 32-fold for <b>24</b>) and at 2 h (IC<sub>50</sub> > 3 μM), which was expected from the “fast-off” binding kinetics of <b>23</b> and <b>24</b> to CDK9 measured by surface plasmon resonance.</div><div class="NLM_p">Thermodynamic solubilities of <b>23</b> and <b>24</b> were further assessed from crystalline batches: 30 mg/L in 1× PBS buffer pH 7.4 and 57 mg/L in 0.1 M acetate buffer pH 4 for compound <b>23</b> (from crystalline Form B<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a>); 17 mg/L in 1× PBS buffer pH 7.4 and 50 mg/L in 0.1 M acetate buffer pH 4 for compound <b>24</b> (from crystalline Form A<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a>). In addition, evaluation of common pharmaceutical excipients suitable for i.v. clinical formulation demonstrated further solubility enhancement. As a result, development of a suitable clinical formulation for i.v. administration was seen as a highly viable option, especially given the anticipated lower therapeutic dose resulting from the increased CDK9 potency of compound <b>24</b> compared to compounds <b>2</b> and <b>6</b>.</div><div class="NLM_p">The pharmacokinetic properties were evaluated in mouse, rat, and dog for compound <b>23</b> and in mouse, rat, dog, and cynomolgus monkey for compound <b>24</b>: in all species evaluated, compounds <b>23</b> and <b>24</b> showed a moderate volume of distribution, as anticipated from their neutral ionic state. Clearance was high in all preclinical species, with the observed plasma clearance values being accurately predicted by scaling the intrinsic clearance derived from isolated hepatocyte incubations. Overall, the high clearance combined with the low/medium volume of distribution resulted in short half-lives (below 1 h) in all species. Scaling of in vitro intrinsic clearances values from human hepatocytes resulted in similar predicted human clearance values for both compounds, which, when combined with the predicted human volume of distribution, resulted in a predicted human <i>t</i><sub>1/2</sub> value of 1.5 h for compound <b>23</b> (predicted human PK parameters: Cl 4.8 mL/min/kg, <i>V</i><sub>ss</sub> 0.61 L/kg, mean <i>t</i><sub>1/2</sub> 1.5 h, see <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>) and 1.6 h for compound <b>24</b> (predicted human PK parameters: Cl 5.3 mL/min/kg, <i>V</i><sub>ss</sub> 0.73 L/kg, mean <i>t</i><sub>1/2</sub> 1.6 h, see <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) respectively</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Pharmacokinetic Properties of Compound <b>23</b> in Preclinical Species and Predicted Human Parameters</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocytes Cl<sub>int</sub> (μL/min/10<sup>6</sup> cells)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma Cl (mL/min/kg)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">104</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left"><i>4.8</i><a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.49</td><td class="colsep0 rowsep0" align="left">0.80</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left"><i>0.61</i><a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.43</td><td class="colsep0 rowsep0" align="left"><i>1.5</i><a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Intrinsic clearance measured from hepatocytes, Cl<sub>int</sub>.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">For mouse and Han Wistar rat studies (<i>n</i> ≥ 2), the compound was administered respectively at a dose of 2.4 μmol/kg and 1.2 μmol/kg i.v. as a solution formulation. For Beagle dogs (<i>n</i> = 2), the compound was administered by intravenous infusion over 0.25 h at a dose of 0.24 μmol/kg as a solution in 10/90 DMSO/10% captisol (<sup>w</sup>/<sub>v</sub>) at the concentration of 0.2 mg/mL.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">Italicized text indicates human PK predictions (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a> for methods).</p></div></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Pharmacokinetic Properties of Compound <b>24</b> in Preclinical Species and Predicted Human Parameters</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocytes Cl<sub>int</sub> (μL/min/10<sup>6</sup> cells)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma Cl (mL/min/kg)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left"><i>5.3</i><a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.45</td><td class="colsep0 rowsep0" align="left">0.68</td><td class="colsep0 rowsep0" align="left">0.67</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left"><i>0.73</i><a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.66</td><td class="colsep0 rowsep0" align="left">0.89</td><td class="colsep0 rowsep0" align="left"><i>1.6</i><a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Intrinsic clearance measured from hepatocytes, Cl<sub>int</sub>.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">For mouse and Han Wistar rat studies (<i>n</i> ≥ 2), the compound was administered respectively at a dose of 2.3 μmol/kg and 1.2 μmol/kg i.v. as a solution formulation. Male Beagle dogs (<i>n</i> = 2) were administered 0.23 μmol/kg by intravenous infusion over 0.25 h formulated as a solution in 10% dimethyl sulfoxide (DMSO)/90% sterile water for injection (adjusted to pH 7–9). For cynomolgus monkeys (<i>n</i> = 2), the compound was administered by intravenous infusion over 0.25 h at a dose of 0.46 μmol/kg as a solution in 2% dimethylacetamide (DMA)/30% polyethylene glycol 400 (PEG400)/68%, 1% (w/v) Tween 80 in sterile water for injection.</p></div><div class="footnote" id="t9fn3"><sup><sup>c</sup></sup><p class="last">Italicized text indicates human PK predictions (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a> for methods).</p></div></div></div><div class="NLM_p">Metabolite identification studies were performed in HLM (and human hepatocytes) for compounds <b>23</b> and <b>24</b>. Both compounds showed analogous metabolic pathways to those observed with compound <b>6</b>, leading to the formation of <b>23-M1</b>, <b>23-M2</b>, and <b>23-M3</b> from compound <b>23</b> and <b>24-M1</b>, <b>24-M2</b>, and <b>24-M3</b> from compound <b>24</b> (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), the M1 metabolite being the most abundant. The structures of <b>24-M1</b> and <b>24-M2</b> were subsequently confirmed by chemical synthesis of authentic standards. From their biological activity and their properties (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>), the risk that the metabolites formed from <b>24</b> would contribute to significant CDK9 activity in the clinical setting was viewed as low. The detailed metabolism of <b>24</b> in vitro and in vivo will be the subject of a separate publication in due course.</div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolite identification of <b>23</b> and <b>24</b> after incubation in HLM. Metabolites shown were considered to have the potential to retain pharmacological activity and do not represent a complete metabolic scheme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. CDK9 Enzymatic and Cellular Potencies and in Vitro Intrinsic Clearance of <b>24</b> and Its Metabolites <b>24-M1</b> and <b>24-M2</b> in HLM and Human Hepatocytes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center">CDK9 enz. [ATP] 5 mM IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">pSer2 cell IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">HLM Cl<sub>lint</sub><a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Hu. heps Cl<sub>lint</sub><a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left"><0.004</td><td class="colsep0 rowsep0" align="left">0.0134</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24-M1</b></td><td class="colsep0 rowsep0" align="left">0.020</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24-M2</b></td><td class="colsep0 rowsep0" align="left">0.139</td><td class="colsep0 rowsep0" align="left">>2.3</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left"><1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Geometric means of at least two IC<sub>50</sub> determinations per compound.</p></div><div class="footnote" id="t10fn2"><sup><sup>b</sup></sup><p class="last">Human liver microsome intrinsic clearance (HLM Cl<sub>int</sub>); μL·min<sup>–1</sup>·mg<sup>–1</sup>.</p></div><div class="footnote" id="t10fn3"><sup><sup>c</sup></sup><p class="last">Intrinsic clearance measured from human hepatocytes, Cl<sub>int</sub>; μL·min<sup>–1</sup>·10<sup>6</sup> cells<sup>–1</sup>.</p></div></div></div><div class="NLM_p">The activity of compound <b>24</b> was recently reported in multiple AML cell lines in vitro and multiple AML xenograft models in vivo.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Consistent with the expected mode of action of a CDK9 inhibitor, compound <b>24</b> showed inhibition of pSer2-RNAP2, reduction of Mcl-1 protein and induction of caspase 3/7 activation in the acute myeloid leukemia cell lines MV-4-11<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and Nomo-1 (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) in a dose- and time-dependent manner.</div><figure id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibition of pSer2-RNAP2, depletion of Mcl-1 protein, and induction of caspase 3/7 activation after a 6-h incubation of compound <b>24</b> (dose response) in the acute myeloid leukemia Nomo-1 cell line. Top panel: Western blot; bottom panel: quantification.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the MV-4-11 xenograft mouse model, compound <b>24</b> showed a dose-dependent cell death driven antitumor efficacy when dosed intermittently (BID 2 h apart by i.p. administration, 2 days on 5 days off) at 5 mg/kg (97% tumor growth inhibition, measurement taken 33 days after commencement of dosing) and 15 mg/kg (100% complete tumor regression that was sustained out to more than 125 days). This antitumor response was driven by cell death as evidenced by induction of caspase 3/7. A concomitant reduction in pSer2-RNAP2 and Mcl-1 demonstrated that this effect is indeed mediated by inhibition of CDK9.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Here we report the in vivo activity of compound <b>24</b> in the Nomo-1 AML xenograft model. Compound <b>24</b> resulted in a similar extent of cell death driven antitumor efficacy using the same doses and schedules, with the 5 mg/kg BID schedule resulting in 65% tumor growth inhibition, and the 15 mg/kg BID schedule resulting in 65% tumor volume regression (assessed 12 days after the commencement of dosing), <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. The extent and duration of reduction of pSer2-RNAP2 in the Nomo-1 xenograft tumors (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) were also similar to that observed in MV-4-11 tumors at both dose levels.</div><figure id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0007.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose-dependent cell death driven antitumor efficacy in the acute myeloid leukemia Nomo-1 xenograft model of compound <b>24</b> by i.p. administration, twice daily 2 h apart, 2 days on 5 days off.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0008.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose-dependent reduction of pSer2-RNAP2 in the acute myeloid leukemia Nomo-1 xenograft model by i.p. administration of compound <b>24</b>, two doses 2 h apart by i.p. administration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the half-maximal effective concentration (EC<sub>50</sub>) for caspase activation in MV-4-11 cells closely aligns with other sensitive AML cell lines screened with compound <b>24</b>,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> MV-4-11 was selected as a representative AML cell line for the purposes of predicting the efficacious dose in clinical AML. The quantitative PKPD/antitumor efficacy model, derived from mouse MV-4-11 xenograft study data (described previously<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a>) was translated to the clinical AML setting (by adjusting system parameter values and replacing the mouse PK model for compound <b>24</b> with a predicted human PBPK model; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>) and used to predict clinical efficacy. Clinical i.v. dose was optimized such that each 2 h i.v. infusion was predicted to result in a 60% reduction in the leukemic cell burden. This extent of antitumor efficacy (per dosing occasion) was similar to what had been achieved in mouse MV-4-11 xenograft models when dosing compound <b>24</b> and was predicted to be sufficient to drive a sustained progressive reduction in leukemic cell burden in AML patients when utilizing a 2 days-on/12 days-off dosing schedule (assuming a 10 day doubling time). The predicted clinical dose of compound <b>24</b> that would be required to achieve this extent of antitumor efficacy was 44 mg. The predicted time-course of free concentration in plasma for a typical patient, at this dose, is shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>.</div><figure id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0009.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Simulated human pharmacokinetic profile of compound <b>24</b> following a 44 mg dose administered by a 2 h continuous i.v. infusion.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Preclinical in vivo toxicological evaluation of compound <b>24</b> supported dosing to patients, and <b>24</b> (AZD4573) is currently in phase 1 clinical trials in patients with relapsed or refractory hematological malignancies (<a href="https://ClinicalTrials.gov" class="ext-link">ClinicalTrials.gov</a> Identifier: NCT03263637).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08662" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08662" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Here we report the optimization of a series of pyrimidine amides as potent and selective CDK9 inhibitors having suitable pharmacokinetic and physicochemical properties for an intravenous agent with short duration of target engagement. Starting from <b>2</b>, a highly selective inhibitor of CDK9 but with physical and pharmacokinetic properties that appeared to be unsuitable for the desired profile, we identified compound <b>24</b> (also known as AZD4573). Compound <b>24</b> is a potent inhibitor of CDK9 (IC<sub>50</sub> of <0.004 μM) with fast-off binding kinetics (<i>t</i><sub>1/2</sub> 16 min) and high selectivity versus other kinases, including other CDK family members. Compound <b>24</b> exhibited a short pharmacokinetic half-life in multiple preclinical species (less than 1 h in rat, dog, and monkey) ,and PBPK modeling predicted a short half-life in humans. While the predictions of human PK may never be completely accurate due to species differences, the predictions for compounds relative to one another are useful in providing a rank order in order to select the most appropriate clinical candidate. Compound <b>24</b> also exhibited suitable solubility for intravenous administration. Short-term treatment with compound <b>24</b> led to a rapid dose- and time-dependent decrease in pSer2-RNAP2 and Mcl-1 in cells, resulting in activation of caspase 3/7 and cell apoptosis in a broad range of hematological cancer cell lines. In vivo efficacy was demonstrated in xenograft models derived from multiple hematological tumors (e.g., regression at 15 mg/kg, i.p administration, BID 2 days on 5 days off, in acute myeloid lymphoma MV-4-11 and Nomo-1 xenografts), with evidence of a decrease of pharmacologically relevant biomarkers (e.g., pSer2-RNAP2). Compound <b>24</b> is currently in phase 1 clinical trials for the treatment of hematological malignancies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88686" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88686" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Methods</h3><div class="NLM_p">All experiments were carried out at ambient temperature under an inert atmosphere. Evaporations were carried out by rotary evaporation or utilizing Genevac equipment or a Biotage v10 evaporator <i>in vacuo</i>, and workup procedures were carried out after the removal of residual solids by filtration. Flash chromatography purifications were performed on an automated Teledyne Isco CombiFlash Rf or Teledyne Isco CombiFlash Companion using prepacked RediSep Rf Gold Silica Columns (20–40 μm, spherical particles), GraceResolv Cartridges (Davisil silica), or Silicycle cartridges (40–63 μm). Ion exchange purification was generally performed using an SCX-2 (Biotage) cartridge. Preparative chromatography was performed on a Gilson prep HPLC instrument with UV collection or on a Waters AutoPurification HPLC-MS instrument with MS- and UV- triggered collection. The purities of the compounds for biological testing were assessed by NMR and mass spectral techniques following liquid chromatography (LCMS or UPLC) and are consistent with the proposed structures characterized; purity was at least 95%. Proton NMR were determined using a Bruker Avance 500 (500 MHz) or Bruker Avance 400 (400 MHz) instrument. Measurements were taken at ambient temperature unless otherwise specified; the following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; ddd, doublet of doublet of doublet; dq, double of quartets; dt, doublet of triplets; tt, triplet of triplets; p, pentet; br, broad signal. UPLC was carried out using a Waters UPLC fitted with Waters SQ mass spectrometer (column temp 40, UV = 220–300 nm, mass spec = ESI with positive/negative switching) at a flow rate of 1 mL/min using a solvent system of 97% A + 3% B to 3% A to 97% B over 1.50 min (total run time with equilibration back to starting conditions back to starting conditions 1.70 min), where A = 0.1% formic acid in water (for acid work) or 0.1% ammonia in water (for base work) B = acetonitrile. For acid analysis, the column used was Waters Acquity HSS T3 1.8 μm 2.1 × 50 mm, and for base analysis the column used was Waters Acquity BEH 1.7 μm 2.1 × 50 mm. Alternatively, UPLC was carried out using a Waters UPLC fitted with a Waters SQ mass spectrometer (column temp 30, UV = 210–400 nm, mass spec = ESI with positive/negative switching) at a flow rate of 1 mL/min using a solvent gradient of 2–98% B over 1.5 min (total runtime with equilibration back to starting conditions: 2 min), where A = 0.1% formic acid in water and B = 0.1% formic acid in acetonitrile (for acid work) or A = 0.1% ammonium hydroxide in water and B = acetonitrile (for base work). For acid analysis, the column used was a Waters Acquity HSS T3 1.8 μm 2.1 × 30 mm, and for base analysis the column used was a Waters Acquity BEH C18 1.7 μm 2.1 × 30 mm; LCMS was carried out using a Waters Alliance HT (2795) fitted with a Waters ZQ ESCi mass spectrometer and a Phenomenex Gemini – NX (5 μm × 2.1 mm) column at a flow rate of 1.1 mL/min 95% A to 95% B over 4 min with a 0.5 min hold. The modifier was kept at a constant 5% C (50:50 acetonitrile/water 0.1% formic acid) or D (50:50 acetonitrile/water 0.1% ammonium hydroxide depending on whether it was an acidic or basic method. Intermediates were not fully purified, but their structure and purity were assessed by NMR, HPLC, or UPLC and mass techniques (unless stated otherwise) and are consistent with the proposed structures.</div><div class="NLM_p">All experimental activities involving animals were carried out in accordance with AstraZeneca animal welfare protocols, which are consistent with the American Chemical Society Publications rules and ethical guidelines.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-[4-(1-isopropyl-2-methyl-1<i>H</i>-imidazol-5-yl)-2-pyridinyl]cyclohexanecarboxamide (<b>3</b>)</h4><div class="NLM_p">A mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (<b>35</b>, 0.650 g, 2.95 mmol), potassium phosphate (0.941 g, 4.43 mmol), and 5-bromo-1-isopropyl-2-methyl-1<i>H</i>-imidazole (<b>36</b>, 0.30 g, 1.5 mmol) in water (8 mL) and 1,4-dioxane (24 mL) was degassed using a stream of nitrogen for 20 min. Then, chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.12 g, 0.15 mmol) was added to the mixture, and the reaction was heated at 110 °C for 3 h. After concentration under reduced pressure, the resulting residue was suspended in MeOH (10 mL) and DCM (30 mL), and the mixture was filtered and concentrated under reduced pressure to give crude 4-(1-isopropyl-2-methyl-1<i>H</i>-imidazol-5-yl)pyridin-2-amine (<b>37</b>, 137 mg, 42%), which was used without purification. MS-ESI <i>m</i>/<i>z</i> 217 [MH<sup>+</sup>].</div><div class="NLM_p">1-Chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine (0.232 g, 1.73 mmol) was added to (1<i>S</i>,3<i>R</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)cyclohexanecarboxylic acid (<b>38</b>, 0.337 g, 1.39 mmol) in DCM (8 mL) at 0 °C. The solution was stirred at room temperature for 30 min. A solution of <b>37</b> (0.25 g, 1.2 mmol) and pyridine (0.14 mL, 1.7 mmol) in THF (8 mL) was then added. The mixture was stirred at room temperature for 18 h. The mixture was then partitioned between EtOAc (50 mL) and water (50 mL), and the layers were separated. The organic layer was concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, eluting with 10–20% MeOH in DCM to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-(1-isopropyl-2-methyl-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate (62 mg, 12%). MS-ESI <i>m</i>/<i>z</i> 442 [MH<sup>+</sup>].</div><div class="NLM_p last">Hydrochloric acid in dioxane (4 M; 0.49 mL, 14.0 mmol) was added to a solution of <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-(1-isopropyl-2-methyl-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate (0.062 g, 0.14 mmol) in MeOH (2 mL). The reaction was stirred at room temperature for 18 h. After concentration under reduced pressure, the resulting residue was diluted in DCM (5 mL) and DIPEA (0.098 mL, 0.56 mmol). Acetyl chloride (0.020 mL, 0.28 mmol) was then added. The reaction was stirred at room temperature for 10 min. The reaction was then concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (column: Xbridge Phenyl 19 mm × 150 mm 5 μm), eluting with 25–45% acetonitrile in water containing 0.2% NH<sub>4</sub>OH (pH 10). Product fractions were concentrated under reduced pressure to give <b>3</b> (26 mg, 48%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.01–1.17 (1H, m), 1.21–1.39 (3H, m), 1.44 (6H, d, <i>J</i> = 7.0 Hz), 1.73–1.82 (6H, m), 1.89 (1H, br d, <i>J</i> = 11.5 Hz), 2.47 (3H, s), 2.58–2.70 (1 H, m), 3.52–3.61 (1H, m), 4.50 (1H, td, <i>J</i> = 7.0, 14.1 Hz), 6.89 (1H, s), 7.05 (1H, dd, <i>J</i> = 1.4, 5.1 Hz), 7.77 (1H, d, <i>J</i> = 8.0 Hz), 8.10 (1H, s), 8.34 (1H, d, <i>J</i> = 5.0 Hz) 10.53 (1 H, s); MS-ESI <i>m</i>/<i>z</i> 384 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 384.2390 [MH<sup>+</sup>], C<sub>22</sub>H<sub>29</sub>ClN<sub>5</sub>O<sub>2</sub> requires 384.2394.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>4</b>)</h4><div class="NLM_p">1-Chloro-<i>N,N</i>,2-trimethylprop-1-en-1-amine (0.57 mL, 4.33 mmol) was added to a solution of <b>38</b> (1.01 g, 4.16 mmol) in DCM (40 mL) at 0 °C. After 1.5 h, a mixture of 4-bromopyridin-2-amine <b>39</b> (0.60 g, 3.5 mmol) and pyridine (1.1 mL, 14 mmol) in DCM (33 mL) was added via cannula. The resulting yellow mixture was allowed to warm to room temperature and was stirred under these conditions for 72 h. The now white mixture was filtered and rinsed with a cold DCM wash, and the white precipitate was dried under a vacuum at 70 °C for 30 min to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-bromopyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>40</b> (1.38 g, 100%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 0.99–1.35 (4H, m) 1.38 (9H, s) 1.68–1.80 (3H, m) 1.88 (1H, d) 2.53–2.64 (1H, m) 3.15–3.35 (1H, m) 6.76 (1H, d) 7.34 (1H, dd) 8.21 (1H, d) 8.33 (1H, d) 10.63 (1H, s). MS-ESI <i>m</i>/<i>z</i> 398, 400 [MH<sup>+</sup>].</div><div class="NLM_p">Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (9.88 mg, 0.01 mmol) was added in one portion to a degassed mixture of <b>40</b> (100 mg, 0.25 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridine <b>41</b> (93 mg, 0.38 mmol), potassium phosphate (160 mg, 0.75 mmol), 1,4-dioxane (2 mL), and water (0.2 mL) at 21 °C under nitrogen. The resulting mixture was stirred at 100 °C for 16 h. The reaction mixture was diluted with EtOAc (10 mL) and washed with saturated NaHCO<sub>3</sub> (10 mL). The aqueous layer was extracted with EtOAc (2 × 10 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 20–80% EtOAc in heptane. Pure fractions were evaporated to dryness to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate (<b>42</b>, 70 mg, 63%) as a white powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.12 (1H, d), 1.21–1.33 (3H, m), 1.39 (9H, s), 1.76 (3H, s), 1.82–1.95 (3H, m), 2.00 (2H, d), 2.59 (1H, s), 2.97 (2H, t), 3.89 (1H, s), 4.12 (2H, t), 6.75 (1H, s), 7.19 (1H, dd), 7.85 (1H, s), 8.22 (2H, d), 10.32 (1H, s). MS-ESI <i>m</i>/<i>z</i> 440 [MH<sup>+</sup>].</div><div class="NLM_p">Hydrochloric acid in dioxane (4 M; 0.20 mL, 0.80 mmol) was added dropwise to <b>42</b> (70 mg, 0.16 mmol) in DCM (2 mL) at 21 °C under nitrogen. The resulting mixture was stirred at 21 °C for 16 h. MeOH (1 mL) was added, and the mixture was purified directly by ion exchange chromatography, using an SCX-2 column. The desired product was eluted using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure to afford (1<i>S</i>,3<i>R</i>)-3-amino<i>-N-</i>(4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (47 mg, 87%) as a white crystalline solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): 0.95–1.08 (1H, m), 1.2–1.4 (3H, m), 1.76–1.91 (5H, m), 1.99 (3H, dtt), 2.44 (1H, ddd), 2.61 (1H, tt), 2.95 (2H, t), 3.25 (1H, s), 4.07 (2H, t), 7.11 (1H, dd), 7.74 (1H, s), 8.07–8.16 (2H, m), NH<sub>2</sub> peak not observed. MS-ESI <i>m</i>/<i>z</i> 340 [MH<sup>+</sup>].</div><div class="NLM_p last">Acetic anhydride (0.016 mL, 0.17 mmol) was added to (1<i>S</i>,3<i>R</i>)-3-amino<i>-N-</i>(4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (47 mg, 0.14 mmol) and triethylamine (0.023 mL, 0.17 mmol) in DCM (1 mL) at 21 °C under nitrogen. The resulting solution was stirred under these conditions for 60 h. The reaction mixture was loaded directly onto silica and purified by flash silica chromatography, elution gradient 1–10% MeOH in DCM. Product fractions were concentrated under reduced pressure to afford <b>4</b> (43 mg, 81%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.07–1.23 (1H, m), 1.37–1.53 (3H, m), 1.87–2.03 (8H, m), 2.03–2.11 (2H, m), 2.25 (1H, d), 2.39–2.51 (1H, m), 3.06 (2H, t), 3.88 (1H, dtq), 4.20 (2H, t), 5.40 (1H, d), 7.10 (1H, dd), 7.80 (1H, s), 8.17 (1H, dd), 8.32 (1H, s), 8.35 (1H, s). MS-ESI <i>m</i>/<i>z</i> 382 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 382.2248 [MH<sup>+</sup>], C<sub>21</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub> requires 382.2238.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(5-fluoro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>5</b>)</h4><div class="NLM_p">Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.092 g, 0.12 mmol) was added to a degassed mixture of <b>41</b> (0.347 g, 1.40 mmol), 2-chloro-5-fluoro-4-iodopyridine <b>45</b> (0.30 g, 1.2 mmol) and potassium phosphate, tribasic (0.61 g, 3.5 mmol) in 1,4-dioxane (10 mL), and water (2 mL). The mixture was degassed and stirred at 90 °C for 2 h under nitrogen. The reaction mixture was concentrated under reduced pressure, and the resulting residue was taken up in water (20 mL). The mixture was extracted with DCM (3 × 20 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–60% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford 3-(2-chloro-5-fluoropyridin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridine <b>46</b> (200 mg, 68%) as a yellow gum. MS-ESI <i>m</i>/<i>z</i> 252 [MH<sup>+</sup>].</div><div class="NLM_p">Tetrakis(triphenylphosphine)palladium(0) (0.092 g, 0.080 mmol) was added to a mixture of <b>46</b> (0.20 g, 0.79 mmol), <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-carbamoylcyclohexyl)carbamate <b>47</b> (0.231 g, 0.95 mmol, see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>), 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (0.092 g, 0.16 mmol), and cesium carbonate (0.777 g, 2.38 mmol) in 1,4-dioxane (6 mL). The mixture was degassed (vacuum) and backfilled with nitrogen, and the resulting suspension was stirred at 120 °C for 2 h in the microwave reactor. The reaction mixture was partitioned between water (20 mL) and DCM (40 mL) and separated using a phase separation cartridge. The organic layer was adsorbed onto silica and purified by flash silica chromatography, elution gradient 0–60% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-fluoro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>48</b> (136 mg). This material was used directly in the next step without further purification. MS-ESI <i>m</i>/<i>z</i> 458 [MH<sup>+</sup>].</div><div class="NLM_p last">Trifluoroacetic acid (0.17 mL, 2.2 mmol) was added to <b>48</b> (0.10 g, 0.22 mmol) in DCM (5 mL). The resulting solution was stirred at room temperature for 1 h. The reaction mixture was purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure to afford (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(5-fluoro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide as a yellow gum. This material was used directly in the next step without further purification. MS-ESI <i>m</i>/<i>z</i> 358 [MH<sup>+</sup>]. Acetic anhydride (0.032 mL, 0.34 mmol) was added to (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(5-fluoro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (0.10 g, 0.28 mmol), triethylamine (0.12 mL, 0.84 mmol), and <i>N</i>,<i>N</i>-dimethylpyridin-4-amine (2 mg, 0.01 mmol) in DCM (5 mL) at room temperature under air. The resulting solution was stirred at room temperature. for 2 h. The reaction mixture was quenched with saturated aqueous ammonium chloride (20 mL) and extracted with DCM (2 × 20 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to afford <b>5</b> (0.047 g, 42%) as a gum. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): 1.03–1.15 (1H, m), 1.23–1.37 (3H, m), 1.74–1.82 (6H, m), 1.83–1.94 (3H, m), 2.00–2.08 (2H, m), 2.56–2.68 (1H, m), 2.91 (2H, t), 3.58–3.61 (1H, m), 4.15 (2H, t), 7.73–7.78 (2H, m), 8.26 (1H, d), 8.30 (1H, d), 10.48 (1H, s). MS-ESI <i>m</i>/<i>z</i> 400 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 400.2144 [MH<sup>+</sup>], C<sub>21</sub>H<sub>27</sub>FN<sub>5</sub>O<sub>2</sub> requires 400.2143.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N-</i>(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>6</b>)</h4><div class="NLM_p">The reaction was split into four separate sealed microwave reaction vessels, each containing 5-chloro-2-fluoro-4-iodopyridine <b>55</b> (750 mg, 2.95 mmol), concentrated aqueous ammonium hydroxide (8.4 mL), and NMP (7.5 mL). The reaction vessels were each heated at 100 °C for 17 h. The combined batches were then diluted with water (50 mL) and extracted with EtOAc (3 × 120 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford a pale-yellow oil. The oil was loaded onto a 20 g SCX-2 column and eluted sequentially with DCM, MeOH, and 1% NH<sub>3</sub> in MeOH. Basic fractions were concentrated to provide 5-chloro-4-iodopyridin-2-amine <b>56</b> (2.9 g, 99%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 6.21 (2H, s), 7.05 (1H, s), 7.93 (1H, s). MS-ESI <i>m</i>/<i>z</i> 255 [MH<sup>+</sup>].</div><div class="NLM_p">Cesium carbonate (13.4 g, 41.2 mmol) and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (0.94 g, 1.2 mmol) were added sequentially to a degassed mixture of <b>56</b> (4.19 g, 16.5 mmol), <b>41</b> (5.72 g, 23.1 mmol), 1,4-dioxane (141 mL), and water (23.5 mL). The resulting red mixture was warmed to 95 °C and became clear. With vigorous stirring, some precipitate formed which gradually redissolved. After 4 h, another 800 mg of <b>41</b> were added; after another 40 min, the reaction was cooled to room temperature and stirred under these conditions for 18 h. The mixture was then diluted with ethyl acetate, and the layers were separated. The organic layer was washed with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting oil was purified by flash silica chromatography, elution gradient 0–10% methanol in ethyl acetate. Product fractions were combined, concentrated under reduced pressure, and the resulting residue was stirred vigorously in 1:1 DCM: hexane for 20 min. The mixture was then diluted with hexane and filtered with a hexane wash. The resulting solid was dried under vacuum to afford 5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-amine <b>57</b> (2.79 g, 68%) as light orange-beige needles. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 1.74–1.88 (2H, m), 1.96–2.06 (2H, m), 2.76 (2H, t), 4.12 (2H, t), 6.03 (2H, br. s), 6.43 (1H, s), 7.63 (1H, s), 7.94 (1H, s). MS-ESI <i>m</i>/<i>z</i> 249 [MH<sup>+</sup>].</div><div class="NLM_p">1-Chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine (1.1 mL, 8.4 mmol) was added to a solution of <b>38</b> (2.01 g, 8.24 mmol) in DCM (50 mL) at 0 °C. The reaction was maintained under these conditions for 100 min. During this time, <b>58</b> (1.64 g, 6.59 mmol), pyridine (2.1 mL, 26 mmol), and DCM (20 mL) were combined in a separate flask. The resulting mixture was warmed gently (∼40 °C) until all solids dissolved. The resulting solution was then cooled to 0 °C, whereupon a homogeneous light-yellow mixture formed. This mixture was added via cannula rapidly to the previously prepared solution of <b>38</b> and 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, resulting in a darker yellow solution. The reaction was allowed to warm to room temperature overnight and was then evaporated to dryness to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>58</b> as a gray mixture (3.12 g). This crude material was taken on to the next step without further purification. MS-ESI <i>m</i>/<i>z</i> 474 [MH<sup>+</sup>].</div><div class="NLM_p">Hydrochloric acid in dioxane (4 M; 10 mL, 40 mmol) was added to a mixture of crude <b>58</b> (3.12 g, 6.59 mmol) in DCM (5 mL) and methanol (5 mL) at 0 °C. The mixture became an amber solution. After 1 h, the amber solution was concentrated under reduced pressure, and the resulting residue was dried under a vacuum to afford (1<i>S</i>,3<i>R</i>)-3-amino-<i>N-</i>(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide as a beige/gray foam solid. This material was carried on to the next step without further purification. MS-ESI <i>m</i>/<i>z</i> 374 [MH<sup>+</sup>]. Acetyl chloride (1.0 mL, 14.5 mmol) was added dropwise to a mixture of (1<i>S</i>,3<i>R</i>)-3-amino-<i>N-</i>(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (2.46 g, 6.59 mmol) and pyridine (6.4 mL, 79 mmol) in DCM (58 mL) at 0 °C. After 45 min, the mixture was washed with saturated aqueous sodium hydrogen carbonate and saturated aqueous sodium chloride before being dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting dark amber oil was purified by flash silica chromatography, elution gradient 0–10% methanol in DCM. Product fractions were concentrated under reduced pressure to afford <b>6</b> (2.6 g, 93% yield over three steps, 96% e.e.) as a light beige foam solid. This material was further purified by preparative SFC conditions (Chiralpak IA column, 5 μm, 30 mm diameter, 250 mm length, 40 °C column temperature, 100 bar outlet pressure, 120 mL/min flow rate), eluting with 40% methanol containing 0.1% dimethylethylamine in CO<sub>2</sub>, to afford faster eluting <b>6</b> and the slower eluting (1<i>R</i>,3<i>S</i>) enantiomer. Product fractions for <b>6</b> were concentrated under reduced pressure to afford an amber-pink solid (2.3 g). This solid was repurified by flash silica (plug) chromatography, elution gradient 0–10% MeOH in ethyl acetate, to afford a white foam solid. The solid was treated with 20 mL of acetonitrile, and the resulting mixture was warmed to reflux conditions before being allowed to cool to rt. Additional acetonitrile (∼5 mL) was added, and the process was repeated until all solid dissolved. The resulting faint yellow solution was cooled to rt, and a precipitate formed. After 1 h the precipitate was filtered and washed with acetonitrile before being dried under vacuum at 65 °C for 1 h. The solid was cooled to rt to afford <b>6</b> (1.76 g, > 98% e.e.).</div><div class="NLM_p last"><b>6</b>: <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 0.97–1.17 (1H, m), 1.20–1.38 (3H, m), 1.68–1.94 (9H, m), 1.96–2.07 (2H, m), 2.54–2.68 (1H, m), 2.80 (2H, t), 3.46–3.65 (1H, m), 4.14 (2H, t), 7.73 (1H, d), 7.76 (1H, s), 8.14 (1H, s), 8.38 (1H, s), 10.57 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): 20.13, 22.89, 22.96, 23.22, 24.49, 28.69, 32.38, 35.64, 43.91, 47.39, 48.22, 113.46, 114.37, 123.66, 138.38, 138.62, 141.16, 148.10, 151.40, 168.56, 174.98. MS-ESI <i>m</i>/<i>z</i> 416 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 416.1851 [MH<sup>+</sup>], C<sub>21</sub>H<sub>27</sub>ClN<sub>5</sub>O<sub>2</sub> requires 416.1848. Analytical SFC: flow: 1 mL/min, column: Chiralpak IA, 5 μ, 4.6 × 150 mm, eluent: 40% methanol in CO<sub>2</sub> containing 0.1% dimethylethylamine), <i>t</i><sub>R</sub>: (<b>6</b>, 1.42 min), ((1<i>R</i>,3<i>S</i>), 2.42 min). [α]<sup>D</sup><sub>25 °C</sub>: + 70.2° in MeOH.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(4-bromo-5-chloropyridin-2-yl)cyclohexanecarboxamide (<b>7</b>)</h4><div class="NLM_p"><i>N-</i>Chloro-succinimide (3.70 g, 27.7 mmol) dissolved in DMF (20 mL) was added dropwise to 4-bromopyridin-2-amine <b>39</b> (4.40 g, 25.4 mmol) in DMF (50 mL) at −78 °C over a period of 30 min under nitrogen. The resulting suspension was then allowed to warm to room temperature. After stirring under these conditions for 24 h, the reaction mixture was diluted with Et<sub>2</sub>O (50 mL) and washed sequentially with aqueous NaOH (1 M; 2 × 50 mL), water (50 mL), and saturated aqueous sodium chloride (25 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–25% EtOAc in DCM. Product fractions were concentrated under reduced pressure to afford 4-bromo-5-chloropyridin-2-amine <b>59</b> (2.30 g, 43.7%) as a cream-colored solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 6.35 (2H, s), 6.82 (1H, s), 8.01 (1H, s). MS-ESI <i>m</i>/<i>z</i> 207, 209 [MH<sup>+</sup>].</div><div class="NLM_p">A solution of <b>38</b> (1.50 g, 6.15 mmol) dissolved in DCM (20 mL) at 0 °C was treated with 1-chloro-<i>N,N</i>,2-trimethylprop-1-en-1-amine (0.976 mL, 7.38 mmol). The mixture was stirred at room temperature for 1.5 h before <b>59</b> (1.02 g, 4.92 mmol) and pyridine (0.59 mL, 7.4 mmol) were added sequentially. The resulting solution was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM (25 mL) and washed sequentially with water (2 × 25 mL) and saturated aqueous sodium chloride (25 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude product was purified by ion exchange chromatography, using an SCX-2 column. The desired product was eluted from the column using methanol to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-bromo-5-chloropyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>60</b> (2.34 g, quantitative) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.12 (1H, dd), 1.22–1.32 (3H, m), 1.38 (9H, s), 1.72 (3H, dd), 1.83–1.94 (2H, m), 2.11 (1H, dt), 8.48 (1H, s), 8.50 (1H, s), 10.77 (1H, s), one proton not observed. MS-ESI <i>m</i>/<i>z</i> 430, 432 [M-H<sup>–</sup>].</div><div class="NLM_p">Hydrochloric acid in dioxane (4 M; 5.9 mL, 24 mmol) was added to <b>60</b> (1.20 g, 2.77 mmol) in MeOH (7.0 mL) under air. The resulting solution was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under reduced pressure to afford crude (1<i>S</i>,3<i>R</i>)-3-amino<i>-N-</i>(4-bromo-5-chloropyridin-2-yl)cyclohexanecarboxamide dihydrochloride as a white solid. This solid was taken up in DCM (8.4 mL), and 4-dimethylaminopyridine (0.014 g, 0.11 mmol) and triethylamine (1.0 mL, 7.1 mmol) were added sequentially. Then acetic anhydride (0.26 mL, 2.7 mmol) was added dropwise. The resulting solution was stirred at room temperature for 18 h before being quenched with saturated aqueous NH<sub>4</sub>Cl (50 mL) and extracted with DCM (2 × 50 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford (1<i>S</i>,3<i>R</i>)-3-acetamido<i>-N-</i>(4-bromo-5-chloropyridin-2-yl)cyclohexanecarboxamide <b>61</b> (0.96 g, 95%) as a white solid. The product was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.23–1.41 (4H, m), 1.67–1.85 (4H, m), 2.39 (3H, tt), 2.75–2.92 (1H, m), 3.53 (1H, dtd), 7.59–7.83 (1H, m), 8.50 (2H, dd), 10.80 (1H, d). MS-ESI <i>m</i>/<i>z</i> 374, 376 [MH<sup>+</sup>].</div><div class="NLM_p last"><b>61</b> (0.10 g, 0.27 mmol) was added to a mixture of 1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (0.065 g, 0.29 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.021 g, 0.03 mmol), and potassium phosphate (0.170 g, 0.80 mmol) in 1,4-dioxane (2.3 mL) and water (0.23 mL). The reaction mixture was then degassed with a stream of nitrogen for 5 min. The resulting mixture was stirred at room temperature for 16 h and subsequently purified by ion exchange chromatography, using an SCX-2 column and eluting first with methanol and then with 1 M NH<sub>3</sub> in methanol. Product fractions were concentrated under reduced pressure to afford a yellow oil. This oil was further purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 50 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to afford <b>7</b> (0.011 g, 11%) as a colorless solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): 0.91–1.17 (1H, m), 1.19–1.4 (3H, m), 1.78 (6H, s), 1.89 (1H, d, <i>J</i> = 12.2 Hz), 2.28 (3H, s), 2.54–2.69 (1H, m), 3.45–3.65 (1H, m), 3.82 (3H, s), 7.60 (1H, s), 7.75 (1H, d, <i>J</i> = 7.9 Hz), 8.08 (1H, s), 8.41(1H, s), 10.60 (1H, s). MS-ESI <i>m</i>/<i>z</i> 390 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 390.1704 [MH<sup>+</sup>], C<sub>19</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub> requires 390.1691.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(5-chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>8</b>)</h4><div class="NLM_p">Pd(PPh<sub>3</sub>)<sub>4</sub> (0.21 g, 0.18 mmol) was added to 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-<i>a</i>]pyridine (0.490 g, 2.01 mmol), 2,5-dichloro-4-iodopyridine (<b>52</b>, 0.500 g, 1.83 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (1.78 g, 5.48 mmol) in dioxane (2 mL) and water (0.2 mL) under nitrogen. The resulting mixture was stirred at 100 °C for 1 h. The reaction mixture was then concentrated under reduced pressure. The resulting mixture was diluted with EtOAc (100 mL) and washed sequentially with water (100 mL) and saturated aqueous sodium chloride (100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–25% EtOAc in petroleum ether. Product fractions were concentrated under reduced pressure to afford 3-(2,5-dichloropyridin-4-yl)pyrazolo[1,5-<i>a</i>]pyridine (<b>53a</b>, 0.310 g, 64%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 7.09 (1H, dt, <i>J</i> = 1.3, 6.9 Hz), 7.46 (1H, ddd, <i>J</i> = 1.1, 6.8, 9.0 Hz), 7.74 (1H, s), 7.80 (1H, td, <i>J</i> = 1.2, 9.0 Hz), 8.44 (1H, s), 8.60 (1H, s), 8.84 (1H, td, J = 1.1, 7.0 Hz). MS-ESI <i>m</i>/<i>z</i> 264 [MH<sup>+</sup>].</div><div class="NLM_p">Pd(PPh<sub>3</sub>)<sub>4</sub> (0.02 g, 0.02 mmol) was added to a mixture of <b>53a</b> (0.054 g, 0.21 mmol), <b>47</b> (0.05 g, 0.21 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.024 g, 0.04 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (0.202 g, 0.62 mmol) in dioxane (2 mL) under nitrogen. The resulting mixture was stirred at 120 °C for 2 h. In a separate flask, Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 g, 0.04 mmol) was added to a mixture of <b>53a</b> (0.109 g, 0.41 mmol), <b>47</b> (0.10 g, 0.41 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.048 g, 0.08 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (0.403 g, 1.24 mmol) in dioxane (2 mL) under nitrogen. The resulting mixture was stirred at 120 °C for 2 h. Both reactions were then combined and filtered through a plug of silica with ethyl acetate wash. The filtrate was concentrated under reduced pressure, and the resulting residue was redissolved in EtOAc (100 mL) before being washed sequentially with water (100 mL) and saturated aqueous sodium chloride (100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by preparative TLC (eluting with 50% EtOAc in petroleum ether), to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate (<b>54a</b>, 0.13 g, 44%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.06–1.13 (1H, m), 1.26–1.30 (3H, m), 1.39 (9H, s), 1.73–1.80 (3H, m), 1.86–1.94 (1H, m), 2.56–2.63 (1H, m), 3.17–3.32 (1H, m), 6.82 (1H, d, <i>J</i> = 8.2 Hz), 7.09 (1H, t, <i>J</i> = 6.8 Hz), 7.45–7.54 (1H, m), 7.80 (1H, d, <i>J</i> = 9.0 Hz), 8.37 (1H, s), 8.45 (1H, s), 8.48 (1H, s), 8.85 (1H, d, <i>J</i> = 6.9 Hz), 10.67 (1H, s). MS-ESI <i>m</i>/<i>z</i> 470 [MH<sup>+</sup>].</div><div class="NLM_p last">TFA (2.0 mL, 26 mmol) was added to <b>54a</b> (0.12 g, 0.26 mmol) in DCM (10 mL). The resulting mixture was stirred at room temperature for 16 h and then concentrated under reduced pressure. The resulting crude yellow gum (100 mg) was dissolved in DCM (2 mL), and then TEA (0.11 mL, 0.81 mmol) and acetic anhydride (0.051 mL, 0.54 mmol) were added sequentially. The resulting mixture was stirred at room temperature for 1 h and was then concentrated under reduced pressure. The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.1% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to afford impure <b>8</b> (0.050 g, 45%) as a white solid. This material was repurified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.05% TFA) and MeCN as eluents. Product fractions were concentrated under reduced pressure to afford <b>8</b> (0.030 g, 27%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 1.02–1.12 (1H, m), 1.19–1.40 (3H, m), 1.74–1.80 (6H, m), 1.85–1.95 (1H, m), 2.59–2.65 (1H, m), 3.52–3.58 (1H, m), 7.07 (1H, dt, <i>J</i> = 1.3, 6.9 Hz), 7.47 (1H, ddd, <i>J</i> = 1.1, 6.8, 9.0 Hz), 7.73–7.84 (2H, m), 8.35 (1H, s), 8.44 (1H, s), 8.47 (1H, s), 8.84 (1H, td, <i>J</i> = 1.1, 7.0 Hz), 10.68 (1H, s). HRMS-ESI: <i>m</i>/<i>z</i> found 412.1537 [MH<sup>+</sup>], C<sub>21</sub>H<sub>23</sub>ClN<sub>5</sub>O<sub>2</sub> requires 412.1535.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(5-chloro-4-(5,6,7,8-tetrahydroimidazo[1,2-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>9</b>)</h4><div class="NLM_p last"><b>61</b> (0.20 g, 0.53 mmol), 5,6,7,8-tetrahydroimidazo[1,2-<i>a</i>]pyridine (47 mg, 0.38 mmol), cesium carbonate (0.14 g, 0.42 mmol), triethylamine (0.11 mL, 0.76 mmol), triphenylphosphine (0.02 g, 0.06 mmol) and diacetoxypalladium (6.85 mg, 0.030 mmol) were suspended in 1,4-dioxane (5 mL) and sealed in a microwave tube. The reaction was heated to 100 °C for 16 h in a microwave reactor and then cooled to room temperature. The reaction was concentrated under reduced pressure, and the resulting residue was purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure. The resulting residue was further purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 50 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to afford <b>9</b> (0.069 g, 44%) as a yellow gum. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): 0.95–1.16 (1H, m), 1.19–1.39 (3H, m), 1.78 (3H, s), 1.83–1.97 (2H, m), 2.55–2.68 (1H, m), 2.84 (2H, s), 3.18 (2H, dd), 3.31 (3H, s), 3.57 (1H, dt), 3.83 (2H, s), 4.08 (1H, q), 7.13 (1H, s), 7.75 (1H, d), 8.16 (1H, s), 8.47 (1H, s), 10.70 (1H, s). MS-ESI <i>m</i>/<i>z</i> 416 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 416.1851 [MH<sup>+</sup>], C<sub>21</sub>H<sub>27</sub>ClN<sub>5</sub>O<sub>2</sub> requires 416.1848.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(5-chloro-4-(1,2-dimethyl-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>10</b>)</h4><div class="NLM_p">Pd(OAc)<sub>2</sub> (0.041 g, 0.18 mmol) was added to 1,2-dimethyl-1<i>H</i>-imidazole (0.175 g, 1.83 mmol), <b>52</b> (0.5 g, 1.83 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1.78 g, 5.48 mmol), and PPh<sub>3</sub> (0.048 g, 0.18 mmol) in dioxane (10 mL) under nitrogen. The resulting mixture was stirred at 120 °C for 16 h and then filtered with an ethyl acetate wash. The filtrate was concentrated under reduced pressure and redissolved in EtOAc (50 mL). This mixture was washed sequentially with water (2 × 50 mL) and saturated aqueous sodium chloride (50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–30% EtOAc in petroleum ether. Product fractions were concentrated under reduced pressure, and the resulting oil was crystallized from hexane to afford 2,5-dichloro-4-(1,2-dimethyl-1<i>H</i>-imidazol-5-yl)pyridine (<b>53b</b>, 0.170 g, 38.5%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 3.17 (3H, s), 3.48 (3H, s), 7.16 (1H, s), 7.65 (1H, s), 8.64 (1H, s). MS-ESI <i>m</i>/<i>z</i> 242 [MH<sup>+</sup>].</div><div class="NLM_p">Pd(PPh<sub>3</sub>)<sub>4</sub> (0.05 g, 0.04 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.05 g, 0.08 mmol) were added to a mixture of <b>53b</b> (0.20 g, 0.41 mmol), <b>47</b> (0.10 g, 0.41 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (0.403 g, 1.24 mmol) in dioxane (3 mL) under nitrogen. The resulting mixture was stirred at 120 °C for 30 min. The reaction was then filtered with an ethyl acetate wash, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by preparative TLC (100% EtOAc), to afford <i>tert</i>-butyl (1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(1,2-dimethyl-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate (<b>54b</b>, 0.140 g, 76%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.08–1.12 (1H, m), 1.22–1.35 (3H, m), 1.38 (9H, s), 1.73–1.77 (3H, m), 1.85–1.93 (1H, m), 2.38 (3H, s), 2.57–2.61 (1H, m), 3.23–3.31 (1H, m), 3.44 (3H, s), 6.77–6.83 (1H, m), 7.01 (1H, s), 8.12 (1H, s), 8.48 (1H, s), 10.72 (1H, s). MS-ESI <i>m</i>/<i>z</i> 448 [MH<sup>+</sup>].</div><div class="NLM_p last">TFA (1 mL, 13 mmol) was added to <b>54b</b> (0.14 g, 0.31 mmol) in DCM (5 mL). The resulting mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure to afford a yellow gum (110 mg). This gum was taken up in DCM (5 mL), and TEA (0.13 mL, 0.95 mmol) was added. Then acetic anhydride (0.032 g, 0.32 mmol) was added dropwise. The resulting mixture was stirred at rt for 1 h and was then concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.1% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents. Product fractions were concentrated under reduced pressure to afford <b>10</b> (40 mg) as a white solid. This solid was repurified by chiral reverse phase HPLC (Chiralpak IA column, 5 μ silica, 20 mm diameter, 250 mm length; flow rate 20 mL/min), eluting with isocratic 30% IPA in hexanes, to afford <b>10</b> (0.030 g, 25%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.01–1.14 (1H, m), 1.19–1.38 (3H, m), 1.69–1.84 (6H, m), 1.85–1.92 (1H, m), 2.38 (3H, s), 2.60–2.64 (1H, m), 3.44 (3H, s), 3.51–3.63 (1H, m), 7.01 (1H, s), 7.78 (1H, d, <i>J</i> = 7.9 Hz), 8.13 (1H, s), 8.48 (1H, s), 10.74 (1H, s). HRMS-ESI: <i>m</i>/<i>z</i> found 390.1701 [MH<sup>+</sup>], C<sub>19</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub> requires 390.1691.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(5-chloro-4-(imidazo[1,2-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>11</b>)</h4><div class="NLM_p last">Imidazo[1,2-<i>a</i>]pyridine (0.045 mL, 0.45 mmol), <b>61</b> (0.235 g, 0.63 mmol), cesium carbonate (0.161 g, 0.49 mmol), triethylamine (0.125 mL, 0.90 mmol), triphenylphosphine (0.019 g, 0.07 mmol), and diacetoxypalladium (8.05 mg, 0.04 mmol) were suspended in 1,4-dioxane (5 mL) in a microwave tube. The reaction was heated at 100 °C for 2 h in a microwave reactor and then cooled to rt. The reaction was then resubjected to microwave conditions (100 °C) for another 4 h and cooled. The reaction mixture was diluted with DCM (20 mL) and washed with water (3 × 25 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–2% MeOH in EtOAc. Product fractions were concentrated under reduced pressure to afford (0.078 g, 42%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.08–1.28 (1H, m), 1.32–1.58 (3H, m), 1.87–1.97 (3H, m), 1.98 (3H, s), 2.26 (1H, d, <i>J</i> = 12.3 Hz), 2.54 (1H, ddd, <i>J</i> = 3.4, 8.2, 11.6 Hz), 3.88 (1H, dtd, <i>J</i> = 4.1, 7.9, 11.7 Hz), 5.69 (1H, d, <i>J</i> = 8.1 Hz), 6.91 (1H, td, <i>J</i> = 1.1, 6.9 Hz), 7.29 (1H, ddd, <i>J</i> = 1.2, 6.8, 9.1 Hz), 7.72 (1H, dt, <i>J</i> = 1.0, 9.1 Hz), 7.95 (1H, s), 8.15 (1H, dt, <i>J</i> = 1.1, 6.9 Hz), 8.38 (1H, s), 8.43 (1H, s), 8.70 (1H, s). MS-ESI <i>m</i>/<i>z</i> 412 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 412.1545 [MH<sup>+</sup>], C<sub>21</sub>H<sub>23</sub>ClN<sub>5</sub>O<sub>2</sub> requires 412.1535.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(5-chloro-4-(4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>12</b>)</h4><div class="NLM_p">1-Chloro-<i>N,N</i>,2-trimethylpropenylamine (1.149 mL, 8.68 mmol) was added to a stirred solution of <b>38</b> (1.41 g, 5.79 mmol) in DCM (25 mL) cooled in an ice bath under a nitrogen atmosphere. The resulting mixture was stirred at ambient temperature for 1 h. <b>56</b> (1.47 g, 5.79 mmol) and pyridine (0.70 mL, 8.7 mmol) were added, and the resulting mixture was stirred at ambient temperature for 16 h. The reaction was quenched by the addition of saturated aqueous NH<sub>4</sub>Cl (50 mL). The resulting mixture was extracted with DCM (3 × 75 mL), and the combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting pale-yellow solid was slurried with Et<sub>2</sub>O (10 mL) and filtered to yield <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-iodopyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>62</b> (1.79 g, 3.73 mmol, 64%) as a cream-colored solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.04–1.18 (1H, m), 1.24–1.41 (2H, m), 1.44 (9H, s), 1.92 (2H, dq), 2.00 (1H, d), 2.28 (1H, d), 2.31–2.41 (1H, m), 3.27–3.62 (2H, m), 4.44 (1H, s), 7.80 (1H, s), 8.19 (1H, s), 8.81 (1H, s). MS-ESI <i>m</i>/<i>z</i> 478 [M – H<sup>–</sup>].</div><div class="NLM_p"><b>62</b> (1 g, 2.08 mmol) was suspended in DCM (15 mL) at ambient temperature. Hydrochloric acid in dioxane (4 M; 2.61 mL, 10.4 mmol) was added, and the resulting mixture stirred for 16 h. The reaction mixture was then loaded onto a 50 g SCX-2 column and eluted sequentially with DCM, MeOH, and 1% NH<sub>3</sub> in MeOH. Basic fractions were concentrated under reduced pressure to afford crude 3-amino-<i>N</i>-(5-chloro-4-iodopyridin-2-yl)cyclohexanecarboxamide as a colorless amorphous solid (782 mg). This solid was dissolved in triethylamine (0.632 mL, 4.53 mmol) in DCM (10 mL) at ambient temperature. Then acetic anhydride (0.214 mL, 2.27 mmol) was added dropwise. The reaction mixture was stirred for 5 days under these conditions before being filtered with a DCM wash to provide (1<i>S</i>,3<i>R</i>)-3-acetamido-<i>N</i>-(5-chloro-4-iodopyridin-2-yl)cyclohexanecarboxamide <b>63</b> (480 mg, 55%) as a colorless solid. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by flash silica chromatography, elution gradient 20 to 60% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford additional <b>63</b> (193 mg, 22%) as a colorless crystalline solid (combined yield: 77%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.01–1.17 (1H, m), 1.18–1.39 (3H, m), 1.68–1.84 (2H, m), 1.78 (3H, s), 1.89 (1H, m), 2.51 (2H, m), 3.48–3.65 (1H, m), 7.74 (1H, d), 8.38 (1H, s), 8.71 (1H, s), 10.66 (1H, s). MS-ESI <i>m</i>/<i>z</i> 422 [MH<sup>+</sup>].</div><div class="NLM_p last">Crude 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-<i>a</i>]pyridine (approximately 0.3 mL solution; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>) was added to a mixture of <b>63</b> (10 mg, 0.02 mmol), Cs<sub>2</sub>CO<sub>3</sub> (15 mg, 0.05 mmol), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (1.9 mg, 2.4 μmol) in 1,4-dioxane (2 mL) and water (0.5 mL) under nitrogen. The resulting mixture was warmed to 60 °C and maintained under these conditions for 45 min. This reaction was then allowed to cool to room temperature. In a separate flask the remaining suspension mixture containing crude 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-<i>a</i>]pyridine (approximately 2.0 mL) was added to a mixture of <b>63</b> (70 mg, 0.17 mmol), Cs<sub>2</sub>CO<sub>3</sub> (325 mg, 1.00 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (26 mg, 0.03 mmol) in 1,4-dioxane (16 mL) and water (4 mL) under nitrogen. The resulting mixture was stirred at 60 °C for 45 min. This reaction was then allowed to cool to room temperature. Both cooled reaction mixtures were combined and then diluted with saturated aqueous sodium chloride (100 mL). The resulting mixture was extracted with EtOAc (3 × 100 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, using an elution gradient of 0 to 100% EtOAc in petroleum ether followed by an elution gradient of 0 to 20% MeOH in EtOAc. Pure fractions were concentrated under reduced pressure. The resulting residue was further purified by preparative HPLC (XBridge Prep C18 OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.8% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to afford <b>12</b> (20 mg, 25%) as a white solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>, 400 MHz): 1.00–1.14 (1H, m), 1.19–1.37 (3H, m), 1.68–1.81 (6H, m), 1.81–1.92 (3H, m), 1.99–2.10 (2H, m), 2.56–2.70 (1H, m), 2.82 (2H, t), 3.51–3.63 (1H, m), 4.42 (2H, t), 7.80 (1H, d), 8.26 (1H, s), 8.48 (1H, s), 10.73 (1H, s). MS-ESI <i>m</i>/<i>z</i> 417 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 417.1795 [MH<sup>+</sup>], C<sub>20</sub>H<sub>26</sub>ClN<sub>6</sub>O<sub>2</sub> requires 417.1800.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(5-chloro-4-(5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>13</b>)</h4><div class="NLM_p">A mixture of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazole (0.14 g, 0.58 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>), <b>62</b> (0.18 g, 0.38 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.03 g, 0.04 mmol), potassium phosphate, dibasic (0.200 g, 1.15 mmol), 1,4-dioxane (4 mL), and water (0.8 mL) was stirred at 21 °C for 18 h. The mixture was then heated at 40 °C for 17 h, and then at 50 °C for another 2 h. The mixture was diluted with EtOAc (30 mL) and then washed with water (10 mL). The organic layer was concentrated under reduced pressure, and the resulting crude product was purified by flash silica chromatography, elution gradient 0 to 70% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(5,6-dihydro-4H-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>64a</b> (0.119 g, 67%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.04–1.17 (1H, m), 1.34–1.41 (2H, m), 1.44 (9H, s), 1.89–2.03 (4H, m), 2.29 (1H, d), 2.33–2.44 (1H, m), 2.69 (2H, p), 3.14–3.21 (2H, m), 3.45–3.59 (1H, m), 4.17–4.24 (2H, m), 4.44 (1H, s), 7.93 (1H, s), 8.15 (1H, s), 8.23 (1H, s), 8.33 (1H, s). MS-ESI <i>m</i>/<i>z</i> 460 [MH<sup>+</sup>].</div><div class="NLM_p last">To a solution of <b>64a</b> (0.12 g, 0.26 mmol) dissolved in DCM (3 mL) was added hydrochloric acid in dioxane (4 M; 1.29 mL, 5.17 mmol). The mixture was stirred at rt for 30 min before being concentrated under reduced pressure. The resulting residue was dissolved in DCM (2 mL) and treated with triethylamine (0.079 mL, 0.57 mmol) followed by acetic anhydride (0.029 mL, 0.31 mmol). The reaction mixture was stirred at rt for 0.5 h and then washed with water. The organic layer was concentrated under reduced pressure and purified by flash silica chromatography, elution gradient 0–10% MeOH in DCM. Product fractions were concentrated under reduced pressure to afford <b>13</b> (0.075 g, 72%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.09–1.22 (1H, m), 1.38–1.58 (2H, m), 1.88–2.03 (6H, m), 2.26 (1H, d), 2.43–2.56 (1H, m), 2.69 (2H, p), 3.14–3.21 (2H, m), 3.49 (1H, s), 3.87 (1H, dtt), 4.21 (2H, t), 5.59 (1H, d), 8.14 (1H, s), 8.22 (1H, s), 8.33 (1H, s), 8.43 (1H, s). MS-ESI <i>m</i>/<i>z</i> 402 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 402.1681 [MH<sup>+</sup>], C<sub>20</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub> requires 402.1691.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(5-chloro-4-(6,7-dihydro-5<i>H</i>-pyrrolo[1,2-<i>a</i>]imidazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>14</b>)</h4><div class="NLM_p last"><b>63</b> (130 mg, 0.31 mmol), (6,7-dihydro-5<i>H</i>-pyrrolo[1,2-<i>a</i>]imidazol-3-yl)boronic acid hydrochloride (145 mg, 0.77 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>), barium hydroxide (211 mg, 1.23 mmol) ,and PdCl<sub>2</sub>(dppf) (22 mg, 0.030 mmol) were suspended in dioxane (2 mL) and water (0.4 mL) and sealed into a microwave tube. The reaction was heated to 75 °C in a microwave reactor and maintained under these conditions for 2 h before being cooled to rt. The reaction mixture was filtered with a methanol wash, and the filtrate was then concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford <b>14</b> (21 mg, 17%) as a solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): 1.09 (1H, d), 1.30 (3H, q), 1.76–1.80 (5H, m), 1.91 (1H, d), 2.57–2.73 (4H, m), 2.85 (2H, t), 3.58 (1H, dd), 4.16 (2H, t), 7.55 (1H, s), 7.75 (1H, d), 8.35 (1H, s), 8.42 (1H, s), 10.67 (1H, s). MS-ESI <i>m</i>/<i>z</i> 402 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 402.1707 [MH<sup>+</sup>], C<sub>20</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub> requires 402.1691.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(5-chloro-4-(5,6,7,8-tetrahydro-4<i>H</i>-pyrazolo[1,5-<i>a</i>]azepin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>15</b>)</h4><div class="NLM_p">Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.16 g, 0.21 mmol) was added to a degassed mixture of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6,7,8-tetrahydro-4<i>H</i>-pyrazolo[1,5-<i>a</i>]azepine (0.656 g, 2.50 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>), <b>62</b> (1.00 g, 2.08 mmol) and potassium phosphate, tribasic (1.09 g, 6.25 mmol) in 1,4-dioxane (20 mL) and water (2 mL). The mixture was again degassed and was stirred at 85 °C for 24 h under nitrogen. The reaction mixture was allowed to cool, and silica added. This new mixture was concentrated under reduced pressure, and the resulting residue was purified by flash silica chromatography, eluting with 50% ethyl acetate in heptane to give <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(5,6,7,8-tetrahydro-4<i>H</i>-pyrazolo[1,5-<i>a</i>]azepin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate (<b>64b</b>, 0.70 g, 69%) as a solid. This material was carried on to the next step without further purification. MS-ESI <i>m</i>/<i>z</i> 488 [MH<sup>+</sup>].</div><div class="NLM_p last">TFA (2 mL) was added to a stirred solution of <b>64b</b> (700 mg, 1.43 mmol) in DCM (10 mL). The reaction was stirred at rt for 24 h, the volatiles removed under a vacuum, and the resulting residue was purified by ion exchange chromatography using an SCX-2 column, eluting with 7 N ammonia in methanol. Product fractions were concentrated under reduced pressure to afford crude (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(5-chloro-4-(5,6,7,8-tetrahydro-4<i>H</i>-pyrazolo[1,5-<i>a</i>]azepin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (550 mg) as a solid. A portion of this solid (450 mg, 1.16 mmol) was dissolved in DCM (10 mL) and triethylamine (0.34 mL, 2.4 mmol). Acetic anhydride (0.13 mL, 1.4 mmol) was added. The reaction mixture was stirred at rt for 4 h. Silica was added, and the mixture was concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, eluting with 0.5% methanol in ethyl acetate, to give <b>15</b> (260 mg, 52%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>): 1.05–1.12 (1H, m), 1.17–1.37 (3H, m), 1.57–1.66 (2H, m), 1.69–1.95 (11H, m), 2.56–2.65 (1H, m), 2.70–2.77 (2H, m), 3.50–3.61 (1H, m), 4.21–4.45 (2H, m), 7.48 (1H, s), 7.73 (1H, d), 8.05 (1H, s), 8.40 (1H, s), 10.58 (1H, s). MS-ESI <i>m</i>/<i>z</i> 430 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 430.2007 [MH<sup>+</sup>], C<sub>22</sub>H<sub>29</sub>ClN<sub>5</sub>O<sub>2</sub> requires 430.2004.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(5-chloro-4-(6,7-dihydro-4<i>H</i>-pyrazolo[5,1-<i>c</i>][1,4]oxazin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>16</b>)</h4><div class="NLM_p">A mixture of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-4<i>H</i>-pyrazolo[5,1-<i>c</i>][1,4]oxazine (0.094 g, 0.38 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>), <b>62</b> (0.120 g, 0.25 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.020 g, 0.03 mmol) and potassium phosphate dibasic (0.131 g, 0.75 mmol) in 1,4-dioxane (4 mL), and water (0.8 mL) was stirred at 50 °C for 1 h. The mixture was then diluted with EtOAc (30 mL). The resulting mixture was washed with water (10 mL), and the organic layer was concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0 to 70% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(6,7-dihydro-4H-pyrazolo[5,1-<i>c</i>][1,4]oxazin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>64c</b> (0.081 g, 68%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.22–1.35 (4H, m), 1.38 (9H, s), 1.75 (3H, s), 1.90 (1H, d), 2.54–2.63 (1H, m), 4.12–4.26 (4H, m), 4.90 (2H, s), 5.75 (1H, s), 6.76 (1H, d), 7.89 (1H, s), 8.01 (1H, s), 8.39 (1H, s), 10.58 (1H, s). MS-ESI <i>m</i>/<i>z</i> 476 [MH<sup>+</sup>].</div><div class="NLM_p last">To a mixture of <b>64c</b> (0.072 g, 0.15 mmol) suspended in DCM (3 mL) at room temperature was added HCl in dioxane (4 M; 0.756 mL, 3.03 mmol). The mixture became a solution which was stirred at room temperature for 30 min. The reaction was concentrated under reduced pressure to yield a solid. This solid was dissolved in DCM (2 mL), and the resulting solution was treated sequentially with triethylamine (0.047 mL, 0.33 mmol) and acetic anhydride (0.017 mL, 0.18 mmol) at room temperature. The reaction mixture was stirred at room temperature for 30 min and then concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 50 to 100% EtOAc in heptane, then 0 to 10% MeOH in DCM. Product fractions were concentrated under reduced pressure to afford <b>16</b> (0.056 g, 88%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.08 (1H, d), 1.29 (4H, q), 1.78 (1H, s), 1.91 (3H, s), 2.61 (2H, s), 3.57 (1H, dt), 4.08–4.27 (4H, m), 4.89 (2H, s), 7.74 (1H, d), 7.88 (1H, s), 8.01 (1H, s), 8.39 (1H, s), 10.59 (1H, s), 11.90 (1H, s). MS-ESI <i>m</i>/<i>z</i> 418 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 418.1640 [MH<sup>+</sup>], C<sub>20</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>3</sub> requires 418.1640.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(5-chloro-4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrazin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>17</b>)</h4><div class="NLM_p">A mixture of <b>62</b> (0.200 g, 0.42 mmol), 5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrazine (0.197 g, 0.750 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.033 g, 0.040 mmol), potassium phosphate dibasic (0.218 g, 1.25 mmol), 1,4-dioxane (4 mL), and water (0.8 mL) was stirred at 45 °C for 18 h. More chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.033 g, 0.04 mmol) was added, and the reaction temperature was raised to 60 °C for 1 h. The reaction mixture was then cooled and passed through an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane, then 0–10% MeOH in DCM. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrazin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>64d</b> (0.054 g, 27%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C): 1.04–1.19 (1H, m), 1.44 (12H, s), 1.87–2.02 (3H, m), 2.29 (1H, d), 2.33–2.46 (1H, m), 2.53 (3H, s), 2.95–3.00 (2H, m), 3.50 (1H, s), 3.76 (2H, s), 4.28 (2H, t), 4.52 (1H, s), 7.85 (1H, s), 8.12 (2H, s), 8.26 (1H, s). MS-ESI <i>m</i>/<i>z</i> 489 [MH<sup>+</sup>].</div><div class="NLM_p last">To a solution of <b>64d</b> (0.042 g, 0.090 mmol) dissolved in DCM (2 mL) was added HCl in dioxane (4 M; 0.429 mL, 1.72 mmol). The mixture was stirred at room temperature for 2 h before being concentrated under reduced pressure to afford a solid (33 mg). This solid was dissolved in DCM (2 mL) and triethylamine (0.026 mL, 0.19 mmol). Then acetic anhydride (9.6 μL, 0.10 mmol) was added. The mixture was stirred at room temperature for 30 min and then concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in (10% MeOH in DCM). Product fractions were concentrated under reduced pressure to afford <b>17</b> (0.027 g, 74%, 94% purity by HPLC) as a colorless dry film. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.09–1.24 (1H, m), 1.41–1.56 (3H, m), 1.87–2.04 (6H, m), 2.25 (1H, d), 2.51 (4H, s), 2.9–2.98 (2H, m), 3.73 (2H, s), 3.87 (1H, dtd), 4.26 (2H, t), 5.60 (1H, d), 7.84 (1H, s), 8.11 (1H, s), 8.25 (1H, d), 8.30 (1H, s). MS-ESI <i>m</i>/<i>z</i> 431 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 431.1955 [MH<sup>+</sup>], C<sub>21</sub>H<sub>28</sub>ClN<sub>6</sub>O<sub>2</sub> requires 431.1957.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>18</b>)</h4><div class="NLM_p">Crude 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>) was added to <b>62</b> (0.160 g, 0.33 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.026 g, 0.03 mmol) and potassium phosphate tribasic (0.175 g, 1.00 mmol) in 1,4-dioxane (4 mL) and water (0.8 mL) at 50 °C. The resulting mixture was stirred at 50 °C for 2 h and then at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue was redissolved in DCM (20 mL) and washed with water (20 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>64e</b> (0.082 g, 52%) as a yellow gum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.44 (12H, s), 1.82–2.46 (8H, m), 3.27–3.36 (3H, m), 4.12 (3H, t), 5.33 (1H, d), 7.80 (1H, s), 8.13 (1H, s), 8.19 (1H, s), 8.20 (1H, s). MS-ESI <i>m</i>/<i>z</i> 475 [MH<sup>+</sup>].</div><div class="NLM_p last"><b>64e</b> (0.086 g, 0.18 mmol) and HCl in dioxane (4 M; 0.362 mL, 1.45 mmol) were dissolved in methanol (2 mL) at room temperature under air. The resulting solution was stirred at room temperature for 3 h before being concentrated under reduced pressure. The resulting material (66 mg) was dissolved in triethylamine (0.081 mL, 0.58 mmol) in DCM (1 mL) at room temperature under nitrogen. Then 4-dimethylaminopyridine (1.14 mg, 9.3 μmol) was added followed by dropwise addition of acetic anhydride (0.021 mL, 0.22 mmol). The resulting solution was stirred at room temperature for 2 h before being quenched with saturated aqueous NH<sub>4</sub>Cl (10 mL). The resulting mixture was extracted with DCM (2 × 10 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting white solid was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane. Fractions were concentrated under reduced pressure to afford semipure product, which was further purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μm silica, 30 mm diameter, 100 mm length) using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to afford <b>18</b> (9.8 mg, 13%, 94% purity by HPLC). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.13 (1H, dd), 1.31–1.52 (4H, m), 1.87–1.95 (2H, m), 1.96 (4H, s), 2.20 (3H, dd), 2.39–2.5 (1H, m), 3.39–3.45 (2H, m), 4.16 (2H, t), 4.81 (1H, s), 5.49 (1H, d), 7.79 (1H, s), 8.14 (1H, s), 8.19 (1H, s), 8.30 (1H, s). MS-ESI <i>m</i>/<i>z</i> 417 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 417.1796 [MH<sup>+</sup>], C<sub>20</sub>H<sub>26</sub>ClN<sub>6</sub>O<sub>2</sub> requires 417.1800.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(5-chloro-4-(6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>19</b>)</h4><div class="NLM_p last"><b>61</b> (0.100 g, 0.27 mmol) was added in one portion to a degassed mixture of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazine (0.067 g, 0.27 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.021 g, 0.03 mmol), potassium phosphate (0.170 g, 0.80 mmol), 1,4-dioxane (2.3 mL) and water (0.45 mL) at room temperature. The resulting mixture was stirred at room temperature for 16 h and then concentrated under reduced pressure before being purified by ion exchange chromatography using an SCX-2 cartridge. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure. The resulting residue was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length) using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to afford <b>19</b> (0.017 g, 16%) as a white gum. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): 1.21–1.32 (1H, m), 1.4–1.53 (3H, m), 1.95 (1H, s), 1.96 (3H, s), 2.06 (1H, d), 2.39–2.48 (2H, m), 2.7–2.85 (3H, m), 3.74 (1H, dt), 4.34 (2H, t), 4.53–4.68 (2H, m), 7.93 (1H, d), 8.05 (1H, s), 8.48 (1H, d), 8.58 (1H, s), 10.62 (1H, s). MS-ESI <i>m</i>/<i>z</i> 418 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 418.1639 [MH<sup>+</sup>], C<sub>20</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>3</sub> requires 418.1640.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>20</b>)</h4><div class="NLM_p"><b>40</b> (1.50 g, 3.77 mmol), potassium acetate (1.11 g, 11.3 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.44 g, 5.65 mmol), and PdCl<sub>2</sub>(dppf) (0.276 g, 0.380 mmol) were charged to a flask. 1,4-Dioxane (30 mL) was added, and the mixture was heated at 90 °C under nitrogen for 3 h. The mixture was allowed to cool, and the solids were removed by filtration. Ethyl acetate (100 mL) and water (50 mL) were added, and the layers were separated. The aqueous layer was extracted with EtOAc (2 × 50 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>43</b> (2.76 g) as a dark brown oil. This oil was used directly in the next step without further purification. MS-ESI <i>m</i>/<i>z</i> 446 [MH<sup>+</sup>].</div><div class="NLM_p">Dichloro[1,1′-bis(di-t-butylphosphino)ferrocene]palladium(II) (44 mg, 0.070 mmol) was added to a degassed solution of <b>43</b> (300 mg, 0.67 mmol), 3-iodo-5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridine (242 mg, 0.88 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>) and potassium phosphate, tribasic (429 mg, 2.02 mmol) in 1,4-dioxane (10 mL), and water (1 mL). The resulting mixture was stirred at 90 °C for 18 h. The crude reaction was cooled and purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure to afford a brown oil. This oil was purified by flash silica chromatography, elution gradient 0–100% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate (<b>44a</b>, 170 mg, 54%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.03 (6H, s), 1.04–1.15 (1H, m), 1.21–1.41 (12H, m), 1.72–1.81 (3H, m), 1.83–1.92 (3H, m), 2.53–2.62 (1H, m), 2.65–2.69 (2H, m), 3.30 (2H, m), 4.16 (2H, t), 6.76 (1H, br d), 7.76 (1H, d), 8.19 (1H, d), 8.29 (1H, d), 10.43 (1H, s). MS-ESI <i>m</i>/<i>z</i> 468 [MH<sup>+</sup>].</div><div class="NLM_p">Trifluoroacetic acid (1 mL) was added to <b>44a</b> (170 mg, 0.36 mmol) in DCM (10 mL). The resulting mixture was stirred at rt for 6 h. The reaction was then concentrated under reduced pressure, and the resulting residue was subjected to ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 2 M NH<sub>3</sub> in MeOH. Product fractions were concentrated under reduced pressure, and the resulting residue was purified by flash silica chromatography, eluting with 7% (1% ammonia in methanol) in DCM to afford (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (70 mg, 52%) as a solid. MS-ESI <i>m</i>/<i>z</i> 368 [MH<sup>+</sup>].</div><div class="NLM_p last">Acetic anhydride (0.022 mL, 0.23 mmol) was added to a stirred solution of (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyridin-2-yl)cyclohexanecarboxamide (70 mg, 0.19 mmol), triethylamine (0.056 mL, 0.40 mmol), and <i>N</i>,<i>N</i>-dimethylpyridin-4-amine (1.2 mg, 9.5 μmol) in DCM (10 mL). The reaction mixture was stirred at rt for 4 h, and the crude reaction was purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH and product fractions were concentrated under reduced pressure. The resulting residue was further purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure to afford <b>20</b> (44 mg, 56%) as a solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): 1.04 (6H, s), 1.06–1.15 (1H, m), 1.32–1.38 (3H, m), 1.66–1.82 (6H, m), 1.83–1.94 (3H, m), 2.58–2.64 (1H, m), 2.78 (2H, s), 3.54–3.62 (1H, m), 4.14 (2H, t), 7.16 (1H, dd), 7.76 (1H, d), 7.84 (1H, s), 8.18 (1H, s), 8.24 (1H, d), 10.34 (1H, s). MS-ESI <i>m</i>/<i>z</i> 410 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 410.2547 [MH<sup>+</sup>], C<sub>23</sub>H<sub>32</sub>N<sub>5</sub>O<sub>2</sub> requires 410.2551.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide (<b>21</b>)</h4><div class="NLM_p"><b>45</b> (1.55 g, 6.03 mmol), 5,5-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridine (<b>49</b>, 2.0 g, 7.2 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.48 g, 0.60 mmol) and potassium phosphate, dibasic (3.15 g, 18.1 mmol) were dissolved in degassed dioxane (20 mL) and water (1 mL) at 21 °C. The mixture was stirred at 90 °C for 24 h and then allowed to cool to room temperature. The mixture was diluted with EtOAc (30 mL), washed with water (10 mL), and the organic layer was concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–50% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford 3-(2-chloro-5-fluoropyridin-4-yl)-5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridine <b>50</b> (1.3 g, 77%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.10 (6H, s), 1.89 (2H, m), 2.68 (2H, s), 4.26 (2H, t), 7.27 (1H, d), 7.80 (1H, d), 8.23 (1H, d). MS-ESI <i>m</i>/<i>z</i> 280 [MH<sup>+</sup>].</div><div class="NLM_p">Tetrakis(triphenylphosphine)palladium(0) (0.496 g, 0.43 mmol) was added to <b>50</b> (1.2 g, 4.29 mmol), <b>47</b> (1.04 g, 4.29 mmol), 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (0.496 g, 0.86 mmol), and cesium carbonate (4.19 g, 12.9 mmol) in 1,4-dioxane (10 mL). The resulting mixture was degassed for 5 min under nitrogen and then subjected to microwave conditions (120 °C; 17 h). The reaction mixture was diluted with water (20 mL) and ethyl acetate (100 mL) before being filtered. The layers were separated, and the organic layer was adsorbed onto silica and purified by flash silica chromatography, eluting with isocratic 50% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)-5-fluoropyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>51</b> (1.1 g, 53%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.03 (6H, s), 1.02–1.14 (1H, m), 1.20–1.35 (3H, m), 1.39 (9H, s), 1.70–1.79 (3H, br m), 1.82–1.92 (3H, m), 2.54–2.63 (1H, m), 2.68 (2H, s), 4.16 (2H, t), 6.76 (1H, br d), 7.76 (1H, d), 8.19 (1H, d), 8.29 (1H, d), 10.43 (1H, s). 1H multiplet under water peak. MS-ESI <i>m</i>/<i>z</i> 486 [MH<sup>+</sup>].</div><div class="NLM_p">TFA (2 mL) was added to a solution of <b>51</b> (1.1 g, 2.27 mmol) in DCM (20 mL). The resulting mixture was stirred at ambient temperature for 24 h, and then the reaction was concentrated under reduced pressure. The resulting residue was purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column with 7 N NH<sub>3</sub> in MeOH. Product fractions were concentrated under reduced pressure to afford (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide (0.87 g, 100%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.01–1.12 (7H, m), 1.31–1.49 (3H, m), 1.83–1.99 (5H, m), 2.14 (1H, d), 2.35 (1H, td), 2.66–2.85 (3H, m), 4.23 (2H, t), 7.85 (1H, d), 7.99–8.18 (2H, m), 8.29 (1H, d). NH<sub>2</sub> signal not observed. MS-ESI <i>m</i>/<i>z</i> 386 [MH<sup>+</sup>].</div><div class="NLM_p last">Acetic anhydride (0.088 mL, 0.93 mmol) was added to a stirred solution of (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(4-(5,5-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyridin-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide (300 mg, 0.78 mmol), triethylamine (0.23 mL, 1.6 mmol) and DCM (10 mL). The reaction mixture was stirred at ambient temperature for 4 h. Silica was added, and the volatiles were removed by concentration under reduced pressure. The resulting residue was purified by flash silica chromatography, eluting with 0.5% methanol in ethyl acetate, to afford <b>21</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.03 (6H, s), 1.02–1.14 (1H, m), 1.24–1.38 (3H, m), 1.72–1.81 (6H, m), 1.86–1.91 (3H, m), 2.55–2.64 (1H, m), 2.69 (2H, s), 3.52–3.64 (1H, m), 4.16 (2H, t), 7.64–7.81 (2H, m), 8.19 (1H, d), 8.29 (1H, d), 10.45 (1H, s). MS-ESI <i>m</i>/<i>z</i> 428 [MH<sup>+</sup>]. <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): 22.75, 24.03, 27.03, 27.06, 28.29, 28.49, 31.91, 34.37, 35.12, 36.14, 43.38, 44.81, 46.93, 109.90, 112.12, 129.97, 135.67, 137.69, 138.80, 148.78, 152.23, 168.07, 174.12. HRMS-ESI: <i>m</i>/<i>z</i> found 428.2459 [MH<sup>+</sup>], C<sub>23</sub>H<sub>31</sub>FN<sub>5</sub>O<sub>2</sub> requires 428.2456.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(4-(5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>22</b>)</h4><div class="NLM_p">Dichloro[1,1′-bis(di-<i>t</i>-butylphosphino)ferrocene]palladium(II) (45.5 mg, 0.07 mmol) was added to a degassed solution of <b>43</b> (518 mg, 0.70 mmol), 3-bromo-5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazole (<b>68</b>, 150 mg, 0.70 mmol; see preparation as an intermediate in the synthesis of <b>23</b>), and potassium phosphate tribasic (444 mg, 2.09 mmol) in 1,4-dioxane (5 mL) and water (0.5 mL). The resulting mixture was stirred at 90 °C for 18 h and then purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and pure fractions were concentrated under reduced pressure to afford crude product as a brown oil. This oil was purified by flash silica chromatography, elution gradient 0–100% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-(5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>44b</b> (100 mg, 31%) as a white solid. MS-ESI <i>m</i>/<i>z</i> 454 [MH<sup>+</sup>].</div><div class="NLM_p last"><b>44b</b> (93 mg, 0.21 mmol) was dissolved in HCl in dioxane (4 M; 0.436 mL, 1.74 mmol) and MeOH (5 mL), and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was then purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure. The resulting residue was further purified by flash silica chromatography, elution gradient 0–10% (7 N ammonia in methanol) in DCM. Product fractions were concentrated under reduced pressure to afford (1<i>S</i>,3<i>R</i>)-3-amino<i>-N-</i>(4-(5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (68 mg, 94%) as a white solid. MS-ESI <i>m</i>/<i>z</i> 354 [MH<sup>+</sup>]. To a stirred solution of (1<i>S</i>,3<i>R</i>)-3-amino<i>-N-</i>(4-(5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (65 mg, 0.18 mmol), triethylamine (0.054 mL, 0.39 mmol) and <i>N,N-</i>dimethylpyridin-4-amine (1.12 mg, 9.2 μmol) in DCM (5 mL) was added acetic anhydride (0.021 mL, 0.22 mmol). The reaction mixture was stirred at room temperature for 1 h and then purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure to afford <b>22</b> (60.0 mg, 82.0%) as a colorless oil which was crystallized from an ether/heptane mix to afford a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.10 (1H, t), 1.29 (9H, s), 1.79 (6H, s), 1.85–1.94 (1H, m), 2.57–2.66 (1H, m), 2.93 (2H, s), 3.58 (1H, dt), 3.90 (2H, s), 7.21 (1H, dd), 7.74 (1H, d), 7.96 (1H, s), 8.18–8.24 (2H, m), 10.32 (1H, s). MS-ESI <i>m</i>/<i>z</i> 396 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 396.2393 [MH<sup>+</sup>], C<sub>22</sub>H<sub>30</sub>N<sub>5</sub>O<sub>2</sub> requires 396.2394.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(4-(5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)-5-fluoropyridin-2-yl)cyclohexanecarboxamide (<b>23</b>)</h4><div class="NLM_p">1<i>H</i>-Pyrazole (20 g, 293.78 mmol), ethyl 3-bromo-2,2-dimethylpropanoate (61.4 g, 293.78 mmol), and cesium carbonate (144 g, 440.68 mmol) in DMA (200 mL) were stirred at 80 °C for 16 h. The mixture was then poured into water (400 mL) and extracted with ethyl acetate (150 mL). The organic layer was concentrated under reduced pressure to give a colorless oil. This oil was purified by flash silica chromatography, elution gradient 10 to 40% ethyl acetate in heptane). Product fractions were concentrated under reduced pressure to afford ethyl 2,2-dimethyl-3-(1<i>H</i>-pyrazol-1-yl)propanoate (46.0 g, 80.0%), as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 0.97 (6H, s), 1.02 (3H, t), 3.93 (2H, q), 4.10 (2H, s), 6.00 (1H, t), 7.16 (1H, d), 7.26 (1H, d). MS-ESI <i>m</i>/<i>z</i> 197 [MH<sup>+</sup>].</div><div class="NLM_p">Aqueous sodium hydroxide (5 M; 94 mL, 46 mmol) was added portion-wise to a stirred solution of ethyl 2,2-dimethyl-3-(1<i>H</i>-pyrazol-1-yl)propanoate (46 g, 234 mmol) dissolved in methanol (250 mL) at room temperature. The mixture was allowed to exotherm to 37 °C during addition. The resulting solution was stirred under these conditions for 30 min and then cooled to room temperature before being concentrated under reduced pressure to 1/3 volume. This new solution was acidified to ∼pH 3 with concentrated aqueous HCl. A colorless oil separated from the mixture. The flask was swirled in an ice bath, and a colorless solid crystallized. The mixture was allowed to stand overnight at room temperature. The solid was isolated by filtration and dried under reduced pressure to afford 2,2-dimethyl-3-(1<i>H</i>-pyrazol-1-yl)propanoic acid <b>65</b> (30.0 g, 76%) as a colorless crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.05 (6H, s), 4.23 (2H, s), 6.21 (1H, t), 7.35–7.44 (1H, m), 7.54–7.67 (1H, m), 12.41 (1H, br s). MS-ESI <i>m</i>/<i>z</i> 169 [MH<sup>+</sup>].</div><div class="NLM_p"><i>n</i>-BuLi in hexane (9.03 mL, 24.4 mmol) was added dropwise to <b>65</b> (2.0 g, 12 mmol) in 2-methyl tetrahydrofuran (40 mL) at −78 °C over a period of 20 min under nitrogen. The resulting suspension was stirred at −78 °C for 15 min, and then the reaction was stirred at approximately −45 °C for 1 h. The mixture was allowed to warm to 15 °C before the reaction was quenched slowly onto ice-cold saturated ammonium chloride (100 mL). The reaction mixture was diluted with EtOAc (100 mL), and the ammonium chloride layer was separated and extracted with EtOAc (50 mL). The combined organic layers were washed with saturated aqueous sodium chloride (50 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford 5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-4-one <b>66</b> (0.97 g, 54%) as a pale-yellow oil which crystallized on standing. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>): 1.29 (6H, s), 4.36 (2H, s), 6.77 (1H, d), 7.89 (1H, d). MS-ESI <i>m</i>/<i>z</i> 151 [MH<sup>+</sup>].</div><div class="NLM_p">Hydrazine hydrate (4.13 mL, 85.2 mmol) was added to a stirred solution of <b>66</b> (2.56 g, 17.1 mmol) dissolved in 2,2′-oxydiethanol (48.5 mL, 511 mmol). The resulting solution was stirred at 180 °C for 1 h. Potassium hydroxide (3.35 mL, 59.7 mmol) was carefully added to the mixture, and the resulting suspension was stirred at 150 °C for 2 h. After being cooled to room temperature, the reaction mixture was diluted with water (50 mL), and the pH was adjusted to 4.5 with aqueous HCl (2 N). Following extraction with Et<sub>2</sub>O (5 × 50 mL), the combined organic layers were washed with water (2 × 20 mL) and then saturated aqueous sodium chloride (20 mL). The organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to give 5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazole <b>67</b> (0.922 g, 40%) as a clear yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.21 (6H, s), 2.61 (2H, s), 3.80 (2H, s), 5.82–5.93 (1H, m), 7.41 (1H, d).</div><div class="NLM_p"><i>N</i>-Bromosuccinimide (1.17 g, 6.55 mmol) was added to a stirred solution of <b>67</b> (892 mg, 6.55 mmol) dissolved in DCM (10 mL) at 23 °C. The resulting mixture was stirred at 23 °C for 16 h before being diluted with DCM (20 mL) and washed sequentially with water (2 × 20 mL) and saturated aqueous sodium chloride (20 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford 3-bromo-5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazole <b>68</b> (1.39 g, 99%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.23 (6H, s), 2.58 (2H, s), 3.83 (2H, s), and 7.35 (1H, s).</div><div class="NLM_p">Pd(P(Cy)<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.25 g, 0.33 mmol) was added to 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.70 g, 6.69 mmol), <b>68</b> (0.720 g, 3.35 mmol), and potassium acetate (1.15 g, 11.7 mmol) in DMA (7 mL). The resulting suspension was degassed and stirred at 85 °C for 5 h. Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium DCM adduct (0.273 g, 0.33 mmol) was then added to the reaction mixture, and stirring was continued under these conditions for 18 h before the reaction mixture was cooled to rt. The reaction mixture was diluted with EtOAc (20 mL) and washed sequentially with water (2 × 15 mL), and saturated aqueous sodium chloride (15 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude product was purified by flash silica chromatography, elution gradient 0–50% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford 5,5-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazole <b>69</b> (0.458 g, 52%) as a cream-colored solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.24 (6H, s), 1.27 (12H, s), 2.79 (2H, s), 3.87 (2H, s), and 7.76 (1H, s).</div><div class="NLM_p"><b>45</b> (1.00 g, 3.88 mmol), <b>69</b> (1.53 g, 5.83 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.31 g, 0.39 mmol), and dibasic potassium phosphate (2.03 g, 11.65 mmol) were dissolved in degassed dioxane (10 mL) and water (2 mL) at 21 °C. The reaction mixture was stirred at 80 °C for 3 h, and then the mixture was cooled, diluted with EtOAc (30 mL), and washed with water (10 mL). The organic layer was concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–50% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford 3-(2-chloro-5-fluoropyridin-4-yl)-5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazole <b>70</b> (1.00 g, 97%) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): 1.36 (6H, s), 2.95 (2H, d), 3.97 (2H, s), 7.31 (1H, d), 7.94 (1H, d), 8.20 (1H, d). MS-ESI <i>m</i>/<i>z</i> 266 [MH<sup>+</sup>].</div><div class="NLM_p last">Tetrakis(triphenylphosphine)palladium(0) (0.13 g, 0.12 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.13 g, 0.23 mmol) were added together in one portion to a degassed mixture of <b>47</b> (0.670 g, 2.76 mmol), <b>70</b> (0.61 g, 2.3 mmol), cesium carbonate (1.88 g, 5.76 mmol), and 1,4-dioxane (26 mL). The mixture was rapidly heated to reflux. After 20 h, the reaction was cooled, diluted with 50% saturated aqueous sodium chloride, and extracted with ethyl acetate (2×). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford crude <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((4-(5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)-5-fluoropyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>71</b> as a light-yellow solid. Hydrochloric acid in dioxane (4 M; 10 mL, 40 mmol) and DCM (5 mL) was added, resulting in a clear orange solution that rapidly became cloudy and yellow. Methanol (∼3 mL) was titrated into the reaction until the mixture became mostly clear. After 15 min, the orange mixture was concentrated under reduced pressure to afford an orange solid. Pyridine (3.7 mL, 46 mmol) was added to this solid along with DCM (19 mL). A slight exotherm was noted, and the reaction was immersed in a water bath. Then acetic anhydride (0.43 mL, 4.6 mmol) was added dropwise. After another 10 min, another 200 μL of acetic anhydride was added. After another 30 min, another 600 μL of anhydride and 6 mL of pyridine were added. The reaction was maintained under these conditions for another 45 min and was then poured into saturated aqueous sodium bicarbonate and ethyl acetate. The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting orange residue was purified by flash silica chromatography, elution gradient 50 to 100% EtOAc in hexane followed by 0–20% methanol in ethyl acetate, and product fractions were concentrated under reduced pressure to afford <b>23</b> (0.89 g, 94%) as a faint yellow foam solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 1.00–1.16 (1H, m), 1.22–1.40 (9H, m), 1.74–1.81 (6H, m), 1.83–1.94 (1H, m), 2.55–2.68 (1H, m), 2.93 (2H, s), 3.49–3.65 (1H, m), 3.94 (s, 2H), 7.75 (1H, d), 7.88 (1H, d), 8.28 (1H, d), 8.30 (1H, d), 10.46 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): 22.75, 24.03, 27.55, 28.25, 31.90, 35.21, 42.99, 43.38, 46.94, 60.23, 107.64, 109.96, 129.59, 135.86, 141.88, 144.44, 148.96, 151.91, 168.07, 174.18. HRMS-ESI: <i>m</i>/<i>z</i> found 414.2302 [MH<sup>+</sup>], C<sub>22</sub>H<sub>29</sub>FN<sub>5</sub>O<sub>2</sub> requires 414.2300.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (1<i>S</i>,3<i>R</i>)-3-Acetamido<i>-N-</i>(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>24</b>)</h4><div class="NLM_p">A mixture of <b>69</b> (433 mg, 0.83 mmol), <b>62</b> (360 mg, 0.75 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (59 mg, 0.08 mmol), and potassium phosphate dibasic (392 mg, 2.25 mmol) in 1,4-dioxane (4 mL) and water (0.8 mL) was stirred at 50 °C for 5 h. The reaction mixture was cooled to room temperature and then purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate <b>72</b> (188 mg, 51%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.25 (12H, d), 1.37 (7H, s), 1.74 (3H, s), 1.87 (1H, d), 2.52–2.62 (1H, m), 2.88 (2H, s), 3.18–3.29 (1H, m), 3.93 (2H, s), 6.80 (1H, d), 7.99 (1H, s), 8.24 (1H, s), 8.32–8.35 (1H, m), 10.56 (1H, s). MS-ESI <i>m</i>/<i>z</i> 488 [MH<sup>+</sup>].</div><div class="NLM_p last"><b>72</b> (186 mg, 0.380 mmol) was dissolved in HCl in dioxane (4 M; 0.81 mL, 3.2 mmol) and MeOH (5 mL), and the resulting solution was stirred at room temperature for 18 h. The reaction mixture was then purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure to afford (1<i>S</i>,3<i>R</i>)-3-amino<i>-N-</i>(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (114 mg, 77%) as a white solid. This material was used directly in the next step. MS-ESI <i>m</i>/<i>z</i> 388 [MH<sup>+</sup>]. This solid was dissolved in DCM (10 mL) and triethylamine (0.084 mL, 0.60 mmol) and <i>N,N-</i>dimethylpyridin-4-amine (1.7 mg, 0.010 mmol) were added. Then acetic anhydride (0.032 mL, 0.34 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 4 h and then purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <b>24</b> (86 mg, 70%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.09 (1H, d), 1.28 (9H, s), 1.78 (6H, s), 1.90 (1H, d), 2.62 (1H, s), 2.89 (2H, s), 3.57 (1H, dt), 3.95 (2H, s), 7.73 (1H, d), 7.99 (1H, s), 8.25 (1H, s), 8.33–8.36 (1H, m), 10.53 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): 23.23, 24.50, 27.95, 28.72, 32.37, 35.60, 43.63, 43.94, 47.40, 60.74, 111.50, 112.56, 122.30, 140.86, 142.35, 145.18, 148.50, 151.56, 168.56, 174.99. MS-ESI <i>m</i>/<i>z</i> 430 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 430.2003 [MH<sup>+</sup>], C<sub>22</sub>H<sub>29</sub>ClN<sub>5</sub>O<sub>2</sub> requires 430.2004.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Isomer 1 and Isomer 2 of (1<i>S</i>,3<i>R</i>)-3-acetamido-<i>N</i>-(5-chloro-4-(5-methyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>27</b> and <b>28</b>)</h4><div class="NLM_p">Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.25 g, 0.31 mmol) was added to a degassed mixture of 5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-<i>b</i>]pyrazole (1.03 g, 3.75 mmol; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">Supporting Information</a>), <b>62</b> (1.50 g, 3.13 mmol), and dibasic potassium phosphate (1.63 g, 9.38 mmol) in 1,4-dioxane (15 mL) and water (3 mL). The resulting mixture was degassed and then stirred at 90 °C for 18 h under nitrogen. The reaction mixture was allowed to cool to rt, diluted with EtOAc (100 mL) and washed sequentially with water (100 mL) and saturated aqueous sodium chloride (50 mL). The organic extract was dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, elution gradient 0–70% EtOAc in heptane. Product fractions were concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>R</i>,3<i>S</i>)-3-((5-chloro-4-(5-methyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)carbamoyl)cyclohexyl)carbamate (<b>64f</b>, 1.0 g, 69%) as a yellow foam. <sup>1</sup>H NMR (400 MHz, DMSO): 1.08 (2H, s), 1.22–1.3 (6H, m), 1.38 (9H, s), 1.76 (3H, s), 1.90 (1H, d), 2.53–2.75 (2H, m), 3.2–3.3 (2H, m), 3.76 (1H, dd), 4.32 (1H, dd), 6.76 (1H, d), 8.00 (1H, s), 8.27 (1H, s), 8.31–8.38 (1H, m), 10.52 (1H, s). MS-ESI <i>m</i>/<i>z</i> 475 [MH<sup>+</sup>].</div><div class="NLM_p"><b>64f</b> (1.11 g, 2.34 mmol) was dissolved in DCM (20 mL). Trifluoroacetic acid (1.8 mL, 23 mmol) was added, and the reaction mixture was stirred at rt for 18 h. The reaction was purified by ion exchange chromatography using an SCX-2 column. The desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH, and product fractions were concentrated under reduced pressure to afford (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(5-chloro-4-(5-methyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (0.68 g, 77%) as a white solid. MS-ESI <i>m</i>/<i>z</i> 374 [MH<sup>+</sup>].</div><div class="NLM_p">Acetic anhydride (0.20 mL, 2.2 mmol) was added to a stirred solution of (1<i>S</i>,3<i>R</i>)-3-amino-<i>N</i>-(5-chloro-4-(5-methyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (670 mg, 1.79 mmol), triethylamine (0.52 mL, 3.8 mmol) and <i>N</i>,<i>N</i>-dimethylpyridin-4-amine (11 mg, 0.09 mmol) in DCM (10 mL). The reaction mixture was stirred at rt for 18 h. The mixture was purified by ion exchange chromatography using an SCX-2 column, and the desired product was eluted from the column using 1 M NH<sub>3</sub> in MeOH. Product fractions were concentrated under reduced pressure. The resulting residue was purified by flash silica chromatography, using an elution gradient of 0 to 100% EtOAc in heptane followed by isocratic 10% MeOH in EtOAc. Product fractions were concentrated under reduced pressure to afford (1<i>S</i>,3<i>R</i>)-3-acetamido-<i>N</i>-(5-chloro-4-(5-methyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (693 mg, 93%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.05–1.11 (1H, m), 1.23 (3H, d), 1.27–1.38 (3H, m), 1.72–1.81 (6H, m), 1.89 (1H, br d), 2.52–2.63 (1H, m), 2.67 (1H, dd), 3.13–3.19 (1H, m), 3.20–3.28 (1H, m), 3.50–3.63 (1H, m), 3.76 (1H, dd), 4.27–4.37 (1H, m), 7.75 (1H, d), 8.00 (1H, s), 8.27 (1H, s), 8.35 (1H, s), 10.55 (1H, s). MS-ESI <i>m</i>/<i>z</i> 416 [MH<sup>+</sup>].</div><div class="NLM_p">(1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(5-chloro-4-(5-methyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (670 mg, 1.79 mmol) was resolved by preparative HPLC (Chiral Technologies IA column, 20 μm silica, 100 mm diameter, 250 mm length), using a 70/15/15 mixture of heptane/EtOH/MeOH as eluents and a flow rate of 450 mL/min, fractions containing the desired compounds were concentrated under reduced pressure to give the faster eluting isomer 1 of (1<i>S</i>,3<i>R</i>)-3-acetamido-<i>N</i>-(5-chloro-4-(5-methyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>27</b>, 356 mg, 48%, 99.3% e.e.) and the slower eluting isomer 2 of (1<i>S</i>,3<i>R</i>)-3-acetamido-<i>N</i>-(5-chloro-4-(5-methyl-5,6-dihydro-4<i>H</i>-pyrrolo[1,2-<i>b</i>]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>28</b>, 348 mg, 47%, 97.5% e.e.).</div><div class="NLM_p"><b>27:</b><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.05–1.15 (1H, m), 1.25 (3H, d), 1.26–1.39 (3H, m), 1.72–1.83 (6H, m), 1.90 (1H, br d), 2.55–2.62 (1H, m), 2.67 (1H, dd), 3.11–3.19 (1H, m), 3.21–3.28 (1H, m), 3.51–3.62 (1H, m), 3.76 (1H, dd), 4.27–4.37 (1H, m), 7.75 (1H, d br), 8.00 (1H, s), 8.27 (1H, s), 8.35 (1H, s), 10.55 (1H, s). MS-ESI <i>m</i>/<i>z</i> 416 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 416.1860 [MH<sup>+</sup>], C<sub>21</sub>H<sub>27</sub>ClN<sub>5</sub>O<sub>2</sub> requires 416.1848.</div><div class="NLM_p"><b>28:</b><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 1.08–1.13 (1H, m), 1.24 (3H, d), 1.25–1.36 (3H, m), 1.62–1.85 (6H, m), 1.91 (1H, br d), 2.52–2.61 (1H, m), 2.67 (1H, dd), 3.13–3.19 (1H, m), 3.21–3.29 (1H, m), 3.51–3.60 (1H, m), 3.76 (1H, dd), 4.32 (1H, dd), 7.74 (1H, d), 7.98 (1H, s), 8.28 (1H, s), 8.34 (1H, s), 10.54 (1H, s). MS-ESI <i>m</i>/<i>z</i> 416 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 416.1849 [MH<sup>+</sup>], C<sub>21</sub>H<sub>27</sub>ClN<sub>5</sub>O<sub>2</sub> requires 416.1848.</div><div class="NLM_p last">Analytical HPLC: flow: 2 mL/min, column: Chiral Technologies IA, 5 μ, 4.6 × 250 mm, eluent: 1:1 ethanol/methanol in heptane), <i>t</i><sub>R</sub>: (<b>27</b>, 7.9 min), (<b>28</b>, 9.3 min).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (1<i>S</i>,3<i>R</i>)-3-Acetamido-<i>N</i>-(5-chloro-4-(6,6-dimethyl-6,7-dihydro-5<i>H</i>-pyrrolo[1,2-<i>a</i>]imidazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide (<b>29</b>)</h4><div class="NLM_p last"><b>63</b> (800 mg, 1.90 mmol), 6,6-dimethyl-6,7-dihydro-5H-pyrrolo[1,2-<i>a</i>]imidazole (825 mg, 5.69 mmol; see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>), palladium acetate (171 mg, 0.76 mmol), and potassium acetate (372 mg, 3.79 mmol) were suspended in DMA (15 mL) and sealed into a microwave tube. The tube was degassed and purged with nitrogen (3×). The reaction was then subjected to microwave conditions (150 °C, 16 h) and cooled to rt. The reaction mixture was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5 μ silica, 30 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>3</sub>) and MeCN as eluents. Fractions containing the desired compound were concentrated under reduced pressure. The resulting light brown solid was recrystallized using EtOAc/heptane and dried under a vacuum to give <b>29</b> (180 mg, 22%) as a white solid. The filtrate was concentrated under reduced pressure to provide a second batch of <b>29</b> (118 mg, 14%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): 1.03–1.16 (1H, m), 1.19–1.41 (9H, m), 1.72–1.81 (6H, m), 1.91 (1H, br. d), 2.57–2.68 (1H, m), 2.71 (2H, s), 3.50–3.62 (1H, m), 3.91 (2H, s), 7.51 (1H, s), 7.75 (1H, d), 8.28 (1H, s), 8.42 (1H, s), 10.66 (1H, s). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): 22.74, 24.01, 27.31, 28.24, 31.86, 35.05, 38.10, 43.14, 43.47, 46.91, 58.27, 111.18, 121.37, 123.87, 134.70, 136.99, 148.20, 151.12, 155.97, 168.09, 174.68. MS-ESI <i>m</i>/<i>z</i> 430 [MH<sup>+</sup>]. HRMS-ESI: <i>m</i>/<i>z</i> found 430.2006 [MH<sup>+</sup>], C<sub>22</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub> requires 430.2004.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01754" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40873" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40873" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01754?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01754</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures for the synthesis and characterization of intermediates and metabolites <b>6-M1</b>, <b>6-M2</b>, <b>24-M1</b>, and <b>24-M2</b>; crystal structure of compound <b>24</b> bound to CDK9 in complex with cyclin T1; ligand docking protocol; procedures for determination of DMPK properties; protocol for human PK predictions and clinical dose projections; biological testing protocol, data, and associated errors (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf">jm0c01754_si_001.pdf (1.36 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_002.csv">jm0c01754_si_002.csv (3.28 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of the crystal structure of compound <b>24</b> bound to CDK9 in complex with cyclin T1 have been deposited under the following code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Z45">6Z45</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01754" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernard Barlaam</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0904-7556" title="Orcid link">http://orcid.org/0000-0002-0904-7556</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d4b6b1a6bab5a6b0fab6b5a6b8b5b5b9e694b5a7a0a6b5aeb1bab1b7b5fab7bbb9"><span class="__cf_email__" data-cfemail="89ebecfbe7e8fbeda7ebe8fbe5e8e8e4bbc9e8fafdfbe8f3ece7eceae8a7eae6e4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Casella</span> - <span class="hlFld-Affiliation affiliation">Advanced
Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justin Cidado</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Calum Cook</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chris De Savi</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span>Present Address:
                        (C.D.S., N.O., B.Y.) Kymera Therapeutics, Kymera Therapeutics, 200 Arsenal Yards, Suite 230, Watertown, MA, 02472, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allan Dishington</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Craig S. Donald</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span>; 
    <span>Present Address:
                        (C.S.D.) Lucideon Limited, Queens Road, Penkhull, Stoke-on-Trent, ST4 7LQ, UK</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Drew</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew D. Ferguson</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span>Present Address:
                        (A.D.F.) X-Chem Inc., 100 Beaver Street, Waltham, MA 02453, USA</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1018-9631" title="Orcid link">http://orcid.org/0000-0002-1018-9631</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas Ferguson</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Glossop</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span>; 
    <span>Present Address:
                        (S.G.) Sai Life Sciences, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tyler Grebe</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chungang Gu</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span>Present Address:
                        (C.G.) Biogen Inc., 225 Binney Street, Cambridge, MA 02142, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sudhir Hande</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janet Hawkins</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander W. Hird</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span>Present Address:
                        (A.W.H.) C4 Therapeutics, 490 Arsenal Way, Suite 200, Watertown, MA 02472, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane Holmes</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Horstick</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yun Jiang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle L. Lamb</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3005-8065" title="Orcid link">http://orcid.org/0000-0002-3005-8065</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas M. McGuire</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane E. Moore</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nichole O’Connell</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span>Present Address:
                        (C.D.S., N.O., B.Y.) Kymera Therapeutics, Kymera Therapeutics, 200 Arsenal Yards, Suite 230, Watertown, MA, 02472, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andy Pike</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kurt G. Pike</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9731-7500" title="Orcid link">http://orcid.org/0000-0002-9731-7500</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Theresa Proia</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan Roberts</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maryann San Martin</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ujjal Sarkar</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenlin Shao</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darren Stead</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Sumner</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kumar Thakur</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa M. Vasbinder</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span>Present Address:
                        (M.M.V.) Ribon Therapeutics, Inc., 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey G. Varnes</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianyan Wang</span> - <span class="hlFld-Affiliation affiliation">Advanced
Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Wang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dedong Wu</span> - <span class="hlFld-Affiliation affiliation">Advanced
Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liangwei Wu</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Yang</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca, Boston, Massachusetts 02451, United States</span>; 
    <span>Present Address:
                        (C.D.S., N.O., B.Y.) Kymera Therapeutics, Kymera Therapeutics, 200 Arsenal Yards, Suite 230, Watertown, MA, 02472, USA</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1499-5569" title="Orcid link">http://orcid.org/0000-0002-1499-5569</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tieguang Yao</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors were employees of AstraZeneca at the time of the described work and have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to acknowledge Matt Peters for assessing the safety risks of this project, Anne Marie Mazzola and Scott Boiko for in vitro and in vivo biology data generation, Tim Ikeda for his input into assay design and data generation, and past and present members of the CDK9 project.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Nonstandard Abbreviations and Acronyms</td></tr><tr><td class="NLM_term">second-generation XPhos precatalyst</td><td class="NLM_def"><p class="first last">chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)</p></td></tr><tr><td class="NLM_term">2-MeTHF</td><td class="NLM_def"><p class="first last">2-methyl tetrahydrofuran</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">Bak</td><td class="NLM_def"><p class="first last">Bcl2 homologous antagonist/killer</p></td></tr><tr><td class="NLM_term">Bax</td><td class="NLM_def"><p class="first last">Bcl2-associated X protein</p></td></tr><tr><td class="NLM_term">BCL2</td><td class="NLM_def"><p class="first last">B-cell lymphoma 2</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">bis in die (twice a day)</p></td></tr><tr><td class="NLM_term">BPin</td><td class="NLM_def"><p class="first last">boronic pinacol ester</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin dependent kinase</p></td></tr><tr><td class="NLM_term">CDT</td><td class="NLM_def"><p class="first last">carboxyl-terminal domain</p></td></tr><tr><td class="NLM_term">CSNK1G1</td><td class="NLM_def"><p class="first last">casein kinase 1 gamma 1</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine</p></td></tr><tr><td class="NLM_term">DYRK</td><td class="NLM_def"><p class="first last">dual specificity tyrosine phosphorylation regulated kinase</p></td></tr><tr><td class="NLM_term">ERK7</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase 7</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">glycogen synthase kinase</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">INSR</td><td class="NLM_def"><p class="first last">insulin receptor kinase</p></td></tr><tr><td class="NLM_term">i.p.</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">i.v.</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">Jnk1</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase 1</p></td></tr><tr><td class="NLM_term">MAP2K7</td><td class="NLM_def"><p class="first last">dual specificity mitogen-activated protein kinase kinase 7</p></td></tr><tr><td class="NLM_term">MAP3K9</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase kinase 9</p></td></tr><tr><td class="NLM_term">MAP4K4</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase kinase kinase 4</p></td></tr><tr><td class="NLM_term">Mcl-1</td><td class="NLM_def"><p class="first last">myeloid cell leukemia 1</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last">N-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NCS</td><td class="NLM_def"><p class="first last">N-chlorosuccinimide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidone</p></td></tr><tr><td class="NLM_term">PBPK</td><td class="NLM_def"><p class="first last">physiologically based pharmacokinetic</p></td></tr><tr><td class="NLM_term">PdCl<sub>2</sub>(dppf)</td><td class="NLM_def"><p class="first last">[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)</p></td></tr><tr><td class="NLM_term">Pd(P(Cy)<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">dichlorobis(tricyclohexylphosphine)palladium(II)</p></td></tr><tr><td class="NLM_term">Puma</td><td class="NLM_def"><p class="first last">p53 upregulated modulator of apoptosis</p></td></tr><tr><td class="NLM_term">RNAP2</td><td class="NLM_def"><p class="first last">RNA polymerase II</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr><tr><td class="NLM_term">xantphos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06212" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06212" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">The hallmarks of cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81683-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+hallmarks+of+cancer&doi=10.1016%2FS0092-8674%2800%2981683-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lh3EqcsVE7YmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520hallmarks%2520of%2520cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70%26doi%3D10.1016%2FS0092-8674%2800%2981683-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cory, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. M.</span></span> <span> </span><span class="NLM_article-title">The Bcl2 family: regulators of the cellular life-or-death switch</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1038/nrc883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrc883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=12209154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslamsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=647-656&author=S.+Coryauthor=J.+M.+Adams&title=The+Bcl2+family%3A+regulators+of+the+cellular+life-or-death+switch&doi=10.1038%2Fnrc883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Bcl2 family: regulators of the cellular life-or-death switch</span></div><div class="casAuthors">Cory, Suzanne; Adams, Jerry M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">647-656</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 154 refs.  Tissue homeostasis is regulated by apoptosis, the cell-suicide program that is executed by proteases called caspases.  The Bcl-2 family of intracellular proteins is the central regulator of caspase activation, and its opposing factions of anti- and pro-apoptotic members arbitrate the life-or-death decision.  Apoptosis is often impaired in cancer and can limit conventional therapy.  A better understanding of how the Bcl-2 family controls caspase activation should result in new, more effective therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1j_rKUocxTbVg90H21EOLACvtfcHk0lh3EqcsVE7YmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslamsrw%253D&md5=856e7f5f43519ecb9be4f6f3ac991249</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc883%26sid%3Dliteratum%253Aachs%26aulast%3DCory%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Bcl2%2520family%253A%2520regulators%2520of%2520the%2520cellular%2520life-or-death%2520switch%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D647%26epage%3D656%26doi%3D10.1038%2Fnrc883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czabotar, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. M.</span></span> <span> </span><span class="NLM_article-title">Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1038/nrm3722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrm3722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=24355989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOjsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=49-63&author=P.+E.+Czabotarauthor=G.+Lesseneauthor=A.+Strasserauthor=J.+M.+Adams&title=Control+of+apoptosis+by+the+BCL-2+protein+family%3A+implications+for+physiology+and+therapy&doi=10.1038%2Fnrm3722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</span></div><div class="casAuthors">Czabotar, Peter E.; Lessene, Guillaume; Strasser, Andreas; Adams, Jerry M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The BCL-2 protein family dets. the commitment of cells to apoptosis, an ancient cell suicide program that is essential for development, tissue homeostasis and immunity.  Too little apoptosis can promote cancer and autoimmune diseases; too much apoptosis can augment ischemic conditions and drive neurodegeneration.  We discuss the biochem., structural and genetic studies that have clarified how the interplay between members of the BCL-2 family on mitochondria sets the apoptotic threshold.  These mechanistic insights into the functions of the BCL-2 family are illuminating the physiol. control of apoptosis, the pathol. consequences of its dysregulation and the promising search for novel cancer therapies that target the BCL-2 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYVpm2heUGBbVg90H21EOLACvtfcHk0lh3EqcsVE7YmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOjsbvI&md5=c18d528c2819c2df93b6798e62132372</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3722%26sid%3Dliteratum%253Aachs%26aulast%3DCzabotar%26aufirst%3DP.%2BE.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DJ.%2BM.%26atitle%3DControl%2520of%2520apoptosis%2520by%2520the%2520BCL-2%2520protein%2520family%253A%2520implications%2520for%2520physiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D49%26epage%3D63%26doi%3D10.1038%2Fnrm3722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urashima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mc Henry, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinchback, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haery, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prensner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liefeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yecies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signoretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepper, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demichelis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">True, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomeroy, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">The landscape of somatic copy-number alteration across human cancers</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span>,  <span class="NLM_fpage">899</span>– <span class="NLM_lpage">905</span>, <span class="refDoi"> DOI: 10.1038/nature08822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnature08822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=20164920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=899-905&author=R.+Beroukhimauthor=C.+H.+Mermelauthor=D.+Porterauthor=G.+Weiauthor=S.+Raychaudhuriauthor=J.+Donovanauthor=J.+Barretinaauthor=J.+S.+Boehmauthor=J.+Dobsonauthor=M.+Urashimaauthor=K.+T.+Mc+Henryauthor=R.+M.+Pinchbackauthor=A.+H.+Ligonauthor=Y.+J.+Choauthor=L.+Haeryauthor=H.+Greulichauthor=M.+Reichauthor=W.+Wincklerauthor=M.+S.+Lawrenceauthor=B.+A.+Weirauthor=K.+E.+Tanakaauthor=D.+Y.+Chiangauthor=A.+J.+Bassauthor=A.+Looauthor=C.+Hoffmanauthor=J.+Prensnerauthor=T.+Liefeldauthor=Q.+Gaoauthor=D.+Yeciesauthor=S.+Signorettiauthor=E.+Maherauthor=F.+J.+Kayeauthor=H.+Sasakiauthor=J.+E.+Tepperauthor=J.+A.+Fletcherauthor=J.+Taberneroauthor=J.+Baselgaauthor=M.+S.+Tsaoauthor=F.+Demichelisauthor=M.+A.+Rubinauthor=P.+A.+Janneauthor=M.+J.+Dalyauthor=C.+Nuceraauthor=R.+L.+Levineauthor=B.+L.+Ebertauthor=S.+Gabrielauthor=A.+K.+Rustgiauthor=C.+R.+Antonescuauthor=M.+Ladanyiauthor=A.+Letaiauthor=L.+A.+Garrawayauthor=M.+Lodaauthor=D.+G.+Beerauthor=L.+D.+Trueauthor=A.+Okamotoauthor=S.+L.+Pomeroyauthor=S.+Singerauthor=T.+R.+Golubauthor=E.+S.+Landerauthor=G.+Getzauthor=W.+R.+Sellersauthor=M.+Meyerson&title=The+landscape+of+somatic+copy-number+alteration+across+human+cancers&doi=10.1038%2Fnature08822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The landscape of somatic copy-number alteration across human cancers</span></div><div class="casAuthors">Beroukhim, Rameen; Mermel, Craig H.; Porter, Dale; Wei, Guo; Raychaudhuri, Soumya; Donovan, Jerry; Barretina, Jordi; Boehm, Jesse S.; Dobson, Jennifer; Urashima, Mitsuyoshi; Mc Henry, Kevin T.; Pinchback, Reid M.; Ligon, Azra H.; Cho, Yoon-Jae; Haery, Leila; Greulich, Heidi; Reich, Michael; Winckler, Wendy; Lawrence, Michael S.; Weir, Barbara A.; Tanaka, Kumiko E.; Chiang, Derek Y.; Bass, Adam J.; Loo, Alice; Hoffman, Carter; Prensner, John; Liefeld, Ted; Gao, Qing; Yecies, Derek; Signoretti, Sabina; Maher, Elizabeth; Kaye, Frederic J.; Sasaki, Hidefumi; Tepper, Joel E.; Fletcher, Jonathan A.; Tabernero, Josep; Baselga, Jose; Tsao, Ming-Sound; Demichelis, Francesca; Rubin, Mark A.; Janne, Pasi A.; Daly, Mark J.; Nucera, Carmelo; Levine, Ross L.; Ebert, Benjamin L.; Gabriel, Stacey; Rustgi, Anil K.; Antonescu, Cristina R.; Ladanyi, Marc; Letai, Anthony; Garraway, Levi A.; Loda, Massimo; Beer, David G.; True, Lawrence D.; Okamoto, Aikou; Pomeroy, Scott L.; Singer, Samuel; Golub, Todd R.; Lander, Eric S.; Getz, Gad; Sellers, William R.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7283</span>),
    <span class="NLM_cas:pages">899-905</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers.  Here we present high-resoln. analyses of somatic copy-no. alterations (SCNAs) from 3131 cancer specimens, belonging largely to 26 histol. types.  We identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions.  Several gene families are enriched among these regions of focal SCNA, including the BCL2 family of apoptosis regulators and the NF-κB pathway.  We show that cancer cells contg. amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival.  Finally, we demonstrate that a large majority of SCNAs identified in individual cancer types are present in several cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCxYRlqR0wXLVg90H21EOLACvtfcHk0lj8QaWfGoKIjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsr0%253D&md5=be6d81f5449cba96dfb4659106f706b0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature08822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08822%26sid%3Dliteratum%253Aachs%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DMermel%26aufirst%3DC.%2BH.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DRaychaudhuri%26aufirst%3DS.%26aulast%3DDonovan%26aufirst%3DJ.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DDobson%26aufirst%3DJ.%26aulast%3DUrashima%26aufirst%3DM.%26aulast%3DMc%2BHenry%26aufirst%3DK.%2BT.%26aulast%3DPinchback%26aufirst%3DR.%2BM.%26aulast%3DLigon%26aufirst%3DA.%2BH.%26aulast%3DCho%26aufirst%3DY.%2BJ.%26aulast%3DHaery%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DTanaka%26aufirst%3DK.%2BE.%26aulast%3DChiang%26aufirst%3DD.%2BY.%26aulast%3DBass%26aufirst%3DA.%2BJ.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DC.%26aulast%3DPrensner%26aufirst%3DJ.%26aulast%3DLiefeld%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DYecies%26aufirst%3DD.%26aulast%3DSignoretti%26aufirst%3DS.%26aulast%3DMaher%26aufirst%3DE.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DTepper%26aufirst%3DJ.%2BE.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26aulast%3DDemichelis%26aufirst%3DF.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DNucera%26aufirst%3DC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DBeer%26aufirst%3DD.%2BG.%26aulast%3DTrue%26aufirst%3DL.%2BD.%26aulast%3DOkamoto%26aufirst%3DA.%26aulast%3DPomeroy%26aufirst%3DS.%2BL.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DThe%2520landscape%2520of%2520somatic%2520copy-number%2520alteration%2520across%2520human%2520cancers%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D899%26epage%3D905%26doi%3D10.1038%2Fnature08822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashkenazi, A.</span></span> <span> </span><span class="NLM_article-title">Directing cancer cells to self-destruct with pro-apoptotic receptor agonists</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1038/nrd2637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrd2637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=18989337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1001-1012&author=A.+Ashkenazi&title=Directing+cancer+cells+to+self-destruct+with+pro-apoptotic+receptor+agonists&doi=10.1038%2Fnrd2637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Directing cancer cells to self-destruct with pro-apoptotic receptor agonists</span></div><div class="casAuthors">Ashkenazi, Avi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1001-1012</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Each day, the human body eliminates billions of unwanted cells by apoptotic suicide.  Apoptosis provides an important barrier against cancer; however, specific mutations enable some tumor cells to escape apoptotic death and become more malignant.  Two signaling pathways initiate apoptosis: one acts through intracellular Bcl-2 proteins, the other through cell-surface pro-apoptotic receptors.  New mol. insights have inspired the development of pro-apoptotic receptor agonists (PARAs), including the recombinant human protein apoptosis ligand 2/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) and agonistic monoclonal antibodies to its signaling receptors.  Acting alone, or in concert with other agents, PARAs may overcome key apoptosis blocks and direct cancer cells to self-destruct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpddvao_FxuwLVg90H21EOLACvtfcHk0lj8QaWfGoKIjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsbnF&md5=6c7fdc551bb0902bdacb869f9b308c18</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2637%26sid%3Dliteratum%253Aachs%26aulast%3DAshkenazi%26aufirst%3DA.%26atitle%3DDirecting%2520cancer%2520cells%2520to%2520self-destruct%2520with%2520pro-apoptotic%2520receptor%2520agonists%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D1001%26epage%3D1012%26doi%3D10.1038%2Fnrd2637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hailfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dörken, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thome, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirnhofer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Ilizaliturri, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzankov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span> <span> </span><span class="NLM_article-title">MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1381</span>– <span class="NLM_lpage">1390</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fleu.2012.367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=23257783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFekur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1381-1390&author=S.+S.+Wenzelauthor=M.+Grauauthor=C.+Mavisauthor=S.+Hailfingerauthor=A.+Wolfauthor=H.+Madleauthor=G.+Deebauthor=B.+D%C3%B6rkenauthor=M.+Thomeauthor=P.+Lenzauthor=S.+Dirnhoferauthor=F.+J.+Hernandez-Ilizaliturriauthor=A.+Tzankovauthor=G.+Lenz&title=MCL1+is+deregulated+in+subgroups+of+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fleu.2012.367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma</span></div><div class="casAuthors">Wenzel, S.-S.; Grau, M.; Mavis, C.; Hailfinger, S.; Wolf, A.; Madle, H.; Deeb, G.; Doerken, B.; Thome, M.; Lenz, P.; Dirnhofer, S.; Hernandez-Ilizaliturri, F. J.; Tzankov, A.; Lenz, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1381-1390</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloid cell leukemia-1 (MCL1) is an anti-apoptotic member of the BCL2 family that is deregulated in various solid and hematol. malignancies.  However, its role in the mol. pathogenesis of diffuse large B-cell lymphoma (DLBCL) is unclear.  We analyzed gene expression profiling data from 350 DLBCL patient samples and detected that activated B-cell-like (ABC) DLBCLs express MCL1 at significantly higher levels compared with germinal center B-cell-like DLBCL patient samples (P=2.7 × 10-10).  Immunohistochem. confirmed high MCL1 protein expression predominantly in ABC DLBCL in an independent patient cohort (n=249; P=0.001).  To elucidate mol. mechanisms leading to aberrant MCL1 expression, we analyzed array comparative genomic hybridization data of 203 DLBCL samples and identified recurrent chromosomal gains/amplifications of the MCL1 locus that occurred in 26% of ABC DLBCLs.  In addn., aberrant STAT3 signaling contributed to high MCL1 expression in this subtype.  Knockdown of MCL1 as well as treatment with the BH3-mimetic obatoclax induced apoptotic cell death in MCL1-pos. DLBCL cell lines.  In summary, MCL1 is deregulated in a significant fraction of ABC DLBCLs and contributes to therapy resistance.  These data suggest that specific inhibition of MCL1 might be utilized therapeutically in a subset of DLBCLs.  Leukemia (2013) 27, 1381-1390; doi:10.1038/leu.2012.367; published online 18 Jan. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN9CxWCi906rVg90H21EOLACvtfcHk0lgLaAC2eU43nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFekur4%253D&md5=91167903f5911feca70ddea39778af94</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.367%26sid%3Dliteratum%253Aachs%26aulast%3DWenzel%26aufirst%3DS.%2BS.%26aulast%3DGrau%26aufirst%3DM.%26aulast%3DMavis%26aufirst%3DC.%26aulast%3DHailfinger%26aufirst%3DS.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DMadle%26aufirst%3DH.%26aulast%3DDeeb%26aufirst%3DG.%26aulast%3DD%25C3%25B6rken%26aufirst%3DB.%26aulast%3DThome%26aufirst%3DM.%26aulast%3DLenz%26aufirst%3DP.%26aulast%3DDirnhofer%26aufirst%3DS.%26aulast%3DHernandez-Ilizaliturri%26aufirst%3DF.%2BJ.%26aulast%3DTzankov%26aufirst%3DA.%26aulast%3DLenz%26aufirst%3DG.%26atitle%3DMCL1%2520is%2520deregulated%2520in%2520subgroups%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D1381%26epage%3D1390%26doi%3D10.1038%2Fleu.2012.367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wuillème-Toumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robillard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gouill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avet-Loiseau, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harousseau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bataille, R.</span></span> <span> </span><span class="NLM_article-title">Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2403784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fsj.leu.2403784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=15902294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVOisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1248-1252&author=S.+Wuill%C3%A8me-Toumiauthor=N.+Robillardauthor=P.+Gomezauthor=P.+Moreauauthor=S.+Le+Gouillauthor=H.+Avet-Loiseauauthor=J.+L.+Harousseauauthor=M.+Amiotauthor=R.+Bataille&title=Mcl-1+is+overexpressed+in+multiple+myeloma+and+associated+with+relapse+and+shorter+survival&doi=10.1038%2Fsj.leu.2403784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival</span></div><div class="casAuthors">Wuilleme-Toumi, S.; Robillard, N.; Gomez, P.; Moreau, P.; Le Gouill, S.; Avet-Loiseau, H.; Harousseau, J-L.; Amiot, M.; Bataille, R.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1248-1252</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We and others have shown that Mcl-1 was essential for the survival of human myeloma cells in vitro.  Furthermore, this antiapoptotic protein is upregulated by interleukin-6, which plays a crit. role in multiple myeloma (MM).  For these reasons, we have evaluated the expression of Mcl-1 in vivo in normal, reactive and malignant plasma cells (PC), i.e., myeloma cells from 51 patients with MM and 21 human myeloma cell lines (HMCL) using flow cytometry.  We show that Mcl-1 is overexpressed in MM in comparison with normal bone marrow PC.  In total, 52% of patients with MM at diagnosis (P=0.017) and 81% at relapse (P=0.014 for comparison with diagnosis) overexpress Mcl-1.  Of note, only HMCL but not reactive plasmacytoses have abnormal Mcl-1 expression, although both PC expansions share similar high proliferation rates.  Of interest, Bcl-2 as opposed to Mcl-1, does not discriminate malignant from normal PC.  Finally, the level of Mcl-1 expression is related to disease severity, the highest values at diagnosis being assocd. with the shortest event-free survival (P=0.002).  In conclusion, Mcl-1, which has been shown to be essential for the survival of human myeloma cells in vitro, is overexpressed in vivo in MM in relation with relapse and shorter survival.  Mcl-1 represents a potential therapeutical target in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ7LKx_LcQybVg90H21EOLACvtfcHk0lgLaAC2eU43nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVOisrk%253D&md5=ab23f9b31bc91704a55b511d4498e4d0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2403784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2403784%26sid%3Dliteratum%253Aachs%26aulast%3DWuill%25C3%25A8me-Toumi%26aufirst%3DS.%26aulast%3DRobillard%26aufirst%3DN.%26aulast%3DGomez%26aufirst%3DP.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DLe%2BGouill%26aufirst%3DS.%26aulast%3DAvet-Loiseau%26aufirst%3DH.%26aulast%3DHarousseau%26aufirst%3DJ.%2BL.%26aulast%3DAmiot%26aufirst%3DM.%26aulast%3DBataille%26aufirst%3DR.%26atitle%3DMcl-1%2520is%2520overexpressed%2520in%2520multiple%2520myeloma%2520and%2520associated%2520with%2520relapse%2520and%2520shorter%2520survival%26jtitle%3DLeukemia%26date%3D2005%26volume%3D19%26spage%3D1248%26epage%3D1252%26doi%3D10.1038%2Fsj.leu.2403784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gores, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trounson, E.</span></span> <span> </span><span class="NLM_article-title">Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1101/gad.186189.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1101%2Fgad.186189.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=22345513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Cmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=305-311&author=G.+J.+Goresauthor=S.+H.+Kaufmannauthor=S.+P.+Glaserauthor=E.+F.+Leeauthor=E.+Trounson&title=Selectively+targeting+Mcl-1+for+the+treatment+of+acute+myelogenous+leukemia+and+solid+tumors&doi=10.1101%2Fgad.186189.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors</span></div><div class="casAuthors">Gores, Gregory J.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-311</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Bcl-2, Bcl-xL, Mcl-1, and A1 are the predominant anti-apoptotic members of the Bcl-2 family in somatic cells.  Malignant B lymphocytes are critically dependent on Bcl-2 or Bcl-xL for survival.  In contrast, a new study by Glaser and colleagues in the Jan. 15, 2012, issue of Genes & Development (pp. 120-125) demonstrates that Mcl-1 is essential for development and survival of acute myelogenous leukemia cells.  These results provide new impetus for the generation of selective Mcl-1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGpI-5exlGV7Vg90H21EOLACvtfcHk0lgLaAC2eU43nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Cmu7w%253D&md5=807ddab7babc0eb9c22fb2b5cc2336e9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1101%2Fgad.186189.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.186189.111%26sid%3Dliteratum%253Aachs%26aulast%3DGores%26aufirst%3DG.%2BJ.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DGlaser%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DE.%2BF.%26aulast%3DTrounson%26aufirst%3DE.%26atitle%3DSelectively%2520targeting%2520Mcl-1%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520and%2520solid%2520tumors%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D305%26epage%3D311%26doi%3D10.1101%2Fgad.186189.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, R. S.</span></span> <span> </span><span class="NLM_article-title">Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3519</span>– <span class="NLM_lpage">3530</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.18632%2Foncotarget.2792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=25784482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnls1ShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=3519-3530&author=M.+M.+Williamsauthor=R.+S.+Cook&title=Bcl-2+family+proteins+in+breast+development+and+cancer%3A+could+Mcl-1+targeting+overcome+therapeutic+resistance%3F&doi=10.18632%2Foncotarget.2792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?</span></div><div class="casAuthors">Williams Michelle M; Cook Rebecca S; Cook Rebecca S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3519-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Apoptosis, cell death executed by caspases, is essential to normal breast development and homeostasis.  Pro-apoptotic and anti-apoptotic signals are tightly regulated in normal breast epithelial cells.  Dysregulation of this balance is required for breast tumorigenesis and increases acquired resistance to treatments, including molecularly targeted therapies, radiation and chemotherapies.  The pro-apoptotic or anti-apoptotic Bcl-2 family members interact with each other to maintain mitochondrial integrity and regulate cellular commitment to apoptosis.  Among the anti-apoptotic Bcl-2 family members, Mcl-1 is uniquely regulated by numerous oncogenic signaling pathways.  This review will focus on the role of Bcl-2 family proteins in normal breast development, breast tumorigenesis and acquired resistance to breast cancer treatment strategies, while highlighting Mcl-1 as a promising target to improve breast cancer tumor cell killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvDoMDseirLH6HPRus0rAafW6udTcc2eZsVwBZMD1kFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnls1ShsQ%253D%253D&md5=22e6af0dd2e25832cedc3dffac2e5a84</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2792%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%2BM.%26aulast%3DCook%26aufirst%3DR.%2BS.%26atitle%3DBcl-2%2520family%2520proteins%2520in%2520breast%2520development%2520and%2520cancer%253A%2520could%2520Mcl-1%2520targeting%2520overcome%2520therapeutic%2520resistance%253F%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D3519%26epage%3D3530%26doi%3D10.18632%2Foncotarget.2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gojo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenton, R. G.</span></span> <span> </span><span class="NLM_article-title">Myeloid cell factor – 1 is a critical survival factor for multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1893</span>, <span class="refDoi"> DOI: 10.1182/blood.V99.6.1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1182%2Fblood.V99.6.1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=11877256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD38XitF2ntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=1885-1893&author=B.+Zhangauthor=I.+Gojoauthor=R.+G.+Fenton&title=Myeloid+cell+factor+%E2%80%93+1+is+a+critical+survival+factor+for+multiple+myeloma&doi=10.1182%2Fblood.V99.6.1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloid cell factor-1 is a critical survival factor for multiple myeloma</span></div><div class="casAuthors">Zhang, Bin; Gojo, Ivana; Fenton, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1885-1893</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow caused primarily by failure of normal homeostatic mechanisms to prevent the expansion of postgerminal center plasma cells.  We have examd. the mol. mechanisms that promote the survival of MM cells and have identified a key role for myeloid cell factor-1 (Mcl-1), an antiapoptotic member of the Bcl-2 family.  These expts. were initiated by the observation that MM cells were exquisitely sensitive to culture in the presence of actinomycin D: caspase activation occurred within 3 h of treatment and cells were not protected by interleukin-6, the main MM cell growth and survival factor.  Actinomycin D-induced apoptosis was blocked by proteasome inhibitors, suggesting that a labile protein was required for MM cell survival.  Further anal. demonstrated that Mcl-1 was likely to be the labile factor governing MM cell survival.  Mcl-1 protein levels decreased rapidly after culture in the presence of actinomycin D in concordance with effector caspase activation, but addn. of proteasome inhibitors reversed the loss of Mcl-1 and maintained cell viability.  The levels of other antiapoptotic proteins, including Bcl-2 and members of the inhibitors-of-apoptosis family, were unaffected by these interventions.  Furthermore, Mcl-1 antisense oligonucleotides caused a rapid down-regulation of Mcl-1 protein levels and the coincident induction of apoptosis, whereas overexpression of Mcl-1 delayed actinomycin D-induced apoptosis with kinetics that correlated with expression levels of Mcl-1.  These data indicate that Mcl-1 expression is required for the survival of MM cells and may represent an important target for future therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_vJkrKUBuA7Vg90H21EOLACvtfcHk0ljYjjakRzG-5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitF2ntro%253D&md5=cce6518090819f837a65726a0b9f5b87</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.6.1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.6.1885%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DFenton%26aufirst%3DR.%2BG.%26atitle%3DMyeloid%2520cell%2520factor%2520%25E2%2580%2593%25201%2520is%2520a%2520critical%2520survival%2520factor%2520for%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D1885%26epage%3D1893%26doi%3D10.1182%2Fblood.V99.6.1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trounson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouillet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span> <span> </span><span class="NLM_article-title">Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1101/gad.182980.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1101%2Fgad.182980.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=22279045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=120-125&author=S.+P.+Glaserauthor=E.+F.+Leeauthor=E.+Trounsonauthor=P.+Bouilletauthor=A.+Weiauthor=W.+D.+Fairlieauthor=D.+J.+Izonauthor=J.+Zuberauthor=A.+R.+Rappaportauthor=M.+J.+Heroldauthor=W.+S.+Alexanderauthor=S.+W.+Loweauthor=L.+Robbauthor=A.+Strasser&title=Anti-apoptotic+Mcl-1+is+essential+for+the+development+and+sustained+growth+of+acute+myeloid+leukemia&doi=10.1101%2Fgad.182980.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia</span></div><div class="casAuthors">Glaser, Stefan P.; Lee, Erinna F.; Trounson, Evelyn; Bouillet, Philippe; Wei, Andrew; Fairlie, W. Douglas; Izon, David J.; Zuber, Johannes; Rappaport, Amy R.; Herold, Marco J.; Alexander, Warren S.; Lowe, Scott W.; Robb, Lorraine; Strasser, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-125</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) frequently relapses after initial treatment.  Drug resistance in AML has been attributed to high levels of the anti-apoptotic Bcl-2 family members Bcl-xL and Mcl-1.  Here we report that removal of Mcl-1, but not loss or pharmacol. blockade of Bcl-xL, Bcl-2, or Bcl-w, caused the death of transformed AML and could cure disease in AML-afflicted mice.  Enforced expression of selective inhibitors of prosurvival Bcl-2 family members revealed that Mcl-1 is crit. for survival of human AML cells.  Thus, targeting of Mcl-1 or regulators of its expression may be a useful strategy for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6z2Lgi2YuK7Vg90H21EOLACvtfcHk0ljYjjakRzG-5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOjs78%253D&md5=5f0cc61da50fddb262d30e243a7e6837</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1101%2Fgad.182980.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.182980.111%26sid%3Dliteratum%253Aachs%26aulast%3DGlaser%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DE.%2BF.%26aulast%3DTrounson%26aufirst%3DE.%26aulast%3DBouillet%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DFairlie%26aufirst%3DW.%2BD.%26aulast%3DIzon%26aufirst%3DD.%2BJ.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DRappaport%26aufirst%3DA.%2BR.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DAlexander%26aufirst%3DW.%2BS.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DRobb%26aufirst%3DL.%26aulast%3DStrasser%26aufirst%3DA.%26atitle%3DAnti-apoptotic%2520Mcl-1%2520is%2520essential%2520for%2520the%2520development%2520and%2520sustained%2520growth%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D120%26epage%3D125%26doi%3D10.1101%2Fgad.182980.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule Mcl-1 inhibitors: emerging anti-tumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.ejmech.2018.01.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=29407973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=471-482&author=Y.+Wanauthor=N.+Daiauthor=Z.+Tangauthor=H.+Fang&title=Small-molecule+Mcl-1+inhibitors%3A+emerging+anti-tumor+agents&doi=10.1016%2Fj.ejmech.2018.01.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents</span></div><div class="casAuthors">Wan, Yichao; Dai, Ningning; Tang, Zilong; Fang, Hao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">471-482</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The anti-apoptotic members of B-cell lymphoma-2 (Bcl-2) proteins family, such as Bcl-2 and myeloid cell leukemia-1 (Mcl-1), are the key regulators of the intrinsic pathway of apoptosis and overexpressed in many tumor cells, which have been confirmed as potential drug targets for cancers.  A no. of Bcl-2 proteins inhibitors have been developed and conducted clin. trials, but no Mcl-1 inhibitors are presented in the clinics.  In addn., Mcl-1 is an important reason for the resistance to radio- and chemotherapies, including inhibitors that target other Bcl-2 family members.  For example, the recently launched Bcl-2-selective inhibitor ABT-199 displays highly potency in the treatment of chronic lymphocytic leukemia (CLL), but it cannot induce the apoptosis controlled by Mcl-1 in some tumor cell lines.  Therefore, developing potent Mcl-1 inhibitors become urgently needed in clin. therapy.  This review briefly introduces the structure of Mcl-1 protein, the role in cancers and focuses on the progress of small-mol. Mcl-1 inhibitors from 2012 to 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpQTzQws7_BLVg90H21EOLACvtfcHk0lgdjEw4WAeFQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WrsL8%253D&md5=3f61029e3cf9195a91f5cb1eb6ee59e6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.076%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DSmall-molecule%2520Mcl-1%2520inhibitors%253A%2520emerging%2520anti-tumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D471%26epage%3D482%26doi%3D10.1016%2Fj.ejmech.2018.01.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span> <span> </span><span class="NLM_article-title">Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1039/C5MD00582E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1039%2FC5MD00582E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVKrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=778-787&author=D.+Nhuauthor=G.+Lesseneauthor=D.+C.+S.+Huangauthor=C.+J.+Burns&title=Small+molecules+targeting+Mcl-1%3A+the+search+for+a+silver+bullet+in+cancer+therapy&doi=10.1039%2FC5MD00582E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy</span></div><div class="casAuthors">Nhu, Duong; Lessene, Guillaume; Huang, David C. S.; Burns, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">778-787</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Mcl-1 (myeloid-cell-leukemia-sequence-1) is a pro-survival member of the Bcl-2 family of proteins.  Mcl-1 has been shown to be crit. to the survival of a variety of cancer cells and to mediate resistance to conventional and targeted chemotherapeutics.  While potent and selective small mol. inhibitors of Bcl-2 and Bcl-XL have been developed, the discovery of selective inhibitors of Mcl-1 has proven more problematic and only very recently have potent and selective inhibitors been described.  In this review we outline key features of Mcl-1 biol., and chem. approaches and outcomes of inhibiting this important survival protein for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkbm3AGAWdW7Vg90H21EOLACvtfcHk0lgdjEw4WAeFQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVKrsLs%253D&md5=567809fcf5f9af519d76bda168e25a9a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1039%2FC5MD00582E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00582E%26sid%3Dliteratum%253Aachs%26aulast%3DNhu%26aufirst%3DD.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26atitle%3DSmall%2520molecules%2520targeting%2520Mcl-1%253A%2520the%2520search%2520for%2520a%2520silver%2520bullet%2520in%2520cancer%2520therapy%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D778%26epage%3D787%26doi%3D10.1039%2FC5MD00582E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Mcl-1 inhibitors: a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1249848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1080%2F13543776.2017.1249848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=27744724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWht7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=163-178&author=L.+Chenauthor=S.+Fletcher&title=Mcl-1+inhibitors%3A+a+patent+review&doi=10.1080%2F13543776.2017.1249848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Mcl-1 inhibitors: a patent review</span></div><div class="casAuthors">Chen, Lijia; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-178</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: The myeloid cell leukemia-1 (MCL-1) protein is one of the key anti-apoptotic members of the B-cell lymphoma-2 (BCL-2) protein family.  Over-expression of MCL-1 has been closely related to tumor progression as well as to resistance, not only to traditional chemotherapies but also to targeted therapeutics including BCL-2 inhibitors such as ABT-263.  Therefore, there has been extensive research and development in the last decade in both academic and industrial settings to address this unmet medical need.  This review covers the research and patent literature of the past 10 years in the field of discovery and development of small-mol. inhibitors of the MCL-1 anti-apoptotic protein.  Small-mol. strategies to disrupt the protein-protein interactions between MCL-1 and its pro-apoptotic counterparts, such as BAK and BIM, have recently emerged.  Several small-mols. based on different scaffolds describe promising in vitro data as MCL-1 selective inhibitors.  While many lead compds. remain at the in vitro preclin. development stage, the two most recent patent applications describe promising in vivo data, and one small mol. inhibitor has recently entered into clin. development.  It is such an exciting moment that the long awaited clin. studies will generate some insight into the therapeutic potential of this anti-cancer approach, and possibly facilitate the further development of other early stage inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtJ0p65xmy37Vg90H21EOLACvtfcHk0lgdjEw4WAeFQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWht7zL&md5=43dcba43e2c278ca3f1da22fcad1f739</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1249848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1249848%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DMcl-1%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D163%26epage%3D178%26doi%3D10.1080%2F13543776.2017.1249848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotschy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szlavik, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragno, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Toumelin-Braizat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanrion, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moujalled, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csekei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paczal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radics, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proszenyak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balint, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokurno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matassova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studeny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lysiak-Auvity, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grave, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riffkin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbraith, L. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrey, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guasconi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauquil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigal-Stephan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colland, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geneste, O.</span></span> <span> </span><span class="NLM_article-title">The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>538</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1038/nature19830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnature19830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=27760111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC2srjs1aquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=538&publication_year=2016&pages=477-482&author=A.+Kotschyauthor=Z.+Szlavikauthor=J.+Murrayauthor=J.+Davidsonauthor=A.+L.+Maragnoauthor=G.+Le+Toumelin-Braizatauthor=M.+Chanrionauthor=G.+L.+Kellyauthor=J.-N.+Gongauthor=D.+M.+Moujalledauthor=A.+Brunoauthor=M.+Csekeiauthor=A.+Paczalauthor=Z.+B.+Szaboauthor=S.+Siposauthor=G.+Radicsauthor=A.+Proszenyakauthor=B.+Balintauthor=L.+Ondiauthor=G.+Blaskoauthor=A.+Robertsonauthor=A.+Surgenorauthor=P.+Dokurnoauthor=I.+Chenauthor=N.+Matassovaauthor=J.+Smithauthor=C.+Pedderauthor=C.+Grahamauthor=A.+Studenyauthor=G.+Lysiak-Auvityauthor=A.-M.+Girardauthor=F.+Graveauthor=D.+Segalauthor=C.+D.+Riffkinauthor=G.+Pomilioauthor=L.+C.+A.+Galbraithauthor=B.+J.+Aubreyauthor=M.+S.+Brennanauthor=M.+J.+Heroldauthor=C.+Changauthor=G.+Guasconiauthor=N.+Cauquilauthor=F.+Melchioreauthor=N.+Guigal-Stephanauthor=B.+Lockhartauthor=F.+Collandauthor=J.+A.+Hickmanauthor=A.+W.+Robertsauthor=D.+C.+S.+Huangauthor=A.+H.+Weiauthor=A.+Strasserauthor=G.+Lesseneauthor=O.+Geneste&title=The+MCL1+inhibitor+S63845+is+tolerable+and+effective+in+diverse+cancer+models&doi=10.1038%2Fnature19830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models</span></div><div class="casAuthors">Kotschy Andras; Szlavik Zoltan; Csekei Marton; Paczal Attila; Szabo Zoltan B; Sipos Szabolcs; Radics Gabor; Proszenyak Agnes; Balint Balazs; Ondi Levente; Blasko Gabor; Murray James; Davidson James; Robertson Alan; Surgenor Allan; Dokurno Pawel; Chen Ijen; Matassova Natalia; Smith Julia; Pedder Christopher; Graham Christopher; Maragno Ana Leticia; Le Toumelin-Braizat Gaetane; Chanrion Maia; Bruno Alain; Studeny Aurelie; Lysiak-Auvity Gaelle; Girard Anne-Marie; Grave Fabienne; Guasconi Ghislaine; Cauquil Nicolas; Colland Frederic; Hickman John A; Geneste Olivier; Kelly Gemma L; Gong Jia-Nan; Segal David; Riffkin Chris D; Galbraith Laura C A; Aubrey Brandon J; Brennan Margs S; Herold Marco J; Chang Catherine; Roberts Andrew W; Huang David C S; Strasser Andreas; Lessene Guillaume; Kelly Gemma L; Gong Jia-Nan; Segal David; Riffkin Chris D; Galbraith Laura C A; Aubrey Brandon J; Brennan Margs S; Herold Marco J; Chang Catherine; Roberts Andrew W; Huang David C S; Strasser Andreas; Lessene Guillaume; Moujalled Donia M; Pomilio Giovanna; Wei Andrew H; Aubrey Brandon J; Roberts Andrew W; Melchiore Fabien; Guigal-Stephan Nolwen; Lockhart Brian; Roberts Andrew W; Wei Andrew H; Lessene Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">538</span>
        (<span class="NLM_cas:issue">7626</span>),
    <span class="NLM_cas:pages">477-482</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Avoidance of apoptosis is critical for the development and sustained growth of tumours.  The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging.  Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1.  Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway.  In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers.  Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines.  These results point towards MCL1 as a target for the treatment of a wide range of tumours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7C_gQBh3bx0EgZCMqtRBifW6udTcc2eZrQUq1NF7HSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srjs1aquw%253D%253D&md5=c435a7621b84063133e41e0cdbad3ac8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnature19830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19830%26sid%3Dliteratum%253Aachs%26aulast%3DKotschy%26aufirst%3DA.%26aulast%3DSzlavik%26aufirst%3DZ.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DDavidson%26aufirst%3DJ.%26aulast%3DMaragno%26aufirst%3DA.%2BL.%26aulast%3DLe%2BToumelin-Braizat%26aufirst%3DG.%26aulast%3DChanrion%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DG.%2BL.%26aulast%3DGong%26aufirst%3DJ.-N.%26aulast%3DMoujalled%26aufirst%3DD.%2BM.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DCsekei%26aufirst%3DM.%26aulast%3DPaczal%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DZ.%2BB.%26aulast%3DSipos%26aufirst%3DS.%26aulast%3DRadics%26aufirst%3DG.%26aulast%3DProszenyak%26aufirst%3DA.%26aulast%3DBalint%26aufirst%3DB.%26aulast%3DOndi%26aufirst%3DL.%26aulast%3DBlasko%26aufirst%3DG.%26aulast%3DRobertson%26aufirst%3DA.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DDokurno%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DMatassova%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DPedder%26aufirst%3DC.%26aulast%3DGraham%26aufirst%3DC.%26aulast%3DStudeny%26aufirst%3DA.%26aulast%3DLysiak-Auvity%26aufirst%3DG.%26aulast%3DGirard%26aufirst%3DA.-M.%26aulast%3DGrave%26aufirst%3DF.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DRiffkin%26aufirst%3DC.%2BD.%26aulast%3DPomilio%26aufirst%3DG.%26aulast%3DGalbraith%26aufirst%3DL.%2BC.%2BA.%26aulast%3DAubrey%26aufirst%3DB.%2BJ.%26aulast%3DBrennan%26aufirst%3DM.%2BS.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGuasconi%26aufirst%3DG.%26aulast%3DCauquil%26aufirst%3DN.%26aulast%3DMelchiore%26aufirst%3DF.%26aulast%3DGuigal-Stephan%26aufirst%3DN.%26aulast%3DLockhart%26aufirst%3DB.%26aulast%3DColland%26aufirst%3DF.%26aulast%3DHickman%26aufirst%3DJ.%2BA.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DWei%26aufirst%3DA.%2BH.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DGeneste%26aufirst%3DO.%26atitle%3DThe%2520MCL1%2520inhibitor%2520S63845%2520is%2520tolerable%2520and%2520effective%2520in%2520diverse%2520cancer%2520models%26jtitle%3DNature%26date%3D2016%26volume%3D538%26spage%3D477%26epage%3D482%26doi%3D10.1038%2Fnature19830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tron, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquila, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boise, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarparin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embrey, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannes, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmirski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulis, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nooka, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hird, A. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">5341</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07551-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fs41467-018-07551-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=30559424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFersLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=5341&author=A.+E.+Tronauthor=M.+A.+Belmonteauthor=A.+Adamauthor=B.+M.+Aquilaauthor=L.+H.+Boiseauthor=E.+Chiarparinauthor=J.+Cidadoauthor=K.+J.+Embreyauthor=E.+Ganglauthor=F.+D.+Gibbonsauthor=G.+P.+Gregoryauthor=D.+Hargreavesauthor=J.+A.+Hendricksauthor=J.+W.+Johannesauthor=R.+W.+Johnstoneauthor=S.+L.+Kazmirskiauthor=J.+G.+Kettleauthor=M.+L.+Lambauthor=S.+M.+Matulisauthor=A.+K.+Nookaauthor=M.+J.+Packerauthor=B.+Pengauthor=P.+B.+Rawlinsauthor=D.+W.+Robbinsauthor=A.+G.+Schullerauthor=N.+Suauthor=W.+Yangauthor=Q.+Yeauthor=X.+Zhengauthor=J.+P.+Secristauthor=E.+A.+Clarkauthor=D.+M.+Wilsonauthor=S.+E.+Fawellauthor=A.+W.+Hird&title=Discovery+of+Mcl-1-specific+inhibitor+AZD5991+and+preclinical+activity+in+multiple+myeloma+and+acute+myeloid+leukemia&doi=10.1038%2Fs41467-018-07551-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia</span></div><div class="casAuthors">Tron, Adriana E.; Belmonte, Matthew A.; Adam, Ammar; Aquila, Brian M.; Boise, Lawrence H.; Chiarparin, Elisabetta; Cidado, Justin; Embrey, Kevin J.; Gangl, Eric; Gibbons, Francis D.; Gregory, Gareth P.; Hargreaves, David; Hendricks, J. Adam; Johannes, Jeffrey W.; Johnstone, Ricky W.; Kazmirski, Steven L.; Kettle, Jason G.; Lamb, Michelle L.; Matulis, Shannon M.; Nooka, Ajay K.; Packer, Martin J.; Peng, Bo; Rawlins, Philip B.; Robbins, Daniel W.; Schuller, Alwin G.; Su, Nancy; Yang, Wenzhan; Ye, Qing; Zheng, Xiaolan; Secrist, J. Paul; Clark, Edwin A.; Wilson, David M.; Fawell, Stephen E.; Hird, Alexander W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5341</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers.  High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 inhibitors as anticancer drugs.  Here, we describe AZD5991, a rationally designed macrocyclic mol. with high selectivity and affinity for Mcl-1 currently in clin. development.  Our studies demonstrate that AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway.  AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax.  Based on these promising data, a Phase I clin. trial has been launched for evaluation of AZD5991 in patients with hematol. malignancies (NCT03218683).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLv1vdwF2TY7Vg90H21EOLACvtfcHk0ligEijQzM0Gaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFersLjK&md5=10ccf1fda947aca212bede3927eaabfa</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07551-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07551-w%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DA.%2BE.%26aulast%3DBelmonte%26aufirst%3DM.%2BA.%26aulast%3DAdam%26aufirst%3DA.%26aulast%3DAquila%26aufirst%3DB.%2BM.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DCidado%26aufirst%3DJ.%26aulast%3DEmbrey%26aufirst%3DK.%2BJ.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DGibbons%26aufirst%3DF.%2BD.%26aulast%3DGregory%26aufirst%3DG.%2BP.%26aulast%3DHargreaves%26aufirst%3DD.%26aulast%3DHendricks%26aufirst%3DJ.%2BA.%26aulast%3DJohannes%26aufirst%3DJ.%2BW.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DKazmirski%26aufirst%3DS.%2BL.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DMatulis%26aufirst%3DS.%2BM.%26aulast%3DNooka%26aufirst%3DA.%2BK.%26aulast%3DPacker%26aufirst%3DM.%2BJ.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DRawlins%26aufirst%3DP.%2BB.%26aulast%3DRobbins%26aufirst%3DD.%2BW.%26aulast%3DSchuller%26aufirst%3DA.%2BG.%26aulast%3DSu%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DSecrist%26aufirst%3DJ.%2BP.%26aulast%3DClark%26aufirst%3DE.%2BA.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DHird%26aufirst%3DA.%2BW.%26atitle%3DDiscovery%2520of%2520Mcl-1-specific%2520inhibitor%2520AZD5991%2520and%2520preclinical%2520activity%2520in%2520multiple%2520myeloma%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D5341%26doi%3D10.1038%2Fs41467-018-07551-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmontes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paras, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zancanella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cajulis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osgood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanaghan, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moujalled, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span> <span> </span><span class="NLM_article-title">AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1582</span>– <span class="NLM_lpage">1597</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=30254093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOmsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1582-1597&author=S.+Caenepeelauthor=S.+P.+Brownauthor=B.+Belmontesauthor=G.+Moodyauthor=K.+S.+Keeganauthor=D.+Chuiauthor=D.+A.+Whittingtonauthor=X.+Huangauthor=L.+Poppeauthor=A.+C.+Chengauthor=M.+Cardozoauthor=J.+Houzeauthor=Y.+Liauthor=B.+Lucasauthor=N.+A.+Parasauthor=X.+Wangauthor=J.+P.+Taygerlyauthor=M.+Vimolratanaauthor=M.+Zancanellaauthor=L.+Zhuauthor=E.+Cajulisauthor=T.+Osgoodauthor=J.+Sunauthor=L.+Damonauthor=R.+K.+Eganauthor=P.+Greningerauthor=J.+D.+McClanaghanauthor=J.+Gongauthor=D.+Moujalledauthor=G.+Pomilioauthor=P.+Beltranauthor=C.+H.+Benesauthor=A.+W.+Robertsauthor=D.+C.+Huangauthor=A.+Weiauthor=J.+Canonauthor=A.+Coxonauthor=P.+E.+Hughes&title=AMG+176%2C+a+selective+MCL1+inhibitor%2C+is+effective+in+hematologic+cancer+models+alone+and+in+combination+with+established+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies</span></div><div class="casAuthors">Caenepeel, Sean; Brown, Sean P.; Belmontes, Brian; Moody, Gordon; Keegan, Kathleen S.; Chui, Danny; Whittington, Douglas A.; Huang, Xin; Poppe, Leszek; Cheng, Alan C.; Cardozo, Mario; Houze, Jonathan; Li, Yunxiao; Lucas, Brian; Paras, Nick A.; Wang, Xianghong; Taygerly, Joshua P.; Vimolratana, Marc; Zancanella, Manuel; Zhu, Liusheng; Cajulis, Elaina; Osgood, Tao; Sun, Jan; Damon, Leah; Egan, Regina K.; Greninger, Patricia; McClanaghan, Joseph D.; Gong, Jianan; Moujalled, Donia; Pomilio, Giovanna; Beltran, Pedro; Benes, Cyril H.; Roberts, Andrew W.; Huang, David C.; Wei, Andrew; Canon, Jude; Coxon, Angela; Hughes, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1582-1597</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer.  To overcome the significant challenges assocd. with inhibition of MCL1 protein-protein interactions, we rigorously applied small-mol. conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans.  We demonstrate that MCL1 inhibition induces a rapid and committed step toward apoptosis in subsets of hematol. cancer cell lines, tumor xenograft models, and primary patient samples.  With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by redns. in B cells, monocytes, and neutrophils.  Furthermore, the combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses.  These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUtMExVVtn5rVg90H21EOLACvtfcHk0liSIsQD1rJI6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOmsb7E&md5=795a713908c3635bbd5e9fc3d95f3ae0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DMoody%26aufirst%3DG.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DChui%26aufirst%3DD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPoppe%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DHouze%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DParas%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DZancanella%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DCajulis%26aufirst%3DE.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DDamon%26aufirst%3DL.%26aulast%3DEgan%26aufirst%3DR.%2BK.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DMcClanaghan%26aufirst%3DJ.%2BD.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DMoujalled%26aufirst%3DD.%26aulast%3DPomilio%26aufirst%3DG.%26aulast%3DBeltran%26aufirst%3DP.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DHuang%26aufirst%3DD.%2BC.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26atitle%3DAMG%2520176%252C%2520a%2520selective%2520MCL1%2520inhibitor%252C%2520is%2520effective%2520in%2520hematologic%2520cancer%2520models%2520alone%2520and%2520in%2520combination%2520with%2520established%2520therapies%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D1582%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><a href="http://clinicaltrials.gov/ct2/show/NCT02992483" class="extLink">http://clinicaltrials.gov/ct2/show/NCT02992483</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02992483."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases</span>. <i>Genome Biology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1186/gb4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1186%2Fgb4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=25180339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=122-131&author=M.+Malumbres&title=Cyclin-dependent+kinases&doi=10.1186%2Fgb4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases</span></div><div class="casAuthors">Malumbres Marcos</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are protein kinases characterized by needing a separate subunit - a cyclin - that provides domains essential for enzymatic activity.  CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and intracellular cues.  The evolutionary expansion of the CDK family in mammals led to the division of CDKs into three cell-cycle-related subfamilies (Cdk1, Cdk4 and Cdk5) and five transcriptional subfamilies (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20).  Unlike the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few cyclins, consistent with functional specialization during evolution.  This review summarizes how, although CDKs are traditionally separated into cell-cycle or transcriptional CDKs, these activities are frequently combined in many family members.  Not surprisingly, deregulation of this family of proteins is a hallmark of several diseases, including cancer, and drug-targeted inhibition of specific members has generated very encouraging results in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQodaug4zJdjgHqQV89nF-2fW6udTcc2eaKH2kOekIZBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D&md5=9fd79ec8f495f712bada681b0a0b5afe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fgb4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb4184%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinases%26jtitle%3DGenome%2520Biology%26date%3D2014%26volume%3D15%26spage%3D122%26epage%3D131%26doi%3D10.1186%2Fgb4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0liSIsQD1rJI6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. M.</span></span> <span> </span><span class="NLM_article-title">The general transcription machinery and general cofactors</span>. <i>Crit. Rev. Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1080/10409230600648736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1080%2F10409230600648736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=16858867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvV2rtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2006&pages=105-178&author=M.+C.+Thomasauthor=C.+M.+Chiang&title=The+general+transcription+machinery+and+general+cofactors&doi=10.1080%2F10409230600648736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The general transcription machinery and general cofactors</span></div><div class="casAuthors">Thomas, Mary C.; Chiang, Cheng-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">105-178</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  In eukaryotes, the core promoter serves as a platform for the assembly of transcription preinitiation complex (PIC) that includes TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, and RNA polymerase II (pol II), which function collectively to specify the transcription start site.  PIC formation usually begins with TFIID binding to the TATA box, initiator, and/or downstream promoter element (DPE) found in most core promoters, followed by the entry of other general transcription factors (GTFs) and pol II through either a sequential assembly or a preassembled pol II holoenzyme pathway.  Formation of this promoter-bound complex is sufficient for a basal level of transcription.  However, for activator-dependent (or regulated) transcription, general cofactors are often required to transmit regulatory signals between gene-specific activators and the general transcription machinery.  Three classes of general cofactors, including TBP-assocd. factors (TAFs), Mediator, and upstream stimulatory activity (USA)-derived pos. cofactors (PC1/PARP-1, PC2, PC3/DNA topoisomerase I, and PC4) and neg. cofactor 1 (NC1/HMGB1), normally function independently or in combination to fine-tune the promoter activity in a gene-specific or cell-type-specific manner.  In addn., other cofactors, such as TAF1, BTAF1, and neg. cofactor 2 (NC2), can also modulate TBP or TFIID binding to the core promoter.  In general, these cofactors are capable of repressing basal transcription when activators are absent and stimulating transcription in the presence of activators.  Here the authors review the roles of these cofactors and GTFs, as well as TBP-related factors (TRFs), TAF-contg. complexes (TFTC, SAGA, SLIK/SALSA, STAGA, and PRC1) and TAF variants, in pol II-mediated transcription, with emphasis on the events occurring after the chromatin has been remodeled but prior to the formation of the first phosphodiester bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWFhQkI2LzYbVg90H21EOLACvtfcHk0lhVAkgigF-A6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvV2rtr8%253D&md5=6c6e557887a24ff4e15abb8ad50cfecb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F10409230600648736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10409230600648736%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%2BC.%26aulast%3DChiang%26aufirst%3DC.%2BM.%26atitle%3DThe%2520general%2520transcription%2520machinery%2520and%2520general%2520cofactors%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D41%26spage%3D105%26epage%3D178%26doi%3D10.1080%2F10409230600648736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varadarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poornima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. M.</span></span> <span> </span><span class="NLM_article-title">Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12668</span>– <span class="NLM_lpage">12681</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.18632%2Foncotarget.3706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=26059440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbit1eiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=12668-12681&author=S.+Varadarajanauthor=P.+Poornimaauthor=M.+Milaniauthor=K.+Gowdaauthor=S.+Aminauthor=H.+G.+Wangauthor=G.+M.+Cohen&title=Maritoclax+and+dinaciclib+inhibit+MCL-1+activity+and+induce+apoptosis+in+both+a+MCL-1-dependent+and+-independent+manner&doi=10.18632%2Foncotarget.3706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner</span></div><div class="casAuthors">Varadarajan Shankar; Poornima Paramasivan; Milani Mateus; Cohen Gerald M; Gowda Krishne; Amin Shantu; Wang Hong-Gang; Wang Hong-Gang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">12668-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The anti-apoptotic BCL-2 family proteins are important targets for cancer chemotherapy.  Specific and potent inhibitors of the BCL-2 family, such as ABT-263 (navitoclax) and ABT-199, are only effective against some members of the BCL-2 family but do not target MCL-1, which is commonly amplified in tumors and associated with chemoresistance.  In this report, the selectivity and potency of two putative MCL-1 inhibitors, dinaciclib and maritoclax, were assessed.  Although both compounds induced Bax/Bak- and caspase-9-dependent apoptosis, dinaciclib was more potent than maritoclax in downregulating MCL-1 and also in inducing apoptosis.  However, the compounds induced apoptosis, even in cells lacking MCL-1, suggesting multiple mechanisms of cell death.  Furthermore, maritoclax induced extensive mitochondrial fragmentation, and a Bax/Bak- but MCL-1-independent accumulation of mitochondrial reactive oxygen species (ROS), with an accompanying loss of complexes I and III of the electron transport chain.  ROS scavengers, such as MitoQ, could not salvage maritoclax-mediated effects on mitochondrial structure and function.  Taken together, our data demonstrate that neither dinaciclib nor maritoclax exclusively target MCL-1.  Although dinaciclib is clearly not a specific MCL-1 inhibitor, its ability to rapidly downregulate MCL-1 may be beneficial in many clinical settings, where it may reverse chemoresistance or sensitize to other chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpx_DiGIJ5y_EeosoOnpOLfW6udTcc2eZfCOfrTiNbKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbit1eiuw%253D%253D&md5=ca7166806754f153cf39c1ec30f2741d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3706%26sid%3Dliteratum%253Aachs%26aulast%3DVaradarajan%26aufirst%3DS.%26aulast%3DPoornima%26aufirst%3DP.%26aulast%3DMilani%26aufirst%3DM.%26aulast%3DGowda%26aufirst%3DK.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DMaritoclax%2520and%2520dinaciclib%2520inhibit%2520MCL-1%2520activity%2520and%2520induce%2520apoptosis%2520in%2520both%2520a%2520MCL-1-dependent%2520and%2520-independent%2520manner%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D12668%26epage%3D12681%26doi%3D10.18632%2Foncotarget.3706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booher, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolinski, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmonay, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Assaad, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebozhyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loboda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angagaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennon, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miselis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monahan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondic, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, P.</span></span> <span> </span><span class="NLM_article-title">MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e108371</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0108371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1371%2Fjournal.pone.0108371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=25289887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e108371&author=R.+N.+Booherauthor=H.+Hatchauthor=B.+M.+Dolinskiauthor=T.+Nguyenauthor=L.+Harmonayauthor=A.-S.+Al-Assaadauthor=M.+Ayersauthor=M.+Nebozhynauthor=A.+Lobodaauthor=H.+A.+Hirschauthor=T.+Zhangauthor=B.+Shiauthor=C.+E.+Merkelauthor=M.+H.+Angagawauthor=Y.+Wangauthor=B.+J.+Longauthor=X.+Q.+Lennonauthor=N.+Miselisauthor=V.+Pucciauthor=J.+W.+Monahanauthor=J.+Leeauthor=A.+G.+Kondicauthor=E.+K.+Imauthor=D.+Mauroauthor=R.+Blanchardauthor=G.+Gillilandauthor=S.+E.+Fawellauthor=L.+Zawelauthor=A.+G.+Schullerauthor=P.+Strack&title=MCL1+and+BCL-xL+levels+in+solid+tumors+are+predictive+of+dinaciclib-induced+apoptosis&doi=10.1371%2Fjournal.pone.0108371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis</span></div><div class="casAuthors">Booher, Robert N.; Hatch, Harold; Dolinski, Brian M.; Nguyen, Thi; Harmonay, Lauren; Al-Assaad, Ali-Samer; Ayers, Mark; Nebozhyn, Michael; Loboda, Andrey; Hirsch, Heather A.; Zhang, Theresa; Shi, Bin; Merkel, Carrie E.; Angagaw, Minilik H.; Wang, Yaolin; Long, Brian J.; Lennon, Xianlu Q.; Miselis, Nathan; Pucci, Vincenzo; Monahan, James W.; Lee, Junghoon; Kondic, Anna Georgieva; Im, Eun Kyung; Mauro, David; Blanchard, Rebecca; Gilliland, Gary; Fawell, Stephen E.; Zawel, Leigh; Schuller, Alwin G.; Strack, Peter</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e108371/1-e108371/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer.  Addnl. understanding of antitumor mechanisms and identification of predictive biomarkers are important for its clin. development.  Here we demonstrate that while dinaciclib can effectively block cell cycle progression, in vitro and in vivo studies, coupled with mouse and human pharmacokinetics, support a model whereby induction of apoptosis is a main mechanism of dinaciclib's antitumor effect and relevant to the clin. duration of exposure.  This was further underscored by kinetics of dinaciclib-induced downregulation of the antiapoptotic BCL2 family member MCL1 and correlation of sensitivity with the MCL1-to-BCL-xL mRNA ratio or MCL1 amplification in solid tumor models in vitro and in vivo.  This MCL1-dependent apoptotic mechanism was addnl. supported by synergy with the BCL2, BCL-xL and BCL-w inhibitor navitoclax (ABT-263).  These results provide the rationale for investigating MCL1 and BCL-xL as predictive biomarkers for dinaciclib antitumor response and testing combinations with BCL2 family member inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMdJOAK4lxgrVg90H21EOLACvtfcHk0lhVAkgigF-A6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjs73L&md5=f1402fd17dd19279cf81ad5d94b3c9df</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0108371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0108371%26sid%3Dliteratum%253Aachs%26aulast%3DBooher%26aufirst%3DR.%2BN.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DDolinski%26aufirst%3DB.%2BM.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DHarmonay%26aufirst%3DL.%26aulast%3DAl-Assaad%26aufirst%3DA.-S.%26aulast%3DAyers%26aufirst%3DM.%26aulast%3DNebozhyn%26aufirst%3DM.%26aulast%3DLoboda%26aufirst%3DA.%26aulast%3DHirsch%26aufirst%3DH.%2BA.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DB.%26aulast%3DMerkel%26aufirst%3DC.%2BE.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DB.%2BJ.%26aulast%3DLennon%26aufirst%3DX.%2BQ.%26aulast%3DMiselis%26aufirst%3DN.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DMonahan%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKondic%26aufirst%3DA.%2BG.%26aulast%3DIm%26aufirst%3DE.%2BK.%26aulast%3DMauro%26aufirst%3DD.%26aulast%3DBlanchard%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DSchuller%26aufirst%3DA.%2BG.%26aulast%3DStrack%26aufirst%3DP.%26atitle%3DMCL1%2520and%2520BCL-xL%2520levels%2520in%2520solid%2520tumors%2520are%2520predictive%2520of%2520dinaciclib-induced%2520apoptosis%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De108371%26doi%3D10.1371%2Fjournal.pone.0108371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bywater, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannan, R. D.</span></span> <span> </span><span class="NLM_article-title">Dysregulation of the basal RNA polymerase transcription apparatus in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1038/nrc3496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrc3496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=23612459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVeiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=299-314&author=M.+J.+Bywaterauthor=R.+B.+Pearsonauthor=G.+McArthurauthor=R.+D.+Hannan&title=Dysregulation+of+the+basal+RNA+polymerase+transcription+apparatus+in+cancer&doi=10.1038%2Fnrc3496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dysregulation of the basal RNA polymerase transcription apparatus in cancer</span></div><div class="casAuthors">Bywater, Megan J.; Pearson, Richard B.; McArthur, Grant A.; Hannan, Ross D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">299-314</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mutations that directly affect transcription by RNA polymerases rank among the most central mediators of malignant transformation, but the frequency of new anticancer drugs that selectively target defective transcription app. entering the clinic has been limited.  This is because targeting the large protein-protein and protein-DNA interfaces that control both generic and selective aspects of RNA polymerase transcription has proved extremely difficult.  However, recent technol. advances have led to a 'quantum leap' in our comprehension of the structure and function of the core RNA polymerase components, how they are dysregulated in a broad range of cancers and how they may be targeted for 'transcription therapy'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTjDkz-NvNvLVg90H21EOLACvtfcHk0lhrvU9838J91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVeiur0%253D&md5=09acaa7f20d40936b8f45903deb4e3f0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrc3496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3496%26sid%3Dliteratum%253Aachs%26aulast%3DBywater%26aufirst%3DM.%2BJ.%26aulast%3DPearson%26aufirst%3DR.%2BB.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DHannan%26aufirst%3DR.%2BD.%26atitle%3DDysregulation%2520of%2520the%2520basal%2520RNA%2520polymerase%2520transcription%2520apparatus%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D299%26epage%3D314%26doi%3D10.1038%2Fnrc3496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adelman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lis, J. T.</span></span> <span> </span><span class="NLM_article-title">Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">720</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1038/nrg3293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrg3293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=22986266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGnsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=720-731&author=K.+Adelmanauthor=J.+T.+Lis&title=Promoter-proximal+pausing+of+RNA+polymerase+II%3A+emerging+roles+in+metazoans&doi=10.1038%2Fnrg3293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans</span></div><div class="casAuthors">Adelman, Karen; Lis, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">720-731</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent years have witnessed a sea change in our understanding of transcription regulation: whereas traditional models focused solely on the events that brought RNA polymerase II (Pol II) to a gene promoter to initiate RNA synthesis, emerging evidence points to the pausing of Pol II during early elongation as a widespread regulatory mechanism in higher eukaryotes.  Current data indicate that pausing is particularly enriched at genes in signal-responsive pathways.  Here the evidence for pausing of Pol II from recent high-throughput studies will be discussed, as well as the potential interconnected functions of promoter-proximally paused Pol II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX1oOoJ6isLrVg90H21EOLACvtfcHk0lhrvU9838J91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGnsL7M&md5=8717dd13ced084695e8f6bc011566164</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrg3293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg3293%26sid%3Dliteratum%253Aachs%26aulast%3DAdelman%26aufirst%3DK.%26aulast%3DLis%26aufirst%3DJ.%2BT.%26atitle%3DPromoter-proximal%2520pausing%2520of%2520RNA%2520polymerase%2520II%253A%2520emerging%2520roles%2520in%2520metazoans%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2012%26volume%3D13%26spage%3D720%26epage%3D731%26doi%3D10.1038%2Fnrg3293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilchrist, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelman, K.</span></span> <span> </span><span class="NLM_article-title">Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.cell.2010.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=21074046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2010&pages=540-551&author=D.+A.+Gilchristauthor=G.+Dos+Santosauthor=D.+C.+Fargoauthor=B.+Xieauthor=Y.+Gaoauthor=L.+Liauthor=K.+Adelman&title=Pausing+of+RNA+polymerase+II+disrupts+DNA-specified+nucleosome+organization+to+enable+precise+gene+regulation&doi=10.1016%2Fj.cell.2010.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation</span></div><div class="casAuthors">Gilchrist, Daniel A.; Dos Santos, Gilberto; Fargo, David C.; Xie, Bin; Gao, Yuan; Li, Leping; Adelman, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">540-551</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Metazoan transcription is controlled through either coordinated recruitment of transcription machinery to the gene promoter or regulated pausing of RNA polymerase II (Pol II) in early elongation.  The authors report that a striking difference between genes that use these distinct regulatory strategies lies in the "default" chromatin architecture specified by their DNA sequences.  Pol II pausing is prominent at highly regulated genes whose sequences inherently disfavor nucleosome formation within the gene but favor occlusion of the promoter by nucleosomes.  In contrast, housekeeping genes that lack pronounced Pol II pausing show higher nucleosome occupancy downstream, but their promoters are deprived of nucleosomes regardless of polymerase binding.  These results indicate that a key role of paused Pol II is to compete with nucleosomes for occupancy of highly regulated promoters, thereby preventing the formation of repressive chromatin architecture to facilitate further or future gene activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2kU07Y9s-H7Vg90H21EOLACvtfcHk0lhrvU9838J91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahtbrF&md5=4df1ccb5962df23bcbfbe8e9c1b38b74</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DGilchrist%26aufirst%3DD.%2BA.%26aulast%3DDos%2BSantos%26aufirst%3DG.%26aulast%3DFargo%26aufirst%3DD.%2BC.%26aulast%3DXie%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DAdelman%26aufirst%3DK.%26atitle%3DPausing%2520of%2520RNA%2520polymerase%2520II%2520disrupts%2520DNA-specified%2520nucleosome%2520organization%2520to%2520enable%2520precise%2520gene%2520regulation%26jtitle%3DCell%26date%3D2010%26volume%3D143%26spage%3D540%26epage%3D551%26doi%3D10.1016%2Fj.cell.2010.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sansó, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Pause, play, repeat: CDKs push RNAP II’s buttons</span>. <i>Transcription</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.4161/trns.25146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.4161%2Ftrns.25146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=23756342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC3sjit1Kgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=146-152&author=M.+Sans%C3%B3author=R.+P.+Fisher&title=Pause%2C+play%2C+repeat%3A+CDKs+push+RNAP+II%E2%80%99s+buttons&doi=10.4161%2Ftrns.25146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pause, play, repeat: CDKs push RNAP II's buttons</span></div><div class="casAuthors">Sanso Miriam; Fisher Robert P</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">146-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) play a central role in governing eukaryotic cell division.  It is becoming clear that the transcription cycle of RNA polymerase II (RNAP II) is also regulated by CDKs; in metazoans, the cell cycle and transcriptional CDK networks even share an upstream activating kinase, which is itself a CDK.  From recent chemical-genetic analyses we know that CDKs and their substrates control events both early in transcription (the transition from initiation to elongation) and late (3' end formation and transcription termination).  Moreover, mutual dependence on CDK activity might couple the "beginning" and "end" of the cycle, to ensure the fidelity of mRNA maturation and the efficient recycling of RNAP II from sites of termination to the transcription start site (TSS).  As is the case for CDKs involved in cell cycle regulation, different transcriptional CDKs act in defined sequence on multiple substrates.  These phosphorylations are likely to influence gene expression by several mechanisms, including direct, allosteric effects on the transcription machinery, co-transcriptional recruitment of proteins needed for mRNA-capping, splicing and 3' end maturation, dependent on multisite phosphorylation of the RNAP II C-terminal domain (CTD) and, perhaps, direct regulation of RNA-processing or histone-modifying machinery.  Here we review these recent advances, and preview the emerging challenges for transcription-cycle research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVCXjX-6gFVbjnyZkbE8yXfW6udTcc2eYzcIoVq0evnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjit1Kgug%253D%253D&md5=4e774056e5b96f6d44504b2f5695f636</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4161%2Ftrns.25146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Ftrns.25146%26sid%3Dliteratum%253Aachs%26aulast%3DSans%25C3%25B3%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DPause%252C%2520play%252C%2520repeat%253A%2520CDKs%2520push%2520RNAP%2520II%25E2%2580%2599s%2520buttons%26jtitle%3DTranscription%26date%3D2013%26volume%3D4%26spage%3D146%26epage%3D152%26doi%3D10.4161%2Ftrns.25146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napoleon, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin dependent kinase 9 inhibitors for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8667</span>– <span class="NLM_lpage">8684</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00150</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00150" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslGjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8667-8684&author=Y.+A.+Sonawaneauthor=M.+A.+Taylorauthor=J.+V.+Napoleonauthor=S.+Ranaauthor=J.+I.+Contrerasauthor=A.+Natarajan&title=Cyclin+dependent+kinase+9+inhibitors+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.6b00150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy</span></div><div class="casAuthors">Sonawane, Yogesh A.; Taylor, Margaret A.; Napoleon, John Victor; Rana, Sandeep; Contreras, Jacob I.; Natarajan, Amarnath</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8667-8684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and crit. functions within the cell.  Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics.  CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is crit. for the survival of transformed cells.  Focused chem. libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors.  Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOIqU9uSujdrVg90H21EOLACvtfcHk0liqAT8SdDBKmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslGjsLo%253D&md5=0910a61f9c915002ff1073b22b5e20d6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00150%26sid%3Dliteratum%253Aachs%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DNapoleon%26aufirst%3DJ.%2BV.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DNatarajan%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%25209%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8667%26epage%3D8684%26doi%3D10.1021%2Facs.jmedchem.6b00150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Midgley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabarek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClue, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLachlan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheleva, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1111</span>– <span class="NLM_lpage">1121</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.chembiol.2010.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=21035734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1111-1121&author=S.+Wangauthor=G.+Griffithsauthor=C.+A.+Midgleyauthor=A.+L.+Barnettauthor=M.+Cooperauthor=J.+Grabarekauthor=L.+Ingramauthor=W.+Jacksonauthor=G.+Kontopidisauthor=S.+J.+McClueauthor=C.+McInnesauthor=J.+McLachlanauthor=C.+Meadesauthor=M.+Meznaauthor=I.+Stuartauthor=M.+P.+Thomasauthor=D.+I.+Zhelevaauthor=D.+P.+Laneauthor=R.+C.+Jacksonauthor=D.+M.+Gloverauthor=D.+G.+Blakeauthor=P.+M.+Fischer&title=Discovery+and+characterization+of+2-anilino-4-+%28thiazol-5-yl%29pyrimidine+transcriptional+CDK+inhibitors+as+anticancer+agents&doi=10.1016%2Fj.chembiol.2010.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Wang, Shu-Dong; Griffiths, Gary; Midgley, Carol A.; Barnett, Anna L.; Cooper, Michael; Grabarek, Joanna; Ingram, Laura; Jackson, Wayne; Kontopidis, George; McClue, Steven J.; McInnes, Campbell; McLachlan, Janice; Meades, Christopher; Mezna, Mokdad; Stuart, Iain; Thomas, Mark P.; Zheleva, Daniella I.; Lane, David P.; Jackson, Robert C.; Glover, David M.; Blake, David G.; Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1111-1121</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The main difficulty in the development of ATP antagonist kinase inhibitors is target specificity, since the ATP-binding motif is present in many proteins.  We introduce a strategy that has allowed us to identify compds. from a kinase inhibitor library that block the cyclin-dependent kinases responsible for regulating transcription, i.e., CDK7 and esp. CDK9.  The screening cascade employs cellular phenotypic assays based on mitotic index and nuclear p53 protein accumulation.  This permitted us to classify compds. into transcriptional, cell cycle, and mitotic inhibitor groups.  We describe the characterization of the transcriptional inhibitor class in terms of kinase inhibition profile, cellular mode of action, and selectivity for transformed cells.  A structural selectivity rationale was used to optimize potency and biopharmaceutical properties and led to the development of a transcriptional inhibitor, 3,4-dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one, with anticancer activity in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryOG4LTevHibVg90H21EOLACvtfcHk0liqAT8SdDBKmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL&md5=08aff2706f6eda4ba1038327267a361e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DMidgley%26aufirst%3DC.%2BA.%26aulast%3DBarnett%26aufirst%3DA.%2BL.%26aulast%3DCooper%26aufirst%3DM.%26aulast%3DGrabarek%26aufirst%3DJ.%26aulast%3DIngram%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DMcLachlan%26aufirst%3DJ.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DZheleva%26aufirst%3DD.%2BI.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DGlover%26aufirst%3DD.%2BM.%26aulast%3DBlake%26aufirst%3DD.%2BG.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDiscovery%2520and%2520characterization%2520of%25202-anilino-4-%2520%2528thiazol-5-yl%2529pyrimidine%2520transcriptional%2520CDK%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D1111%26epage%3D1121%26doi%3D10.1016%2Fj.chembiol.2010.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassington, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byth, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMiken, H. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcombe, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauptit, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanway, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span> <span> </span><span class="NLM_article-title">Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5487</span>– <span class="NLM_lpage">5492</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.bmcl.2008.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=18815031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5487-5492&author=M.+Andersonauthor=D.+M.+Andrewsauthor=A.+J.+Barkerauthor=C.+A.+Brassingtonauthor=J.+Breedauthor=K.+F.+Bythauthor=J.+D.+Culshawauthor=M.+R.+V.+Finlayauthor=E.+Fisherauthor=H.+H.+J.+McMikenauthor=C.+P.+Greenauthor=D.+W.+Heatonauthor=I.+A.+Nashauthor=N.+J.+Newcombeauthor=S.+E.+Oakesauthor=R.+A.+Pauptitauthor=A.+Robertsauthor=J.+J.+Stanwayauthor=A.+P.+Thomasauthor=J.+A.+Tuckerauthor=M.+Walkerauthor=H.+M.+Weir&title=Imidazoles%3A+SAR+and+development+of+a+potent+class+of+cyclin-dependent+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2008.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors</span></div><div class="casAuthors">Anderson, Malcolm; Andrews, David M.; Barker, Andy J.; Brassington, Claire A.; Breed, Jason; Byth, Kate F.; Culshaw, Janet D.; Finlay, M. Raymond V.; Fisher, Eric; McMiken, Helen H. J.; Green, Clive P.; Heaton, Dave W.; Nash, Ian A.; Newcombe, Nicholas J.; Oakes, Sandra E.; Pauptit, Richard A.; Roberts, Andrew; Stanway, Judith J.; Thomas, Andrew P.; Tucker, Julie A.; Walker, Mike; Weir, Hazel M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5487-5492</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed.  Protein inhibitor structure detn. has provided an understanding of the emerging structure activity trends for the imidazole series.  The introduction of a Me sulfone at the aniline terminus led to a more orally bioavailable CDK inhibitor that was progressed into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSg0heaJEiurVg90H21EOLACvtfcHk0lgVZnN-n6P_sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs7zM&md5=c2967070f2ab5480c2fddb111a18687b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DBrassington%26aufirst%3DC.%2BA.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DByth%26aufirst%3DK.%2BF.%26aulast%3DCulshaw%26aufirst%3DJ.%2BD.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DFisher%26aufirst%3DE.%26aulast%3DMcMiken%26aufirst%3DH.%2BH.%2BJ.%26aulast%3DGreen%26aufirst%3DC.%2BP.%26aulast%3DHeaton%26aufirst%3DD.%2BW.%26aulast%3DNash%26aufirst%3DI.%2BA.%26aulast%3DNewcombe%26aufirst%3DN.%2BJ.%26aulast%3DOakes%26aufirst%3DS.%2BE.%26aulast%3DPauptit%26aufirst%3DR.%2BA.%26aulast%3DRoberts%26aufirst%3DA.%26aulast%3DStanway%26aufirst%3DJ.%2BJ.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26atitle%3DImidazoles%253A%2520SAR%2520and%2520development%2520of%2520a%2520potent%2520class%2520of%2520cyclin-dependent%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5487%26epage%3D5492%26doi%3D10.1016%2Fj.bmcl.2008.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapenna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle kinases as therapeutic targets for cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nrd2907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrd2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=19568282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+cycle+kinases+as+therapeutic+targets+for+cancer&doi=10.1038%2Fnrd2907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Lapenna, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-566</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells.  Although several mols. that inhibit cell cycle kinases have been developed and clin. screened as potential anticancer agents, none of these has been approved for com. use and an effective strategy to specifically control malignant cell proliferation has yet to be established.  However, recent genetic and biochem. studies have provided information about the requirement for certain cell cycle kinases by specific tumors and specialized tissue types.  Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7YptkwzjgrVg90H21EOLACvtfcHk0lgVZnN-n6P_sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D&md5=7acb71b7aaf0ab644227103f7c14b892</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2907%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520cycle%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566%26doi%3D10.1038%2Fnrd2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span>; <span class="NLM_string-name">Shen, M.</span>; <span class="NLM_string-name">Grondine, M.</span>; <span class="NLM_string-name">Boiko, S.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Borodovsky, A.</span>; <span class="NLM_string-name">Mazzola, A. M.</span>; <span class="NLM_string-name">Wu, A.</span>; <span class="NLM_string-name">Lawson, D.</span>; <span class="NLM_string-name">Ferguson, F.</span>; <span class="NLM_string-name">Gao, B.</span>; <span class="NLM_string-name">Cui, A.</span>; <span class="NLM_string-name">D’Cruz, C.</span>; <span class="NLM_string-name">Drew, L.</span></span> <span> </span><span class="NLM_article-title">AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, April 16–20, 2016</span>.  <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">76</span> (<span class="NLM_issue">14 Suppl.</span>), Abstract  <span class="NLM_fpage">3572</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=27197168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3572&issue=14+Suppl.&author=J.+Cidado&author=M.+Shen&author=M.+Grondine&author=S.+Boiko&author=H.+Wang&author=A.+Borodovsky&author=A.+M.+Mazzola&author=A.+Wu&author=D.+Lawson&author=F.+Ferguson&author=B.+Gao&author=A.+Cui&author=C.+D%E2%80%99Cruz&author=L.+Drew&title=AZ5576%2C+a+novel+potent+and+selective+CDK9+inhibitor%2C+induces+rapid+cell+death+and+achieves+efficacy+in+multiple+preclinical+hematological+models.+Proceedings+of+the+107th+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+New+Orleans%2C+April+16%E2%80%9320%2C+2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCidado%26aufirst%3DJ.%26atitle%3DAZ5576%252C%2520a%2520novel%2520potent%2520and%2520selective%2520CDK9%2520inhibitor%252C%2520induces%2520rapid%2520cell%2520death%2520and%2520achieves%2520efficacy%2520in%2520multiple%2520preclinical%2520hematological%2520models.%2520Proceedings%2520of%2520the%2520107th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520New%2520Orleans%252C%2520April%252016%25E2%2580%259320%252C%25202016%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D14%2520Suppl%26spage%3D3572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span> AZ5576 is also
known
as PC585:<span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Cuellar, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Füller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäthner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetzner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeitlmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slany, R. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1435</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fleu.2014.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=24445865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlSitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=1427-1435&author=M.+P.+Garcia-Cuellarauthor=E.+F%C3%BCllerauthor=E.+M%C3%A4thnerauthor=C.+Breitingerauthor=K.+Hetznerauthor=L.+Zeitlmannauthor=A.+Borkhardtauthor=R.+K.+Slany&title=Efficacy+of+cyclin-dependent-kinase+9+inhibitors+in+a+murine+model+of+mixed-lineage+leukemia&doi=10.1038%2Fleu.2014.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia</span></div><div class="casAuthors">Garcia-Cuellar, M.-P.; Fueller, E.; Maethner, E.; Breitinger, C.; Hetzner, K.; Zeitlmann, L.; Borkhardt, A.; Slany, R. K.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1427-1435</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mixed-lineage leukemia fusion proteins activate their target genes predominantly by stimulating transcriptional elongation.  A core component necessary for this activity is cyclin-dependent kinase 9.  Here we explored the effectiveness of small mols. targeting this enzyme as potential therapeutics.  A screen of seven compds. with anti-CDK9 activity applied to a panel of leukemia cell lines identified flavopiridol and the exptl. inhibitor PC585 as superior in efficacy with inhibitory concns. in the submicromolar range.  Both substances induced rapid dephosphorylation of the RNA polymerase II C-terminal domain, accompanied by downregulation of CDK9-dependent transcripts for MYC and HOXA9.  Global gene expression anal. indicated the induction of a general stress response program, culminating in widespread apoptosis.  Importantly, colony-forming activity in leukemia lines and primary patient samples could be completely inhibited under conditions that did not affect native precursors from bone marrow.  In vivo application in a mouse transplant model significantly delayed disease with PC585 showing also oral activity.  These results suggest CDK9 inhibition as novel treatment option for mixed-lineage leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpw5z9XGY1zbVg90H21EOLACvtfcHk0lj3XwoO2z8ANQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlSitLk%253D&md5=d0160dbc9e168218924e55501cf7b375</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.40%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Cuellar%26aufirst%3DM.%2BP.%26aulast%3DF%25C3%25BCller%26aufirst%3DE.%26aulast%3DM%25C3%25A4thner%26aufirst%3DE.%26aulast%3DBreitinger%26aufirst%3DC.%26aulast%3DHetzner%26aufirst%3DK.%26aulast%3DZeitlmann%26aufirst%3DL.%26aulast%3DBorkhardt%26aufirst%3DA.%26aulast%3DSlany%26aufirst%3DR.%2BK.%26atitle%3DEfficacy%2520of%2520cyclin-dependent-kinase%25209%2520inhibitors%2520in%2520a%2520murine%2520model%2520of%2520mixed-lineage%2520leukemia%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D1427%26epage%3D1435%26doi%3D10.1038%2Fleu.2014.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span>AZ5576
was described in patent literature: <span class="NLM_contrib-group"><span class="NLM_string-name">Heiser, U.</span>; <span class="NLM_string-name">Niestroj, A. J.</span>; <span class="NLM_string-name">Zeitlmann, L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Protein Kinases</span>. PCT Int. Appl., WO 2011110612, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=U.+Heiser&author=A.+J.+Niestroj&author=L.+Zeitlmann&title=Inhibitors+of+Protein+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeiser%26aufirst%3DU.%26atitle%3DInhibitors%2520of%2520Protein%2520Kinases%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albert, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisterernst, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1111/bph.12408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1111%2Fbph.12408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=24102143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2mtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=55-68&author=T.+K.+Albertauthor=C.+Rigaultauthor=J.+Eickhoffauthor=K.+Baumgartauthor=C.+Antrechtauthor=B.+Kleblauthor=G.+Mittlerauthor=M.+Meisterernst&title=Characterization+of+molecular+and+cellular+functions+of+the+cyclin-dependent+kinase+CDK9+using+a+novel+specific+inhibitor&doi=10.1111%2Fbph.12408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor</span></div><div class="casAuthors">Albert, T. K.; Rigault, C.; Eickhoff, J.; Baumgart, K.; Antrecht, C.; Klebl, B.; Mittler, G.; Meisterernst, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The cyclin-dependent kinase CDK9 is an important therapeutic target but currently available inhibitors exhibit low specificity and/or narrow therapeutic windows.  Here we have used a new highly specific CDK9 inhibitor, LDC000067 to interrogate gene control mechanisms mediated by CDK9.  Exptl. Approach : The selectivity of LDC000067 was established in functional kinase assays.  Functions of CDK9 in gene expression were assessed with in vitro transcription expts., single gene analyses and genome-wide expression profiling.  Cultures of mouse embryonic stem cells, HeLa cells, several cancer cell lines, along with cells from patients with acute myelogenous leukemia were also used to investigate cellular responses to LDC000067.  Key Results : The selectivity of LDC000067 for CDK9 over other CDKs exceeded that of the known inhibitors flavopiridol and DRB.  LDC000067 inhibited in vitro transcription in an ATP-competitive and dose-dependent manner.  Gene expression profiling of cells treated with LDC000067 demonstrated a selective redn. of short-lived mRNAs, including important regulators of proliferation and apoptosis.  Anal. of de novo RNA synthesis suggested a wide ranging pos. role of CDK9.  At the mol. and cellular level, LDC000067 reproduced effects characteristic of CDK9 inhibition such as enhanced pausing of RNA polymerase II on genes and, most importantly, induction of apoptosis in cancer cells.  Conclusions and Implications : Our study provides a framework for the mechanistic understanding of cellular responses to CDK9 inhibition.  LDC000067 represents a promising lead for the development of clin. useful, highly specific CDK9 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphlq2wB8J8BbVg90H21EOLACvtfcHk0lj3XwoO2z8ANQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2mtLbF&md5=61dccacb940578e746fb5f3962ccd87e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fbph.12408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12408%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DT.%2BK.%26aulast%3DRigault%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBaumgart%26aufirst%3DK.%26aulast%3DAntrecht%26aufirst%3DC.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMittler%26aufirst%3DG.%26aulast%3DMeisterernst%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520molecular%2520and%2520cellular%2520functions%2520of%2520the%2520cyclin-dependent%2520kinase%2520CDK9%2520using%2520a%2520novel%2520specific%2520inhibitor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D55%26epage%3D68%26doi%3D10.1111%2Fbph.12408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreklau, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fales, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carballares, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajamie, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronier, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeckner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sissons, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halstead, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoho, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaynor, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span> <span> </span><span class="NLM_article-title">A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1442</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1158%2F1535-7163.MCT-13-0849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=24688048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Kqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1442-1456&author=T.+Yinauthor=M.+J.+Lallenaauthor=E.+L.+Kreklauauthor=K.+R.+Falesauthor=S.+Carballaresauthor=R.+Torresauthor=G.+N.+Wishartauthor=R.+T.+Ajamieauthor=D.+M.+Cronierauthor=P.+W.+Iversenauthor=T.+I.+Meierauthor=R.+T.+Foremanauthor=D.+Zecknerauthor=S.+E.+Sissonsauthor=B.+W.+Halsteadauthor=A.+B.+Linauthor=G.+P.+Donohoauthor=Y.+Qianauthor=S.+Liauthor=S.+Wuauthor=A.+Aggarwalauthor=X.+S.+Yeauthor=J.+J.+Starlingauthor=R.+B.+Gaynorauthor=A.+de+Diosauthor=J.+Du&title=A+novel+CDK9+inhibitor+shows+potent+antitumor+efficacy+in+preclinical+hematologic+tumor+models&doi=10.1158%2F1535-7163.MCT-13-0849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models</span></div><div class="casAuthors">Yin, Tinggui; Lallena, Maria J.; Kreklau, Emiko L.; Fales, Kevin R.; Carballares, Santiago; Torrres, Raquel; Wishart, Graham N.; Ajamie, Rose T.; Cronier, Damien M.; Iversen, Phillip W.; Meier, Timothy I.; Foreman, Robert T.; Zeckner, Douglas; Sissons, Sean E.; Halstead, Bart W.; Lin, Aimee B.; Donoho, Gregory P.; Qian, Yuewei; Li, Shuyu; Wu, Song; Aggarwal, Amit; Ye, Xiang S.; Starling, James J.; Gaynor, Richard B.; de Dios, Alfonso; Du, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1442-1456</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">DNA-dependent RNA polymerase II (RNAP II) largest subunit RPB1 C-terminal domain (CTD) kinases, including CDK9, are serine/threonine kinases known to regulate transcriptional initiation and elongation by phosphorylating Ser 2, 5, and 7 residues on CTD.  Given the reported dysregulation of these kinases in some cancers, we asked whether inhibiting CDK9 may induce stress response and preferentially kill tumor cells.  Herein, we describe a potent CDK9 inhibitor, LY2857785, that significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.  This mol. inhibits the growth of a broad panel of cancer cell lines, and is particularly efficacious in leukemia cells, including orthotopic leukemia preclin. models as well as in ex vivo acute myeloid leukemia and chronic lymphocytic leukemia patient tumor samples.  Thus, inhibition of CDK9 may represent an interesting approach as a cancer therapeutic target, esp. in hematol. malignancies.  Mol Cancer Ther; 13(6); 1442-56. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAbH82lPOkSbVg90H21EOLACvtfcHk0lj3XwoO2z8ANQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Kqu7c%253D&md5=1e8a21ce9aed0a08012e9b58d8d668b9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0849%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DT.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3DKreklau%26aufirst%3DE.%2BL.%26aulast%3DFales%26aufirst%3DK.%2BR.%26aulast%3DCarballares%26aufirst%3DS.%26aulast%3DTorres%26aufirst%3DR.%26aulast%3DWishart%26aufirst%3DG.%2BN.%26aulast%3DAjamie%26aufirst%3DR.%2BT.%26aulast%3DCronier%26aufirst%3DD.%2BM.%26aulast%3DIversen%26aufirst%3DP.%2BW.%26aulast%3DMeier%26aufirst%3DT.%2BI.%26aulast%3DForeman%26aufirst%3DR.%2BT.%26aulast%3DZeckner%26aufirst%3DD.%26aulast%3DSissons%26aufirst%3DS.%2BE.%26aulast%3DHalstead%26aufirst%3DB.%2BW.%26aulast%3DLin%26aufirst%3DA.%2BB.%26aulast%3DDonoho%26aufirst%3DG.%2BP.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DAggarwal%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DX.%2BS.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DGaynor%26aufirst%3DR.%2BB.%26aulast%3Dde%2BDios%26aufirst%3DA.%26aulast%3DDu%26aufirst%3DJ.%26atitle%3DA%2520novel%2520CDK9%2520inhibitor%2520shows%2520potent%2520antitumor%2520efficacy%2520in%2520preclinical%2520hematologic%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1442%26epage%3D1456%26doi%3D10.1158%2F1535-7163.MCT-13-0849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Luecking, U.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Boemer, U.</span>; <span class="NLM_string-name">Ellinghaus, P.</span>; <span class="NLM_string-name">Walter, A. O.</span>; <span class="NLM_string-name">Valencia, R.</span>; <span class="NLM_string-name">Ince, S.</span>; <span class="NLM_string-name">von
Nussbaum, F.</span>; <span class="NLM_string-name">Mumberg, D.</span>; <span class="NLM_string-name">Brands, M.</span>; <span class="NLM_string-name">Karl Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, April 18–22, 2015</span>.  <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume">75</span> (<span class="NLM_issue">15 Suppl.</span>), Abstract  <span class="NLM_fpage">DDT02</span>– <span class="NLM_lpage">02</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=DDT02-02&issue=15+Suppl.&author=A.+Scholz&author=U.+Luecking&author=G.+Siemeister&author=P.+Lienau&author=U.+Boemer&author=P.+Ellinghaus&author=A.+O.+Walter&author=R.+Valencia&author=S.+Ince&author=F.+von%0ANussbaum&author=D.+Mumberg&author=M.+Brands&author=K.+Karl+Ziegelbauer&title=BAY+1143572%3A+A+first-in-class%2C+highly+selective%2C+potent+and+orally+available+inhibitor+of+PTEFb%2FCDK9+currently+in+phase+I%2C+inhibits+MYC+and+shows+convincing+anti-tumor+activity+in+multiple+xenograft+models+by+the+induction+of+apoptosis.+Proceedings+of+the+106th+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Philadelphia%2C+April+18%E2%80%9322%2C+2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScholz%26aufirst%3DA.%26atitle%3DBAY%25201143572%253A%2520A%2520first-in-class%252C%2520highly%2520selective%252C%2520potent%2520and%2520orally%2520available%2520inhibitor%2520of%2520PTEFb%252FCDK9%2520currently%2520in%2520phase%2520I%252C%2520inhibits%2520MYC%2520and%2520shows%2520convincing%2520anti-tumor%2520activity%2520in%2520multiple%2520xenograft%2520models%2520by%2520the%2520induction%2520of%2520apoptosis.%2520Proceedings%2520of%2520the%2520106th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520Philadelphia%252C%2520April%252018%25E2%2580%259322%252C%25202015%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D15%2520Suppl%26spage%3DDDT02%26epage%3D02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebesi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boemer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruehter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span> <span> </span><span class="NLM_article-title">Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1002%2Fcmdc.201700447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=28961375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1776-1793&author=U.+Lueckingauthor=A.+Scholzauthor=P.+Lienauauthor=G.+Siemeisterauthor=D.+Kosemundauthor=R.+Bohlmannauthor=H.+Briemauthor=I.+Terebesiauthor=K.+Meyerauthor=K.+Prelleauthor=K.+Dennerauthor=U.+Boemerauthor=M.+Schaeferauthor=K.+Eisauthor=R.+Valenciaauthor=S.+Inceauthor=F.+von+Nussbaumauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=B.+Kleblauthor=A.+Choidasauthor=P.+Nussbaumerauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=G.+Ruehterauthor=J.+Eickhoffauthor=M.+Brands&title=Identification+of+atuveciclib+%28BAY+1143572%29%2C+the+first+highly+selective%2C+clinical+PTEFb%2FCDK9+inhibitor+for+the+treatment+of+cancer&doi=10.1002%2Fcmdc.201700447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Luecking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Boemer, Ulf; Schaefer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbauer, Karl; Klebl, Bert; Choidas, Axel; Nussbaumer, Peter; Baumann, Matthias; Schultz-Fademrecht, Carsten; Ruehter, Gerd; Eickhoff, Jan; Brands, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1776-1793</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy.  Starting from lead compd. BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochem. and DMPK properties finally led to the identification of the orally available clin. candidate atuveciclib (BAY 1143572).  Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats.  BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypgkxBuypa7Vg90H21EOLACvtfcHk0lh38kEgeMcweA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ&md5=04fb5dae9956246889e1313c87339990</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700447%26sid%3Dliteratum%253Aachs%26aulast%3DLuecking%26aufirst%3DU.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DTerebesi%26aufirst%3DI.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DPrelle%26aufirst%3DK.%26aulast%3DDenner%26aufirst%3DK.%26aulast%3DBoemer%26aufirst%3DU.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DEis%26aufirst%3DK.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DInce%26aufirst%3DS.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DRuehter%26aufirst%3DG.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBrands%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520atuveciclib%2520%2528BAY%25201143572%2529%252C%2520the%2520first%2520highly%2520selective%252C%2520clinical%2520PTEFb%252FCDK9%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1776%26epage%3D1793%26doi%3D10.1002%2Fcmdc.201700447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U. T. R.</span>; <span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Bohlmann, R.</span>; <span class="NLM_string-name">Briem, H.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Terebesi, I.</span>; <span class="NLM_string-name">Meyer, K.</span>; <span class="NLM_string-name">Prelle, K.</span>; <span class="NLM_string-name">Valencia, R.</span>; <span class="NLM_string-name">Ince, S.</span>; <span class="NLM_string-name">von Nussbaum, F.</span>; <span class="NLM_string-name">Mumberg, D.</span>; <span class="NLM_string-name">Ziegelbauer, K.</span>; <span class="NLM_string-name">Brands, M.</span></span>. <span> </span><span class="NLM_article-title">Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops. Proceedings of the 2017 Annual Meeting of the American Association for Cancer Research (AACR), Washington D.C., April 1–5, 2017</span>,  <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">77</span> (<span class="NLM_issue">13 Suppl.</span>), Abstract  <span class="NLM_fpage">984</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=984&issue=13+Suppl.&author=U.+T.+R.+Luecking&author=A.+Scholz&author=D.+Kosemund&author=R.+Bohlmann&author=H.+Briem&author=P.+Lienau&author=G.+Siemeister&author=I.+Terebesi&author=K.+Meyer&author=K.+Prelle&author=R.+Valencia&author=S.+Ince&author=F.+von+Nussbaum&author=D.+Mumberg&author=K.+Ziegelbauer&author=M.+Brands&title=Identification+of+potent+and+highly+selective+PTEFb+inhibitor+BAY+1251152+for+the+treatment+of+cancer%3A+from+p.o.+to+i.v.+application+via+scaffold+hops.+Proceedings+of+the+2017+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Washington+D.C.%2C+April+1%E2%80%935%2C+2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuecking%26aufirst%3DU.%2BT.%2BR.%26atitle%3DIdentification%2520of%2520potent%2520and%2520highly%2520selective%2520PTEFb%2520inhibitor%2520BAY%25201251152%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520from%2520p.o.%2520to%2520i.v.%2520application%2520via%2520scaffold%2520hops.%2520Proceedings%2520of%2520the%25202017%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520Washington%2520D.C.%252C%2520April%25201%25E2%2580%25935%252C%25202017%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520Suppl%26spage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span> <span> </span><span class="NLM_article-title">Novel Parham-type cycloacylations of 1<i>H</i>-pyrazole-1-alkanoic acids</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>1997</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1055/s-1997-955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1055%2Fs-1997-955" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1997&publication_year=1997&pages=1013-1014&author=S.+D.+Larsen&title=Novel+Parham-type+cycloacylations+of+1H-pyrazole-1-alkanoic+acids&doi=10.1055%2Fs-1997-955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1055%2Fs-1997-955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1997-955%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26atitle%3DNovel%2520Parham-type%2520cycloacylations%2520of%25201H-pyrazole-1-alkanoic%2520acids%26jtitle%3DSynlett%26date%3D1997%26volume%3D1997%26spage%3D1013%26epage%3D1014%26doi%3D10.1055%2Fs-1997-955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galeta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenora, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potacek, M.</span></span> <span> </span><span class="NLM_article-title">Dihydropyrrolo[1,2-b]pyrazoles: withasomnine and related compounds</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">7139</span>– <span class="NLM_lpage">7146</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2013.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.tet.2013.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=7139-7146&author=J.+Galetaauthor=L.+Tenoraauthor=S.+Manauthor=M.+Potacek&title=Dihydropyrrolo%5B1%2C2-b%5Dpyrazoles%3A+withasomnine+and+related+compounds&doi=10.1016%2Fj.tet.2013.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydropyrrolo[1,2-b]pyrazoles: withasomnine and related compounds</span></div><div class="casAuthors">Galeta, Juraj; Tenora, Lukas; Man, Stanislav; Potacek, Milan</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">7139-7146</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A methodol. involving the prepn. of substituted dihydropyrrolo[1,2-b]pyrazoles, e.g., I, focuses on withasomnine and the synthesis of several structurally related compds, is reported.  The developed reaction protocols enable the prepn. of the mentioned bicyclic system with broadly diverse substitution.  The reaction protocol, consisting of two multi-step synthetic pathways, includes Sonogashira and Suzuki-Miyaura cross-coupling reactions, allenyl synthon formation, Kulinkovich cyclopropanation, ring transformations, and nonsym. homoallenyl azines cycloaddns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ6qZtfek5lrVg90H21EOLACvtfcHk0lhLynMKrS9c4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCru7rI&md5=ae731d6c6d5c3902a6348b7d6eb02e00</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2013.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2013.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DGaleta%26aufirst%3DJ.%26aulast%3DTenora%26aufirst%3DL.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DPotacek%26aufirst%3DM.%26atitle%3DDihydropyrrolo%255B1%252C2-b%255Dpyrazoles%253A%2520withasomnine%2520and%2520related%2520compounds%26jtitle%3DTetrahedron%26date%3D2013%26volume%3D69%26spage%3D7139%26epage%3D7146%26doi%3D10.1016%2Fj.tet.2013.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1021/jm301495v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+structural+and+functional+studies+of+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+inhibitors+suggest+the+basis+for+isotype+selectivity&doi=10.1021%2Fjm301495v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span></div><div class="casAuthors">Hole, Alison J.; Baumli, Sonja; Shao, Hao; Shi, Shenhua; Huang, Shiliang; Pepper, Chris; Fischer, Peter M.; Wang, Shudong; Endicott, Jane A.; Noble, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer that constitutes pos. transcription elongation factor b, is a well-validated target for treatment of several diseases, including cancer and cardiac hypertrophy.  In order to aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T and CDK2/cyclin A.  We find that for a given CDK, the melting temp. of a CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that differential scanning fluorometry (DSF) is a useful orthogonal measure of inhibitory activity for this series.  We have used DSF to demonstrate that the binding of these compds. is independent of the presence or absence of the C-terminal tail region of CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimidazone-1-β-D-ribofuranoside (DRB).  Finally, on the basis of 11 cocrystal structures bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather than from the formation of specific polar contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGJy-t5isJBbVg90H21EOLACvtfcHk0lhLynMKrS9c4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE&md5=8c09b13b5f828b7a013607cab64b0b80</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520structural%2520and%2520functional%2520studies%2520of%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520inhibitors%2520suggest%2520the%2520basis%2520for%2520isotype%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670%26doi%3D10.1021%2Fjm301495v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daunt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loddick, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span> <span> </span><span class="NLM_article-title">The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6369</span>– <span class="NLM_lpage">6373</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.bmcl.2008.10.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=18996007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWjs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6369-6373&author=C.+D.+Jonesauthor=D.+M.+Andrewsauthor=A.+J.+Barkerauthor=K.+Bladesauthor=P.+Dauntauthor=S.+Eastauthor=C.+Gehauthor=M.+A.+Grahamauthor=K.+M.+Johnsonauthor=S.+A.+Loddickauthor=H.+M.+McFarlandauthor=A.+McGregorauthor=L.+Mossauthor=D.+A.+Rudgeauthor=P.+B.+Simpsonauthor=M.+L.+Swainauthor=K.+Y.+Tamauthor=J.+A.+Tuckerauthor=M.+Walker&title=The+discovery+of+AZD5597%2C+a+potent+imidazole+pyrimidine+amide+CDK+inhibitor+suitable+for+intravenous+dosing&doi=10.1016%2Fj.bmcl.2008.10.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing</span></div><div class="casAuthors">Jones, Clifford D.; Andrews, David M.; Barker, Andrew J.; Blades, Kevin; Daunt, Paula; East, Simon; Geh, Catherine; Graham, Mark A.; Johnson, Keith M.; Loddick, Sarah A.; McFarland, Heather M.; McGregor, Alexandra; Moss, Louise; Rudge, David A.; Simpson, Peter B.; Swain, Michael L.; Tam, Kin Y.; Tucker, Julie A.; Walker, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6369-6373</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described.  Optimization of inhibitory potency against multiple CDK's (1, 2 and 9) resulted in imidazole pyrimidine amides with potent in vitro anti-proliferative effects against a range of cancer cell lines.  Excellent physiochem. properties and large margins against inhibition of CYP isoforms and the hERG ion channel were achieved by modification of lipophilicity and amine basicity.  A candidate with disease model activity in human cancer cell line xenografts and with suitable physiochem. and pharmacokinetic profiles for i.v. (iv) dosing was selected for further development as AZD5597 (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnX9-GP03dzbVg90H21EOLACvtfcHk0lhLynMKrS9c4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWjs7bP&md5=084ed54076134c7173953ebbdb23fd86</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.102%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DDaunt%26aufirst%3DP.%26aulast%3DEast%26aufirst%3DS.%26aulast%3DGeh%26aufirst%3DC.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMcFarland%26aufirst%3DH.%2BM.%26aulast%3DMcGregor%26aufirst%3DA.%26aulast%3DMoss%26aufirst%3DL.%26aulast%3DRudge%26aufirst%3DD.%2BA.%26aulast%3DSimpson%26aufirst%3DP.%2BB.%26aulast%3DSwain%26aufirst%3DM.%2BL.%26aulast%3DTam%26aufirst%3DK.%2BY.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWalker%26aufirst%3DM.%26atitle%3DThe%2520discovery%2520of%2520AZD5597%252C%2520a%2520potent%2520imidazole%2520pyrimidine%2520amide%2520CDK%2520inhibitor%2520suitable%2520for%2520intravenous%2520dosing%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6369%26epage%3D6373%26doi%3D10.1016%2Fj.bmcl.2008.10.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span>Compounds <b>6</b>, <b>23</b>, and <b>24</b> have been disclosed
in <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span>; <span class="NLM_string-name">Barlaam, B. C.</span>; <span class="NLM_string-name">Hawkins, J.</span>; <span class="NLM_string-name">De Savi, C.</span>; <span class="NLM_string-name">Vasbinder, M. M.</span>; <span class="NLM_string-name">Hird, A.</span>; <span class="NLM_string-name">Lamb, M.</span></span> <span> </span><span class="NLM_article-title">Polycyclic Amide Derivatives as CDK9 Inhibitors</span>. PCT Int. Appl., WO2017001354, <span class="NLM_year">2017</span>. Preparation and characterization of crystalline forms (e.g. Form B of <b>6</b>, Form B of <b>23</b> and Form A of <b>24</b>) are described herein.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+G.+Pike&author=B.+C.+Barlaam&author=J.+Hawkins&author=C.+De+Savi&author=M.+M.+Vasbinder&author=A.+Hird&author=M.+Lamb&title=Polycyclic+Amide+Derivatives+as+CDK9+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26atitle%3DPolycyclic%2520Amide%2520Derivatives%2520as%2520CDK9%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of distribution in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0lhgZhrdOJrhcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boiko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscione, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pop-Damkov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roamio Franklin, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhar Reddy Chilamakuri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Santos, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span> <span> </span><span class="NLM_article-title">AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-1853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1158%2F1078-0432.CCR-19-1853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=31699827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslylsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=922-934&author=J.+Cidadoauthor=S.+Boikoauthor=T.+Proiaauthor=D.+Fergusonauthor=S.+W.+Criscioneauthor=M.+San+Martinauthor=P.+Pop-Damkovauthor=N.+Suauthor=V.+N.+Roamio+Franklinauthor=C.+Sekhar+Reddy+Chilamakuriauthor=C.+S.+D%E2%80%99Santosauthor=W.+Shaoauthor=J.+C.+Saehauthor=R.+Kochauthor=D.+M.+Weinstockauthor=M.+Zindaauthor=S.+E.+Fawellauthor=L.+Drew&title=AZD4573+is+a+highly+selective+CDK9+inhibitor+that+suppresses+Mcl-1+and+induces+apoptosis+in+hematological+cancer+cells&doi=10.1158%2F1078-0432.CCR-19-1853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells</span></div><div class="casAuthors">Cidado, Justin; Boiko, Scott; Proia, Theresa; Ferguson, Douglas; Criscione, Steven W.; Martin, Maryann San; Pop-Damkov, Petar; Su, Nancy; Franklin, Valar Nila Roamio; Chilamakuri, Chandra Sekhar Reddy; D'Santos, Clive S.; Shao, Wenlin; Saeh, Jamal C.; Koch, Raphael; Weinstock, David M.; Zinda, Michael; Fawell, Stephen E.; Drew, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">922-934</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CDK9 is a transcriptional regulator and potential therapeutic target for many cancers.  Multiple nonselective CDK9 inhibitors have progressed clin. but were limited by a narrow therapeutic window.  This work describes a novel, potent, and highly selective CDK9 inhibitor, AZD4573.  The antitumor activity of AZD4573 was detd. across broad cancer cell line panels in vitro as well as cell line- and patient-derived xenograft models in vivo.  Multiple approaches, including integrated transcriptomic and proteomic analyses, loss-of-function pathway interrogation, and pharmacol. comparisons, were employed to further understand the major mechanism driving AZD4573 activity and to establish an exposure/effect relationship.  AZD4573 is a highly selective and potent CDK9 inhibitor.  It demonstrated rapid induction of apoptosis and subsequent cell death broadly across hematol. cancer models in vitro, and MCL-1 depletion in a dose- and time-dependent manner was identified as a major mechanism through which AZD4573 induces cell death in tumor cells.  This understanding of the mechanism, exposure, and antitumor activity of AZD4573 facilitated development of a robust pharmacokinetic/PD/efficacy model used to inform the clin. trial design.  Selective targeting of CDK9 enables the indirect inhibition of MCL-1, providing a therapeutic option for MCL-1-dependent diseases.  Accordingly, AZD4573 is currently being evaluated in a phase I clin. trial for patients with hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp213MDHb0Y7rVg90H21EOLACvtfcHk0lhgZhrdOJrhcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslylsLrK&md5=18be82de651b9be77a95f3d7c423b6aa</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-1853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-1853%26sid%3Dliteratum%253Aachs%26aulast%3DCidado%26aufirst%3DJ.%26aulast%3DBoiko%26aufirst%3DS.%26aulast%3DProia%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DCriscione%26aufirst%3DS.%2BW.%26aulast%3DSan%2BMartin%26aufirst%3DM.%26aulast%3DPop-Damkov%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DN.%26aulast%3DRoamio%2BFranklin%26aufirst%3DV.%2BN.%26aulast%3DSekhar%2BReddy%2BChilamakuri%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Santos%26aufirst%3DC.%2BS.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DKoch%26aufirst%3DR.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DDrew%26aufirst%3DL.%26atitle%3DAZD4573%2520is%2520a%2520highly%2520selective%2520CDK9%2520inhibitor%2520that%2520suppresses%2520Mcl-1%2520and%2520induces%2520apoptosis%2520in%2520hematological%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D922%26epage%3D934%26doi%3D10.1158%2F1078-0432.CCR-19-1853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yunsong Tong, Alan S. Florjancic, Rick F. Clark, Chunqiu Lai, Anthony Mastracchio, Gui-dong Zhu, Morey L. Smith, Peter J. Kovar, Bailin Shaw, Daniel H. Albert, Wei Qiu, Kenton L. Longenecker, Xiaoqin Liu, Amanda M. Olson, Donald J. Osterling, Stephen K. Tahir, Darren C. Phillips, Joel D. Leverson, Andrew J. Souers, <span class="NLM_string-name hlFld-ContribAuthor">Thomas D. Penning</span>. </span><span class="cited-content_cbyCitation_article-title">Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (7)
                                     , 1108-1115. <a href="https://doi.org/10.1021/acsmedchemlett.1c00161" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00161%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBalancing%252BProperties%252Bwith%252BCarboxylates%25253A%252BA%252BLead%252BOptimization%252BCampaign%252Bfor%252BSelective%252Band%252BOrally%252BActive%252BCDK9%252BInhibitors%26aulast%3DTong%26aufirst%3DYunsong%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19032021%26date%3D18062021%26date%3D22062021%26volume%3D12%26issue%3D7%26spage%3D1108%26epage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaya  Padmanabhan</span>, <span class="hlFld-ContribAuthor ">Biswarup  Saha</span>, <span class="hlFld-ContribAuthor ">Chase  Powell</span>, <span class="hlFld-ContribAuthor ">Qianxing  Mo</span>, <span class="hlFld-ContribAuthor ">Bradford A.  Perez</span>, <span class="hlFld-ContribAuthor ">Srikumar  Chellappan</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (15)
                                     , 3906. <a href="https://doi.org/10.3390/cancers13153906" title="DOI URL">https://doi.org/10.3390/cancers13153906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13153906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13153906%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DInhibitors%252BTargeting%252BCDK9%252BShow%252BHigh%252BEfficacy%252Bagainst%252BOsimertinib%252Band%252BAMG510%252BResistant%252BLung%252BAdenocarcinoma%252BCells%26aulast%3DPadmanabhan%26aufirst%3DJaya%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D15%26spage%3D3906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ranadip  Mandal</span>, <span class="hlFld-ContribAuthor ">Sven  Becker</span>, <span class="hlFld-ContribAuthor ">Klaus  Strebhardt</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting CDK9 for Anti-Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (9)
                                     , 2181. <a href="https://doi.org/10.3390/cancers13092181" title="DOI URL">https://doi.org/10.3390/cancers13092181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13092181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13092181%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BCDK9%252Bfor%252BAnti-Cancer%252BTherapeutics%26aulast%3DMandal%26aufirst%3DRanadip%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D9%26spage%3D2181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected CDK9 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) <b>36</b>, second generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 110 °C; (b) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C to rt, then <b>37</b>, pyridine, THF, rt; (c) HCl, dioxane–MeOH, rt then AcCl, DIPEA, DCM, rt.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C, then <b>39</b>, pyridine, DCM, THF, 0 °C to rt; (b) <b>41</b>, second generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 100 °C; (c) HCl, dioxane–DCM, rt; (d) Ac<sub>2</sub>O, NEt<sub>3</sub>, DCM, DMAP (optional), rt; (e) (BPin)<sub>2</sub>, PdCl<sub>2</sub>(dppf), KOAc, dioxane, 90 °C; (f) Het-Br or Het-I, PdCl<sub>2</sub>(dppf), K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 90 °C; (g) TFA, DCM, rt or HCl, dioxane–DCM, rt.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) Het-BPin, second generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 90 °C; (b) <b>47</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 120 °C; (c) TFA, DCM, rt; (d) Ac<sub>2</sub>O, NEt<sub>3</sub>, DMAP (optional), DCM, rt; (e) Het-BPin, Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane–water, 100 °C (for <b>53a</b>); (f) 1,2-dimethylimidazole, Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 120 °C (for <b>53b</b>).</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) conc. aq. ammonia, NMP, 100 °C (microwave); (b) <b>41</b>, PdCl<sub>2</sub>(dppf), Cs<sub>2</sub>CO<sub>3</sub>, dioxane–water, 95 °C; (c) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C, then <b>57</b>, pyridine, DCM, 0 °C to rt; (d) HCl, dioxane–DCM–MeOH, 0 °C; (e) AcCl, pyridine, DCM, rt, 0 °C.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) NCS, DMF, −78 °C to rt; (b) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C, then <b>57</b>, pyridine, DCM, THF, 0 °C to rt; (c) HCl, dioxane-MeOH, 0 °C; (d) Ac<sub>2</sub>O, DMAP, NEt<sub>3</sub>, DCM, rt; (e) Het-BPin, second-generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, rt (for <b>7</b> and <b>19</b>) or Het-H, Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, NEt<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C (for <b>9</b> and <b>11</b>); (f) <b>38</b>, 1-chloro-<i>N</i>,<i>N</i>,2-trimethylprop-1-en-1-amine, DCM, 0 °C, then <b>56</b>, pyridine, rt; (g) HCl, dioxane-DCM, rt; (h) Ac<sub>2</sub>O, DMAP (optional), NEt<sub>3</sub>, DCM, rt; (i) Het-BPin, second generation XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 60 °C (for <b>12</b> from <b>63</b>) or Het-B(OH)<sub>2</sub>, PdCl<sub>2</sub>(dppf), Ba(OH)<sub>2</sub>, dioxane–water, 75 °C (for <b>14</b> from <b>63</b>) or Pd(OAc)<sub>2</sub>, KOAc, DMA, 150 °C (microwave) (for <b>29</b> from <b>63</b>); (j) Het-BPin, second generation XPhos precatalyst, K<sub>2</sub>HPO<sub>4</sub> or K<sub>3</sub>PO<sub>4</sub>, dioxane-water, rt to 50–80 °C (for <b>13, 15–18, 27–28</b> from <b>62</b>); (k) chiral purification (for <b>27</b>–<b>28</b> only).</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0015.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) BrCH<sub>2</sub>C(Me)<sub>2</sub>CO<sub>2</sub>Et, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 80 °C; aq. NaOH, MeOH, rt; (b) <i>n</i>-BuLi, 2-MeTHF, −78 °C to rt; (c) hydrazine hydrate, 2,2′-oxidiethanol, 180 °C, then NaOH, 150 °C; (d) NBS, DCM, rt; (e) Pd(P(Cy)<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, (BPin)<sub>2</sub>, KOAc, PdCl<sub>2</sub>(dppf), DMA, 85 °C; (f) <b>69</b>, second generation XPhos precatalyst, K<sub>2</sub>HPO<sub>4</sub>, dioxane–water, 80 °C; (g) <b>47</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 120 °C; (h) HCl, dioxane–DCM–MeOH, rt; (i) Ac<sub>2</sub>O, pyridine or NEt<sub>3</sub>, DMAP (optional), DCM, rt ; (j) <b>69</b>, second generation XPhos precatalyst, K<sub>2</sub>HPO<sub>4</sub>, dioxane-water, 50 °C.</p></p></figure><figure data-id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>2</b> (green) docked into the ATP binding site of a publicly available crystal structure of CDK9–cyclinT1 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>), with CDK9 shown as a blue ribbon and CyclinT1 as a gray surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Metabolites of <b>6</b> after incubation in HLM. Metabolites shown were considered to have the potential to retain pharmacological activity and do not represent a complete metabolic scheme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>24</b> bound to the complex of CDK9 (blue) and cyclin T1 (gray) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Z45">6Z45</a>). The ligand carbon atoms are shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolite identification of <b>23</b> and <b>24</b> after incubation in HLM. Metabolites shown were considered to have the potential to retain pharmacological activity and do not represent a complete metabolic scheme.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibition of pSer2-RNAP2, depletion of Mcl-1 protein, and induction of caspase 3/7 activation after a 6-h incubation of compound <b>24</b> (dose response) in the acute myeloid leukemia Nomo-1 cell line. Top panel: Western blot; bottom panel: quantification.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0007.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose-dependent cell death driven antitumor efficacy in the acute myeloid leukemia Nomo-1 xenograft model of compound <b>24</b> by i.p. administration, twice daily 2 h apart, 2 days on 5 days off.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0008.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose-dependent reduction of pSer2-RNAP2 in the acute myeloid leukemia Nomo-1 xenograft model by i.p. administration of compound <b>24</b>, two doses 2 h apart by i.p. administration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/medium/jm0c01754_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0009.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Simulated human pharmacokinetic profile of compound <b>24</b> following a 44 mg dose administered by a 2 h continuous i.v. infusion.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01754/20201218/images/large/jm0c01754_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01754&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">The hallmarks of cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81683-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+hallmarks+of+cancer&doi=10.1016%2FS0092-8674%2800%2981683-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0li7IEORusJeyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520hallmarks%2520of%2520cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70%26doi%3D10.1016%2FS0092-8674%2800%2981683-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cory, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. M.</span></span> <span> </span><span class="NLM_article-title">The Bcl2 family: regulators of the cellular life-or-death switch</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">656</span>, <span class="refDoi"> DOI: 10.1038/nrc883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrc883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=12209154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmslamsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=647-656&author=S.+Coryauthor=J.+M.+Adams&title=The+Bcl2+family%3A+regulators+of+the+cellular+life-or-death+switch&doi=10.1038%2Fnrc883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Bcl2 family: regulators of the cellular life-or-death switch</span></div><div class="casAuthors">Cory, Suzanne; Adams, Jerry M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">647-656</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 154 refs.  Tissue homeostasis is regulated by apoptosis, the cell-suicide program that is executed by proteases called caspases.  The Bcl-2 family of intracellular proteins is the central regulator of caspase activation, and its opposing factions of anti- and pro-apoptotic members arbitrate the life-or-death decision.  Apoptosis is often impaired in cancer and can limit conventional therapy.  A better understanding of how the Bcl-2 family controls caspase activation should result in new, more effective therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1j_rKUocxTbVg90H21EOLACvtfcHk0li7IEORusJeyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmslamsrw%253D&md5=856e7f5f43519ecb9be4f6f3ac991249</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc883%26sid%3Dliteratum%253Aachs%26aulast%3DCory%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Bcl2%2520family%253A%2520regulators%2520of%2520the%2520cellular%2520life-or-death%2520switch%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D647%26epage%3D656%26doi%3D10.1038%2Fnrc883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czabotar, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. M.</span></span> <span> </span><span class="NLM_article-title">Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1038/nrm3722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrm3722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=24355989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOjsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=49-63&author=P.+E.+Czabotarauthor=G.+Lesseneauthor=A.+Strasserauthor=J.+M.+Adams&title=Control+of+apoptosis+by+the+BCL-2+protein+family%3A+implications+for+physiology+and+therapy&doi=10.1038%2Fnrm3722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</span></div><div class="casAuthors">Czabotar, Peter E.; Lessene, Guillaume; Strasser, Andreas; Adams, Jerry M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The BCL-2 protein family dets. the commitment of cells to apoptosis, an ancient cell suicide program that is essential for development, tissue homeostasis and immunity.  Too little apoptosis can promote cancer and autoimmune diseases; too much apoptosis can augment ischemic conditions and drive neurodegeneration.  We discuss the biochem., structural and genetic studies that have clarified how the interplay between members of the BCL-2 family on mitochondria sets the apoptotic threshold.  These mechanistic insights into the functions of the BCL-2 family are illuminating the physiol. control of apoptosis, the pathol. consequences of its dysregulation and the promising search for novel cancer therapies that target the BCL-2 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYVpm2heUGBbVg90H21EOLACvtfcHk0lgaYoxsca65ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOjsbvI&md5=c18d528c2819c2df93b6798e62132372</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3722%26sid%3Dliteratum%253Aachs%26aulast%3DCzabotar%26aufirst%3DP.%2BE.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DJ.%2BM.%26atitle%3DControl%2520of%2520apoptosis%2520by%2520the%2520BCL-2%2520protein%2520family%253A%2520implications%2520for%2520physiology%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D49%26epage%3D63%26doi%3D10.1038%2Fnrm3722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mermel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urashima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mc Henry, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinchback, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haery, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prensner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liefeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yecies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signoretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepper, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demichelis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">True, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomeroy, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">The landscape of somatic copy-number alteration across human cancers</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span>,  <span class="NLM_fpage">899</span>– <span class="NLM_lpage">905</span>, <span class="refDoi"> DOI: 10.1038/nature08822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnature08822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=20164920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=899-905&author=R.+Beroukhimauthor=C.+H.+Mermelauthor=D.+Porterauthor=G.+Weiauthor=S.+Raychaudhuriauthor=J.+Donovanauthor=J.+Barretinaauthor=J.+S.+Boehmauthor=J.+Dobsonauthor=M.+Urashimaauthor=K.+T.+Mc+Henryauthor=R.+M.+Pinchbackauthor=A.+H.+Ligonauthor=Y.+J.+Choauthor=L.+Haeryauthor=H.+Greulichauthor=M.+Reichauthor=W.+Wincklerauthor=M.+S.+Lawrenceauthor=B.+A.+Weirauthor=K.+E.+Tanakaauthor=D.+Y.+Chiangauthor=A.+J.+Bassauthor=A.+Looauthor=C.+Hoffmanauthor=J.+Prensnerauthor=T.+Liefeldauthor=Q.+Gaoauthor=D.+Yeciesauthor=S.+Signorettiauthor=E.+Maherauthor=F.+J.+Kayeauthor=H.+Sasakiauthor=J.+E.+Tepperauthor=J.+A.+Fletcherauthor=J.+Taberneroauthor=J.+Baselgaauthor=M.+S.+Tsaoauthor=F.+Demichelisauthor=M.+A.+Rubinauthor=P.+A.+Janneauthor=M.+J.+Dalyauthor=C.+Nuceraauthor=R.+L.+Levineauthor=B.+L.+Ebertauthor=S.+Gabrielauthor=A.+K.+Rustgiauthor=C.+R.+Antonescuauthor=M.+Ladanyiauthor=A.+Letaiauthor=L.+A.+Garrawayauthor=M.+Lodaauthor=D.+G.+Beerauthor=L.+D.+Trueauthor=A.+Okamotoauthor=S.+L.+Pomeroyauthor=S.+Singerauthor=T.+R.+Golubauthor=E.+S.+Landerauthor=G.+Getzauthor=W.+R.+Sellersauthor=M.+Meyerson&title=The+landscape+of+somatic+copy-number+alteration+across+human+cancers&doi=10.1038%2Fnature08822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The landscape of somatic copy-number alteration across human cancers</span></div><div class="casAuthors">Beroukhim, Rameen; Mermel, Craig H.; Porter, Dale; Wei, Guo; Raychaudhuri, Soumya; Donovan, Jerry; Barretina, Jordi; Boehm, Jesse S.; Dobson, Jennifer; Urashima, Mitsuyoshi; Mc Henry, Kevin T.; Pinchback, Reid M.; Ligon, Azra H.; Cho, Yoon-Jae; Haery, Leila; Greulich, Heidi; Reich, Michael; Winckler, Wendy; Lawrence, Michael S.; Weir, Barbara A.; Tanaka, Kumiko E.; Chiang, Derek Y.; Bass, Adam J.; Loo, Alice; Hoffman, Carter; Prensner, John; Liefeld, Ted; Gao, Qing; Yecies, Derek; Signoretti, Sabina; Maher, Elizabeth; Kaye, Frederic J.; Sasaki, Hidefumi; Tepper, Joel E.; Fletcher, Jonathan A.; Tabernero, Josep; Baselga, Jose; Tsao, Ming-Sound; Demichelis, Francesca; Rubin, Mark A.; Janne, Pasi A.; Daly, Mark J.; Nucera, Carmelo; Levine, Ross L.; Ebert, Benjamin L.; Gabriel, Stacey; Rustgi, Anil K.; Antonescu, Cristina R.; Ladanyi, Marc; Letai, Anthony; Garraway, Levi A.; Loda, Massimo; Beer, David G.; True, Lawrence D.; Okamoto, Aikou; Pomeroy, Scott L.; Singer, Samuel; Golub, Todd R.; Lander, Eric S.; Getz, Gad; Sellers, William R.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7283</span>),
    <span class="NLM_cas:pages">899-905</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers.  Here we present high-resoln. analyses of somatic copy-no. alterations (SCNAs) from 3131 cancer specimens, belonging largely to 26 histol. types.  We identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions.  Several gene families are enriched among these regions of focal SCNA, including the BCL2 family of apoptosis regulators and the NF-κB pathway.  We show that cancer cells contg. amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival.  Finally, we demonstrate that a large majority of SCNAs identified in individual cancer types are present in several cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCxYRlqR0wXLVg90H21EOLACvtfcHk0ljspUzcOeTMUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsr0%253D&md5=be6d81f5449cba96dfb4659106f706b0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature08822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08822%26sid%3Dliteratum%253Aachs%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DMermel%26aufirst%3DC.%2BH.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DRaychaudhuri%26aufirst%3DS.%26aulast%3DDonovan%26aufirst%3DJ.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DDobson%26aufirst%3DJ.%26aulast%3DUrashima%26aufirst%3DM.%26aulast%3DMc%2BHenry%26aufirst%3DK.%2BT.%26aulast%3DPinchback%26aufirst%3DR.%2BM.%26aulast%3DLigon%26aufirst%3DA.%2BH.%26aulast%3DCho%26aufirst%3DY.%2BJ.%26aulast%3DHaery%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DTanaka%26aufirst%3DK.%2BE.%26aulast%3DChiang%26aufirst%3DD.%2BY.%26aulast%3DBass%26aufirst%3DA.%2BJ.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DHoffman%26aufirst%3DC.%26aulast%3DPrensner%26aufirst%3DJ.%26aulast%3DLiefeld%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DYecies%26aufirst%3DD.%26aulast%3DSignoretti%26aufirst%3DS.%26aulast%3DMaher%26aufirst%3DE.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DTepper%26aufirst%3DJ.%2BE.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DTsao%26aufirst%3DM.%2BS.%26aulast%3DDemichelis%26aufirst%3DF.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DNucera%26aufirst%3DC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DBeer%26aufirst%3DD.%2BG.%26aulast%3DTrue%26aufirst%3DL.%2BD.%26aulast%3DOkamoto%26aufirst%3DA.%26aulast%3DPomeroy%26aufirst%3DS.%2BL.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DThe%2520landscape%2520of%2520somatic%2520copy-number%2520alteration%2520across%2520human%2520cancers%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D899%26epage%3D905%26doi%3D10.1038%2Fnature08822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashkenazi, A.</span></span> <span> </span><span class="NLM_article-title">Directing cancer cells to self-destruct with pro-apoptotic receptor agonists</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1038/nrd2637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrd2637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=18989337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1001-1012&author=A.+Ashkenazi&title=Directing+cancer+cells+to+self-destruct+with+pro-apoptotic+receptor+agonists&doi=10.1038%2Fnrd2637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Directing cancer cells to self-destruct with pro-apoptotic receptor agonists</span></div><div class="casAuthors">Ashkenazi, Avi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1001-1012</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Each day, the human body eliminates billions of unwanted cells by apoptotic suicide.  Apoptosis provides an important barrier against cancer; however, specific mutations enable some tumor cells to escape apoptotic death and become more malignant.  Two signaling pathways initiate apoptosis: one acts through intracellular Bcl-2 proteins, the other through cell-surface pro-apoptotic receptors.  New mol. insights have inspired the development of pro-apoptotic receptor agonists (PARAs), including the recombinant human protein apoptosis ligand 2/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) and agonistic monoclonal antibodies to its signaling receptors.  Acting alone, or in concert with other agents, PARAs may overcome key apoptosis blocks and direct cancer cells to self-destruct.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpddvao_FxuwLVg90H21EOLACvtfcHk0ljspUzcOeTMUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsbnF&md5=6c7fdc551bb0902bdacb869f9b308c18</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2637%26sid%3Dliteratum%253Aachs%26aulast%3DAshkenazi%26aufirst%3DA.%26atitle%3DDirecting%2520cancer%2520cells%2520to%2520self-destruct%2520with%2520pro-apoptotic%2520receptor%2520agonists%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D1001%26epage%3D1012%26doi%3D10.1038%2Fnrd2637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hailfinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dörken, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thome, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirnhofer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Ilizaliturri, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzankov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span> <span> </span><span class="NLM_article-title">MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1381</span>– <span class="NLM_lpage">1390</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fleu.2012.367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=23257783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFekur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1381-1390&author=S.+S.+Wenzelauthor=M.+Grauauthor=C.+Mavisauthor=S.+Hailfingerauthor=A.+Wolfauthor=H.+Madleauthor=G.+Deebauthor=B.+D%C3%B6rkenauthor=M.+Thomeauthor=P.+Lenzauthor=S.+Dirnhoferauthor=F.+J.+Hernandez-Ilizaliturriauthor=A.+Tzankovauthor=G.+Lenz&title=MCL1+is+deregulated+in+subgroups+of+diffuse+large+B-cell+lymphoma&doi=10.1038%2Fleu.2012.367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma</span></div><div class="casAuthors">Wenzel, S.-S.; Grau, M.; Mavis, C.; Hailfinger, S.; Wolf, A.; Madle, H.; Deeb, G.; Doerken, B.; Thome, M.; Lenz, P.; Dirnhofer, S.; Hernandez-Ilizaliturri, F. J.; Tzankov, A.; Lenz, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1381-1390</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloid cell leukemia-1 (MCL1) is an anti-apoptotic member of the BCL2 family that is deregulated in various solid and hematol. malignancies.  However, its role in the mol. pathogenesis of diffuse large B-cell lymphoma (DLBCL) is unclear.  We analyzed gene expression profiling data from 350 DLBCL patient samples and detected that activated B-cell-like (ABC) DLBCLs express MCL1 at significantly higher levels compared with germinal center B-cell-like DLBCL patient samples (P=2.7 × 10-10).  Immunohistochem. confirmed high MCL1 protein expression predominantly in ABC DLBCL in an independent patient cohort (n=249; P=0.001).  To elucidate mol. mechanisms leading to aberrant MCL1 expression, we analyzed array comparative genomic hybridization data of 203 DLBCL samples and identified recurrent chromosomal gains/amplifications of the MCL1 locus that occurred in 26% of ABC DLBCLs.  In addn., aberrant STAT3 signaling contributed to high MCL1 expression in this subtype.  Knockdown of MCL1 as well as treatment with the BH3-mimetic obatoclax induced apoptotic cell death in MCL1-pos. DLBCL cell lines.  In summary, MCL1 is deregulated in a significant fraction of ABC DLBCLs and contributes to therapy resistance.  These data suggest that specific inhibition of MCL1 might be utilized therapeutically in a subset of DLBCLs.  Leukemia (2013) 27, 1381-1390; doi:10.1038/leu.2012.367; published online 18 Jan. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN9CxWCi906rVg90H21EOLACvtfcHk0ljaA-vxbL2TeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFekur4%253D&md5=91167903f5911feca70ddea39778af94</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.367%26sid%3Dliteratum%253Aachs%26aulast%3DWenzel%26aufirst%3DS.%2BS.%26aulast%3DGrau%26aufirst%3DM.%26aulast%3DMavis%26aufirst%3DC.%26aulast%3DHailfinger%26aufirst%3DS.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DMadle%26aufirst%3DH.%26aulast%3DDeeb%26aufirst%3DG.%26aulast%3DD%25C3%25B6rken%26aufirst%3DB.%26aulast%3DThome%26aufirst%3DM.%26aulast%3DLenz%26aufirst%3DP.%26aulast%3DDirnhofer%26aufirst%3DS.%26aulast%3DHernandez-Ilizaliturri%26aufirst%3DF.%2BJ.%26aulast%3DTzankov%26aufirst%3DA.%26aulast%3DLenz%26aufirst%3DG.%26atitle%3DMCL1%2520is%2520deregulated%2520in%2520subgroups%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%26jtitle%3DLeukemia%26date%3D2013%26volume%3D27%26spage%3D1381%26epage%3D1390%26doi%3D10.1038%2Fleu.2012.367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wuillème-Toumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robillard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gouill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avet-Loiseau, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harousseau, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bataille, R.</span></span> <span> </span><span class="NLM_article-title">Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2403784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fsj.leu.2403784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=15902294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVOisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1248-1252&author=S.+Wuill%C3%A8me-Toumiauthor=N.+Robillardauthor=P.+Gomezauthor=P.+Moreauauthor=S.+Le+Gouillauthor=H.+Avet-Loiseauauthor=J.+L.+Harousseauauthor=M.+Amiotauthor=R.+Bataille&title=Mcl-1+is+overexpressed+in+multiple+myeloma+and+associated+with+relapse+and+shorter+survival&doi=10.1038%2Fsj.leu.2403784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival</span></div><div class="casAuthors">Wuilleme-Toumi, S.; Robillard, N.; Gomez, P.; Moreau, P.; Le Gouill, S.; Avet-Loiseau, H.; Harousseau, J-L.; Amiot, M.; Bataille, R.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1248-1252</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We and others have shown that Mcl-1 was essential for the survival of human myeloma cells in vitro.  Furthermore, this antiapoptotic protein is upregulated by interleukin-6, which plays a crit. role in multiple myeloma (MM).  For these reasons, we have evaluated the expression of Mcl-1 in vivo in normal, reactive and malignant plasma cells (PC), i.e., myeloma cells from 51 patients with MM and 21 human myeloma cell lines (HMCL) using flow cytometry.  We show that Mcl-1 is overexpressed in MM in comparison with normal bone marrow PC.  In total, 52% of patients with MM at diagnosis (P=0.017) and 81% at relapse (P=0.014 for comparison with diagnosis) overexpress Mcl-1.  Of note, only HMCL but not reactive plasmacytoses have abnormal Mcl-1 expression, although both PC expansions share similar high proliferation rates.  Of interest, Bcl-2 as opposed to Mcl-1, does not discriminate malignant from normal PC.  Finally, the level of Mcl-1 expression is related to disease severity, the highest values at diagnosis being assocd. with the shortest event-free survival (P=0.002).  In conclusion, Mcl-1, which has been shown to be essential for the survival of human myeloma cells in vitro, is overexpressed in vivo in MM in relation with relapse and shorter survival.  Mcl-1 represents a potential therapeutical target in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ7LKx_LcQybVg90H21EOLACvtfcHk0ljaA-vxbL2TeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVOisrk%253D&md5=ab23f9b31bc91704a55b511d4498e4d0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2403784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2403784%26sid%3Dliteratum%253Aachs%26aulast%3DWuill%25C3%25A8me-Toumi%26aufirst%3DS.%26aulast%3DRobillard%26aufirst%3DN.%26aulast%3DGomez%26aufirst%3DP.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DLe%2BGouill%26aufirst%3DS.%26aulast%3DAvet-Loiseau%26aufirst%3DH.%26aulast%3DHarousseau%26aufirst%3DJ.%2BL.%26aulast%3DAmiot%26aufirst%3DM.%26aulast%3DBataille%26aufirst%3DR.%26atitle%3DMcl-1%2520is%2520overexpressed%2520in%2520multiple%2520myeloma%2520and%2520associated%2520with%2520relapse%2520and%2520shorter%2520survival%26jtitle%3DLeukemia%26date%3D2005%26volume%3D19%26spage%3D1248%26epage%3D1252%26doi%3D10.1038%2Fsj.leu.2403784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gores, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trounson, E.</span></span> <span> </span><span class="NLM_article-title">Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1101/gad.186189.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1101%2Fgad.186189.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=22345513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Cmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=305-311&author=G.+J.+Goresauthor=S.+H.+Kaufmannauthor=S.+P.+Glaserauthor=E.+F.+Leeauthor=E.+Trounson&title=Selectively+targeting+Mcl-1+for+the+treatment+of+acute+myelogenous+leukemia+and+solid+tumors&doi=10.1101%2Fgad.186189.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors</span></div><div class="casAuthors">Gores, Gregory J.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-311</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Bcl-2, Bcl-xL, Mcl-1, and A1 are the predominant anti-apoptotic members of the Bcl-2 family in somatic cells.  Malignant B lymphocytes are critically dependent on Bcl-2 or Bcl-xL for survival.  In contrast, a new study by Glaser and colleagues in the Jan. 15, 2012, issue of Genes & Development (pp. 120-125) demonstrates that Mcl-1 is essential for development and survival of acute myelogenous leukemia cells.  These results provide new impetus for the generation of selective Mcl-1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGpI-5exlGV7Vg90H21EOLACvtfcHk0ljaA-vxbL2TeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Cmu7w%253D&md5=807ddab7babc0eb9c22fb2b5cc2336e9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1101%2Fgad.186189.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.186189.111%26sid%3Dliteratum%253Aachs%26aulast%3DGores%26aufirst%3DG.%2BJ.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DGlaser%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DE.%2BF.%26aulast%3DTrounson%26aufirst%3DE.%26atitle%3DSelectively%2520targeting%2520Mcl-1%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%2520and%2520solid%2520tumors%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D305%26epage%3D311%26doi%3D10.1101%2Fgad.186189.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, R. S.</span></span> <span> </span><span class="NLM_article-title">Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3519</span>– <span class="NLM_lpage">3530</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.18632%2Foncotarget.2792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=25784482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnls1ShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=3519-3530&author=M.+M.+Williamsauthor=R.+S.+Cook&title=Bcl-2+family+proteins+in+breast+development+and+cancer%3A+could+Mcl-1+targeting+overcome+therapeutic+resistance%3F&doi=10.18632%2Foncotarget.2792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?</span></div><div class="casAuthors">Williams Michelle M; Cook Rebecca S; Cook Rebecca S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3519-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Apoptosis, cell death executed by caspases, is essential to normal breast development and homeostasis.  Pro-apoptotic and anti-apoptotic signals are tightly regulated in normal breast epithelial cells.  Dysregulation of this balance is required for breast tumorigenesis and increases acquired resistance to treatments, including molecularly targeted therapies, radiation and chemotherapies.  The pro-apoptotic or anti-apoptotic Bcl-2 family members interact with each other to maintain mitochondrial integrity and regulate cellular commitment to apoptosis.  Among the anti-apoptotic Bcl-2 family members, Mcl-1 is uniquely regulated by numerous oncogenic signaling pathways.  This review will focus on the role of Bcl-2 family proteins in normal breast development, breast tumorigenesis and acquired resistance to breast cancer treatment strategies, while highlighting Mcl-1 as a promising target to improve breast cancer tumor cell killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvDoMDseirLH6HPRus0rAafW6udTcc2ebxx8qlANWq7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnls1ShsQ%253D%253D&md5=22e6af0dd2e25832cedc3dffac2e5a84</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2792%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DM.%2BM.%26aulast%3DCook%26aufirst%3DR.%2BS.%26atitle%3DBcl-2%2520family%2520proteins%2520in%2520breast%2520development%2520and%2520cancer%253A%2520could%2520Mcl-1%2520targeting%2520overcome%2520therapeutic%2520resistance%253F%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D3519%26epage%3D3530%26doi%3D10.18632%2Foncotarget.2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gojo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenton, R. G.</span></span> <span> </span><span class="NLM_article-title">Myeloid cell factor – 1 is a critical survival factor for multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1893</span>, <span class="refDoi"> DOI: 10.1182/blood.V99.6.1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1182%2Fblood.V99.6.1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=11877256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD38XitF2ntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=1885-1893&author=B.+Zhangauthor=I.+Gojoauthor=R.+G.+Fenton&title=Myeloid+cell+factor+%E2%80%93+1+is+a+critical+survival+factor+for+multiple+myeloma&doi=10.1182%2Fblood.V99.6.1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Myeloid cell factor-1 is a critical survival factor for multiple myeloma</span></div><div class="casAuthors">Zhang, Bin; Gojo, Ivana; Fenton, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1885-1893</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow caused primarily by failure of normal homeostatic mechanisms to prevent the expansion of postgerminal center plasma cells.  We have examd. the mol. mechanisms that promote the survival of MM cells and have identified a key role for myeloid cell factor-1 (Mcl-1), an antiapoptotic member of the Bcl-2 family.  These expts. were initiated by the observation that MM cells were exquisitely sensitive to culture in the presence of actinomycin D: caspase activation occurred within 3 h of treatment and cells were not protected by interleukin-6, the main MM cell growth and survival factor.  Actinomycin D-induced apoptosis was blocked by proteasome inhibitors, suggesting that a labile protein was required for MM cell survival.  Further anal. demonstrated that Mcl-1 was likely to be the labile factor governing MM cell survival.  Mcl-1 protein levels decreased rapidly after culture in the presence of actinomycin D in concordance with effector caspase activation, but addn. of proteasome inhibitors reversed the loss of Mcl-1 and maintained cell viability.  The levels of other antiapoptotic proteins, including Bcl-2 and members of the inhibitors-of-apoptosis family, were unaffected by these interventions.  Furthermore, Mcl-1 antisense oligonucleotides caused a rapid down-regulation of Mcl-1 protein levels and the coincident induction of apoptosis, whereas overexpression of Mcl-1 delayed actinomycin D-induced apoptosis with kinetics that correlated with expression levels of Mcl-1.  These data indicate that Mcl-1 expression is required for the survival of MM cells and may represent an important target for future therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_vJkrKUBuA7Vg90H21EOLACvtfcHk0lgB-crYpgblcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitF2ntro%253D&md5=cce6518090819f837a65726a0b9f5b87</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.6.1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.6.1885%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DFenton%26aufirst%3DR.%2BG.%26atitle%3DMyeloid%2520cell%2520factor%2520%25E2%2580%2593%25201%2520is%2520a%2520critical%2520survival%2520factor%2520for%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D1885%26epage%3D1893%26doi%3D10.1182%2Fblood.V99.6.1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trounson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouillet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappaport, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span> <span> </span><span class="NLM_article-title">Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1101/gad.182980.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1101%2Fgad.182980.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=22279045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=120-125&author=S.+P.+Glaserauthor=E.+F.+Leeauthor=E.+Trounsonauthor=P.+Bouilletauthor=A.+Weiauthor=W.+D.+Fairlieauthor=D.+J.+Izonauthor=J.+Zuberauthor=A.+R.+Rappaportauthor=M.+J.+Heroldauthor=W.+S.+Alexanderauthor=S.+W.+Loweauthor=L.+Robbauthor=A.+Strasser&title=Anti-apoptotic+Mcl-1+is+essential+for+the+development+and+sustained+growth+of+acute+myeloid+leukemia&doi=10.1101%2Fgad.182980.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia</span></div><div class="casAuthors">Glaser, Stefan P.; Lee, Erinna F.; Trounson, Evelyn; Bouillet, Philippe; Wei, Andrew; Fairlie, W. Douglas; Izon, David J.; Zuber, Johannes; Rappaport, Amy R.; Herold, Marco J.; Alexander, Warren S.; Lowe, Scott W.; Robb, Lorraine; Strasser, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-125</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) frequently relapses after initial treatment.  Drug resistance in AML has been attributed to high levels of the anti-apoptotic Bcl-2 family members Bcl-xL and Mcl-1.  Here we report that removal of Mcl-1, but not loss or pharmacol. blockade of Bcl-xL, Bcl-2, or Bcl-w, caused the death of transformed AML and could cure disease in AML-afflicted mice.  Enforced expression of selective inhibitors of prosurvival Bcl-2 family members revealed that Mcl-1 is crit. for survival of human AML cells.  Thus, targeting of Mcl-1 or regulators of its expression may be a useful strategy for the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6z2Lgi2YuK7Vg90H21EOLACvtfcHk0lgB-crYpgblcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOjs78%253D&md5=5f0cc61da50fddb262d30e243a7e6837</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1101%2Fgad.182980.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.182980.111%26sid%3Dliteratum%253Aachs%26aulast%3DGlaser%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DE.%2BF.%26aulast%3DTrounson%26aufirst%3DE.%26aulast%3DBouillet%26aufirst%3DP.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DFairlie%26aufirst%3DW.%2BD.%26aulast%3DIzon%26aufirst%3DD.%2BJ.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DRappaport%26aufirst%3DA.%2BR.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DAlexander%26aufirst%3DW.%2BS.%26aulast%3DLowe%26aufirst%3DS.%2BW.%26aulast%3DRobb%26aufirst%3DL.%26aulast%3DStrasser%26aufirst%3DA.%26atitle%3DAnti-apoptotic%2520Mcl-1%2520is%2520essential%2520for%2520the%2520development%2520and%2520sustained%2520growth%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DGenes%2520Dev.%26date%3D2012%26volume%3D26%26spage%3D120%26epage%3D125%26doi%3D10.1101%2Fgad.182980.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span> <span> </span><span class="NLM_article-title">Small-molecule Mcl-1 inhibitors: emerging anti-tumor agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.ejmech.2018.01.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=29407973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=471-482&author=Y.+Wanauthor=N.+Daiauthor=Z.+Tangauthor=H.+Fang&title=Small-molecule+Mcl-1+inhibitors%3A+emerging+anti-tumor+agents&doi=10.1016%2Fj.ejmech.2018.01.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents</span></div><div class="casAuthors">Wan, Yichao; Dai, Ningning; Tang, Zilong; Fang, Hao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">471-482</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The anti-apoptotic members of B-cell lymphoma-2 (Bcl-2) proteins family, such as Bcl-2 and myeloid cell leukemia-1 (Mcl-1), are the key regulators of the intrinsic pathway of apoptosis and overexpressed in many tumor cells, which have been confirmed as potential drug targets for cancers.  A no. of Bcl-2 proteins inhibitors have been developed and conducted clin. trials, but no Mcl-1 inhibitors are presented in the clinics.  In addn., Mcl-1 is an important reason for the resistance to radio- and chemotherapies, including inhibitors that target other Bcl-2 family members.  For example, the recently launched Bcl-2-selective inhibitor ABT-199 displays highly potency in the treatment of chronic lymphocytic leukemia (CLL), but it cannot induce the apoptosis controlled by Mcl-1 in some tumor cell lines.  Therefore, developing potent Mcl-1 inhibitors become urgently needed in clin. therapy.  This review briefly introduces the structure of Mcl-1 protein, the role in cancers and focuses on the progress of small-mol. Mcl-1 inhibitors from 2012 to 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpQTzQws7_BLVg90H21EOLACvtfcHk0ljqqV_ckbiUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WrsL8%253D&md5=3f61029e3cf9195a91f5cb1eb6ee59e6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.076%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDai%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DSmall-molecule%2520Mcl-1%2520inhibitors%253A%2520emerging%2520anti-tumor%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D471%26epage%3D482%26doi%3D10.1016%2Fj.ejmech.2018.01.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span> <span> </span><span class="NLM_article-title">Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1039/C5MD00582E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1039%2FC5MD00582E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVKrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=778-787&author=D.+Nhuauthor=G.+Lesseneauthor=D.+C.+S.+Huangauthor=C.+J.+Burns&title=Small+molecules+targeting+Mcl-1%3A+the+search+for+a+silver+bullet+in+cancer+therapy&doi=10.1039%2FC5MD00582E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy</span></div><div class="casAuthors">Nhu, Duong; Lessene, Guillaume; Huang, David C. S.; Burns, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">778-787</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Mcl-1 (myeloid-cell-leukemia-sequence-1) is a pro-survival member of the Bcl-2 family of proteins.  Mcl-1 has been shown to be crit. to the survival of a variety of cancer cells and to mediate resistance to conventional and targeted chemotherapeutics.  While potent and selective small mol. inhibitors of Bcl-2 and Bcl-XL have been developed, the discovery of selective inhibitors of Mcl-1 has proven more problematic and only very recently have potent and selective inhibitors been described.  In this review we outline key features of Mcl-1 biol., and chem. approaches and outcomes of inhibiting this important survival protein for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkbm3AGAWdW7Vg90H21EOLACvtfcHk0ljqqV_ckbiUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVKrsLs%253D&md5=567809fcf5f9af519d76bda168e25a9a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1039%2FC5MD00582E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00582E%26sid%3Dliteratum%253Aachs%26aulast%3DNhu%26aufirst%3DD.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26atitle%3DSmall%2520molecules%2520targeting%2520Mcl-1%253A%2520the%2520search%2520for%2520a%2520silver%2520bullet%2520in%2520cancer%2520therapy%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D778%26epage%3D787%26doi%3D10.1039%2FC5MD00582E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span> <span> </span><span class="NLM_article-title">Mcl-1 inhibitors: a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1249848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1080%2F13543776.2017.1249848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=27744724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWht7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=163-178&author=L.+Chenauthor=S.+Fletcher&title=Mcl-1+inhibitors%3A+a+patent+review&doi=10.1080%2F13543776.2017.1249848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Mcl-1 inhibitors: a patent review</span></div><div class="casAuthors">Chen, Lijia; Fletcher, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-178</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: The myeloid cell leukemia-1 (MCL-1) protein is one of the key anti-apoptotic members of the B-cell lymphoma-2 (BCL-2) protein family.  Over-expression of MCL-1 has been closely related to tumor progression as well as to resistance, not only to traditional chemotherapies but also to targeted therapeutics including BCL-2 inhibitors such as ABT-263.  Therefore, there has been extensive research and development in the last decade in both academic and industrial settings to address this unmet medical need.  This review covers the research and patent literature of the past 10 years in the field of discovery and development of small-mol. inhibitors of the MCL-1 anti-apoptotic protein.  Small-mol. strategies to disrupt the protein-protein interactions between MCL-1 and its pro-apoptotic counterparts, such as BAK and BIM, have recently emerged.  Several small-mols. based on different scaffolds describe promising in vitro data as MCL-1 selective inhibitors.  While many lead compds. remain at the in vitro preclin. development stage, the two most recent patent applications describe promising in vivo data, and one small mol. inhibitor has recently entered into clin. development.  It is such an exciting moment that the long awaited clin. studies will generate some insight into the therapeutic potential of this anti-cancer approach, and possibly facilitate the further development of other early stage inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtJ0p65xmy37Vg90H21EOLACvtfcHk0ljqqV_ckbiUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWht7zL&md5=43dcba43e2c278ca3f1da22fcad1f739</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1249848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1249848%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFletcher%26aufirst%3DS.%26atitle%3DMcl-1%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D163%26epage%3D178%26doi%3D10.1080%2F13543776.2017.1249848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotschy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szlavik, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragno, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Toumelin-Braizat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanrion, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moujalled, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csekei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paczal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radics, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proszenyak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balint, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokurno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matassova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studeny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lysiak-Auvity, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grave, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riffkin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbraith, L. C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrey, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guasconi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauquil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guigal-Stephan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colland, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geneste, O.</span></span> <span> </span><span class="NLM_article-title">The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>538</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1038/nature19830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnature19830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=27760111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC2srjs1aquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=538&publication_year=2016&pages=477-482&author=A.+Kotschyauthor=Z.+Szlavikauthor=J.+Murrayauthor=J.+Davidsonauthor=A.+L.+Maragnoauthor=G.+Le+Toumelin-Braizatauthor=M.+Chanrionauthor=G.+L.+Kellyauthor=J.-N.+Gongauthor=D.+M.+Moujalledauthor=A.+Brunoauthor=M.+Csekeiauthor=A.+Paczalauthor=Z.+B.+Szaboauthor=S.+Siposauthor=G.+Radicsauthor=A.+Proszenyakauthor=B.+Balintauthor=L.+Ondiauthor=G.+Blaskoauthor=A.+Robertsonauthor=A.+Surgenorauthor=P.+Dokurnoauthor=I.+Chenauthor=N.+Matassovaauthor=J.+Smithauthor=C.+Pedderauthor=C.+Grahamauthor=A.+Studenyauthor=G.+Lysiak-Auvityauthor=A.-M.+Girardauthor=F.+Graveauthor=D.+Segalauthor=C.+D.+Riffkinauthor=G.+Pomilioauthor=L.+C.+A.+Galbraithauthor=B.+J.+Aubreyauthor=M.+S.+Brennanauthor=M.+J.+Heroldauthor=C.+Changauthor=G.+Guasconiauthor=N.+Cauquilauthor=F.+Melchioreauthor=N.+Guigal-Stephanauthor=B.+Lockhartauthor=F.+Collandauthor=J.+A.+Hickmanauthor=A.+W.+Robertsauthor=D.+C.+S.+Huangauthor=A.+H.+Weiauthor=A.+Strasserauthor=G.+Lesseneauthor=O.+Geneste&title=The+MCL1+inhibitor+S63845+is+tolerable+and+effective+in+diverse+cancer+models&doi=10.1038%2Fnature19830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models</span></div><div class="casAuthors">Kotschy Andras; Szlavik Zoltan; Csekei Marton; Paczal Attila; Szabo Zoltan B; Sipos Szabolcs; Radics Gabor; Proszenyak Agnes; Balint Balazs; Ondi Levente; Blasko Gabor; Murray James; Davidson James; Robertson Alan; Surgenor Allan; Dokurno Pawel; Chen Ijen; Matassova Natalia; Smith Julia; Pedder Christopher; Graham Christopher; Maragno Ana Leticia; Le Toumelin-Braizat Gaetane; Chanrion Maia; Bruno Alain; Studeny Aurelie; Lysiak-Auvity Gaelle; Girard Anne-Marie; Grave Fabienne; Guasconi Ghislaine; Cauquil Nicolas; Colland Frederic; Hickman John A; Geneste Olivier; Kelly Gemma L; Gong Jia-Nan; Segal David; Riffkin Chris D; Galbraith Laura C A; Aubrey Brandon J; Brennan Margs S; Herold Marco J; Chang Catherine; Roberts Andrew W; Huang David C S; Strasser Andreas; Lessene Guillaume; Kelly Gemma L; Gong Jia-Nan; Segal David; Riffkin Chris D; Galbraith Laura C A; Aubrey Brandon J; Brennan Margs S; Herold Marco J; Chang Catherine; Roberts Andrew W; Huang David C S; Strasser Andreas; Lessene Guillaume; Moujalled Donia M; Pomilio Giovanna; Wei Andrew H; Aubrey Brandon J; Roberts Andrew W; Melchiore Fabien; Guigal-Stephan Nolwen; Lockhart Brian; Roberts Andrew W; Wei Andrew H; Lessene Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">538</span>
        (<span class="NLM_cas:issue">7626</span>),
    <span class="NLM_cas:pages">477-482</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Avoidance of apoptosis is critical for the development and sustained growth of tumours.  The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging.  Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1.  Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway.  In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers.  Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines.  These results point towards MCL1 as a target for the treatment of a wide range of tumours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7C_gQBh3bx0EgZCMqtRBifW6udTcc2eY7sHIyB1tMXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srjs1aquw%253D%253D&md5=c435a7621b84063133e41e0cdbad3ac8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnature19830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19830%26sid%3Dliteratum%253Aachs%26aulast%3DKotschy%26aufirst%3DA.%26aulast%3DSzlavik%26aufirst%3DZ.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DDavidson%26aufirst%3DJ.%26aulast%3DMaragno%26aufirst%3DA.%2BL.%26aulast%3DLe%2BToumelin-Braizat%26aufirst%3DG.%26aulast%3DChanrion%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DG.%2BL.%26aulast%3DGong%26aufirst%3DJ.-N.%26aulast%3DMoujalled%26aufirst%3DD.%2BM.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DCsekei%26aufirst%3DM.%26aulast%3DPaczal%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DZ.%2BB.%26aulast%3DSipos%26aufirst%3DS.%26aulast%3DRadics%26aufirst%3DG.%26aulast%3DProszenyak%26aufirst%3DA.%26aulast%3DBalint%26aufirst%3DB.%26aulast%3DOndi%26aufirst%3DL.%26aulast%3DBlasko%26aufirst%3DG.%26aulast%3DRobertson%26aufirst%3DA.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DDokurno%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DMatassova%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DPedder%26aufirst%3DC.%26aulast%3DGraham%26aufirst%3DC.%26aulast%3DStudeny%26aufirst%3DA.%26aulast%3DLysiak-Auvity%26aufirst%3DG.%26aulast%3DGirard%26aufirst%3DA.-M.%26aulast%3DGrave%26aufirst%3DF.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DRiffkin%26aufirst%3DC.%2BD.%26aulast%3DPomilio%26aufirst%3DG.%26aulast%3DGalbraith%26aufirst%3DL.%2BC.%2BA.%26aulast%3DAubrey%26aufirst%3DB.%2BJ.%26aulast%3DBrennan%26aufirst%3DM.%2BS.%26aulast%3DHerold%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGuasconi%26aufirst%3DG.%26aulast%3DCauquil%26aufirst%3DN.%26aulast%3DMelchiore%26aufirst%3DF.%26aulast%3DGuigal-Stephan%26aufirst%3DN.%26aulast%3DLockhart%26aufirst%3DB.%26aulast%3DColland%26aufirst%3DF.%26aulast%3DHickman%26aufirst%3DJ.%2BA.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DWei%26aufirst%3DA.%2BH.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DGeneste%26aufirst%3DO.%26atitle%3DThe%2520MCL1%2520inhibitor%2520S63845%2520is%2520tolerable%2520and%2520effective%2520in%2520diverse%2520cancer%2520models%26jtitle%3DNature%26date%3D2016%26volume%3D538%26spage%3D477%26epage%3D482%26doi%3D10.1038%2Fnature19830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tron, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquila, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boise, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarparin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embrey, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannes, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmirski, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulis, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nooka, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hird, A. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">5341</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07551-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fs41467-018-07551-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=30559424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFersLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=5341&author=A.+E.+Tronauthor=M.+A.+Belmonteauthor=A.+Adamauthor=B.+M.+Aquilaauthor=L.+H.+Boiseauthor=E.+Chiarparinauthor=J.+Cidadoauthor=K.+J.+Embreyauthor=E.+Ganglauthor=F.+D.+Gibbonsauthor=G.+P.+Gregoryauthor=D.+Hargreavesauthor=J.+A.+Hendricksauthor=J.+W.+Johannesauthor=R.+W.+Johnstoneauthor=S.+L.+Kazmirskiauthor=J.+G.+Kettleauthor=M.+L.+Lambauthor=S.+M.+Matulisauthor=A.+K.+Nookaauthor=M.+J.+Packerauthor=B.+Pengauthor=P.+B.+Rawlinsauthor=D.+W.+Robbinsauthor=A.+G.+Schullerauthor=N.+Suauthor=W.+Yangauthor=Q.+Yeauthor=X.+Zhengauthor=J.+P.+Secristauthor=E.+A.+Clarkauthor=D.+M.+Wilsonauthor=S.+E.+Fawellauthor=A.+W.+Hird&title=Discovery+of+Mcl-1-specific+inhibitor+AZD5991+and+preclinical+activity+in+multiple+myeloma+and+acute+myeloid+leukemia&doi=10.1038%2Fs41467-018-07551-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia</span></div><div class="casAuthors">Tron, Adriana E.; Belmonte, Matthew A.; Adam, Ammar; Aquila, Brian M.; Boise, Lawrence H.; Chiarparin, Elisabetta; Cidado, Justin; Embrey, Kevin J.; Gangl, Eric; Gibbons, Francis D.; Gregory, Gareth P.; Hargreaves, David; Hendricks, J. Adam; Johannes, Jeffrey W.; Johnstone, Ricky W.; Kazmirski, Steven L.; Kettle, Jason G.; Lamb, Michelle L.; Matulis, Shannon M.; Nooka, Ajay K.; Packer, Martin J.; Peng, Bo; Rawlins, Philip B.; Robbins, Daniel W.; Schuller, Alwin G.; Su, Nancy; Yang, Wenzhan; Ye, Qing; Zheng, Xiaolan; Secrist, J. Paul; Clark, Edwin A.; Wilson, David M.; Fawell, Stephen E.; Hird, Alexander W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5341</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers.  High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 inhibitors as anticancer drugs.  Here, we describe AZD5991, a rationally designed macrocyclic mol. with high selectivity and affinity for Mcl-1 currently in clin. development.  Our studies demonstrate that AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway.  AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax.  Based on these promising data, a Phase I clin. trial has been launched for evaluation of AZD5991 in patients with hematol. malignancies (NCT03218683).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLv1vdwF2TY7Vg90H21EOLACvtfcHk0liiljN1TrSzqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFersLjK&md5=10ccf1fda947aca212bede3927eaabfa</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07551-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07551-w%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DA.%2BE.%26aulast%3DBelmonte%26aufirst%3DM.%2BA.%26aulast%3DAdam%26aufirst%3DA.%26aulast%3DAquila%26aufirst%3DB.%2BM.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26aulast%3DChiarparin%26aufirst%3DE.%26aulast%3DCidado%26aufirst%3DJ.%26aulast%3DEmbrey%26aufirst%3DK.%2BJ.%26aulast%3DGangl%26aufirst%3DE.%26aulast%3DGibbons%26aufirst%3DF.%2BD.%26aulast%3DGregory%26aufirst%3DG.%2BP.%26aulast%3DHargreaves%26aufirst%3DD.%26aulast%3DHendricks%26aufirst%3DJ.%2BA.%26aulast%3DJohannes%26aufirst%3DJ.%2BW.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DKazmirski%26aufirst%3DS.%2BL.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DMatulis%26aufirst%3DS.%2BM.%26aulast%3DNooka%26aufirst%3DA.%2BK.%26aulast%3DPacker%26aufirst%3DM.%2BJ.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DRawlins%26aufirst%3DP.%2BB.%26aulast%3DRobbins%26aufirst%3DD.%2BW.%26aulast%3DSchuller%26aufirst%3DA.%2BG.%26aulast%3DSu%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DSecrist%26aufirst%3DJ.%2BP.%26aulast%3DClark%26aufirst%3DE.%2BA.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DHird%26aufirst%3DA.%2BW.%26atitle%3DDiscovery%2520of%2520Mcl-1-specific%2520inhibitor%2520AZD5991%2520and%2520preclinical%2520activity%2520in%2520multiple%2520myeloma%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D5341%26doi%3D10.1038%2Fs41467-018-07551-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmontes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paras, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vimolratana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zancanella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cajulis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osgood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanaghan, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moujalled, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomilio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span> <span> </span><span class="NLM_article-title">AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1582</span>– <span class="NLM_lpage">1597</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=30254093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOmsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1582-1597&author=S.+Caenepeelauthor=S.+P.+Brownauthor=B.+Belmontesauthor=G.+Moodyauthor=K.+S.+Keeganauthor=D.+Chuiauthor=D.+A.+Whittingtonauthor=X.+Huangauthor=L.+Poppeauthor=A.+C.+Chengauthor=M.+Cardozoauthor=J.+Houzeauthor=Y.+Liauthor=B.+Lucasauthor=N.+A.+Parasauthor=X.+Wangauthor=J.+P.+Taygerlyauthor=M.+Vimolratanaauthor=M.+Zancanellaauthor=L.+Zhuauthor=E.+Cajulisauthor=T.+Osgoodauthor=J.+Sunauthor=L.+Damonauthor=R.+K.+Eganauthor=P.+Greningerauthor=J.+D.+McClanaghanauthor=J.+Gongauthor=D.+Moujalledauthor=G.+Pomilioauthor=P.+Beltranauthor=C.+H.+Benesauthor=A.+W.+Robertsauthor=D.+C.+Huangauthor=A.+Weiauthor=J.+Canonauthor=A.+Coxonauthor=P.+E.+Hughes&title=AMG+176%2C+a+selective+MCL1+inhibitor%2C+is+effective+in+hematologic+cancer+models+alone+and+in+combination+with+established+therapies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies</span></div><div class="casAuthors">Caenepeel, Sean; Brown, Sean P.; Belmontes, Brian; Moody, Gordon; Keegan, Kathleen S.; Chui, Danny; Whittington, Douglas A.; Huang, Xin; Poppe, Leszek; Cheng, Alan C.; Cardozo, Mario; Houze, Jonathan; Li, Yunxiao; Lucas, Brian; Paras, Nick A.; Wang, Xianghong; Taygerly, Joshua P.; Vimolratana, Marc; Zancanella, Manuel; Zhu, Liusheng; Cajulis, Elaina; Osgood, Tao; Sun, Jan; Damon, Leah; Egan, Regina K.; Greninger, Patricia; McClanaghan, Joseph D.; Gong, Jianan; Moujalled, Donia; Pomilio, Giovanna; Beltran, Pedro; Benes, Cyril H.; Roberts, Andrew W.; Huang, David C.; Wei, Andrew; Canon, Jude; Coxon, Angela; Hughes, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1582-1597</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer.  To overcome the significant challenges assocd. with inhibition of MCL1 protein-protein interactions, we rigorously applied small-mol. conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans.  We demonstrate that MCL1 inhibition induces a rapid and committed step toward apoptosis in subsets of hematol. cancer cell lines, tumor xenograft models, and primary patient samples.  With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by redns. in B cells, monocytes, and neutrophils.  Furthermore, the combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses.  These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUtMExVVtn5rVg90H21EOLACvtfcHk0lhCQwYYl2oyCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOmsb7E&md5=795a713908c3635bbd5e9fc3d95f3ae0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DMoody%26aufirst%3DG.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DChui%26aufirst%3DD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPoppe%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DHouze%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DParas%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DZancanella%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DCajulis%26aufirst%3DE.%26aulast%3DOsgood%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DDamon%26aufirst%3DL.%26aulast%3DEgan%26aufirst%3DR.%2BK.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DMcClanaghan%26aufirst%3DJ.%2BD.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DMoujalled%26aufirst%3DD.%26aulast%3DPomilio%26aufirst%3DG.%26aulast%3DBeltran%26aufirst%3DP.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DHuang%26aufirst%3DD.%2BC.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DCoxon%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DP.%2BE.%26atitle%3DAMG%2520176%252C%2520a%2520selective%2520MCL1%2520inhibitor%252C%2520is%2520effective%2520in%2520hematologic%2520cancer%2520models%2520alone%2520and%2520in%2520combination%2520with%2520established%2520therapies%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D1582%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><a href="http://clinicaltrials.gov/ct2/show/NCT02992483" class="extLink">http://clinicaltrials.gov/ct2/show/NCT02992483</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02992483."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases</span>. <i>Genome Biology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1186/gb4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1186%2Fgb4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=25180339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=122-131&author=M.+Malumbres&title=Cyclin-dependent+kinases&doi=10.1186%2Fgb4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases</span></div><div class="casAuthors">Malumbres Marcos</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are protein kinases characterized by needing a separate subunit - a cyclin - that provides domains essential for enzymatic activity.  CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and intracellular cues.  The evolutionary expansion of the CDK family in mammals led to the division of CDKs into three cell-cycle-related subfamilies (Cdk1, Cdk4 and Cdk5) and five transcriptional subfamilies (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20).  Unlike the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few cyclins, consistent with functional specialization during evolution.  This review summarizes how, although CDKs are traditionally separated into cell-cycle or transcriptional CDKs, these activities are frequently combined in many family members.  Not surprisingly, deregulation of this family of proteins is a hallmark of several diseases, including cancer, and drug-targeted inhibition of specific members has generated very encouraging results in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQodaug4zJdjgHqQV89nF-2fW6udTcc2eaqfvwzkq-s4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D&md5=9fd79ec8f495f712bada681b0a0b5afe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fgb4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb4184%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinases%26jtitle%3DGenome%2520Biology%26date%3D2014%26volume%3D15%26spage%3D122%26epage%3D131%26doi%3D10.1186%2Fgb4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lhCQwYYl2oyCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. M.</span></span> <span> </span><span class="NLM_article-title">The general transcription machinery and general cofactors</span>. <i>Crit. Rev. Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1080/10409230600648736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1080%2F10409230600648736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=16858867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvV2rtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2006&pages=105-178&author=M.+C.+Thomasauthor=C.+M.+Chiang&title=The+general+transcription+machinery+and+general+cofactors&doi=10.1080%2F10409230600648736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The general transcription machinery and general cofactors</span></div><div class="casAuthors">Thomas, Mary C.; Chiang, Cheng-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">105-178</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  In eukaryotes, the core promoter serves as a platform for the assembly of transcription preinitiation complex (PIC) that includes TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, and RNA polymerase II (pol II), which function collectively to specify the transcription start site.  PIC formation usually begins with TFIID binding to the TATA box, initiator, and/or downstream promoter element (DPE) found in most core promoters, followed by the entry of other general transcription factors (GTFs) and pol II through either a sequential assembly or a preassembled pol II holoenzyme pathway.  Formation of this promoter-bound complex is sufficient for a basal level of transcription.  However, for activator-dependent (or regulated) transcription, general cofactors are often required to transmit regulatory signals between gene-specific activators and the general transcription machinery.  Three classes of general cofactors, including TBP-assocd. factors (TAFs), Mediator, and upstream stimulatory activity (USA)-derived pos. cofactors (PC1/PARP-1, PC2, PC3/DNA topoisomerase I, and PC4) and neg. cofactor 1 (NC1/HMGB1), normally function independently or in combination to fine-tune the promoter activity in a gene-specific or cell-type-specific manner.  In addn., other cofactors, such as TAF1, BTAF1, and neg. cofactor 2 (NC2), can also modulate TBP or TFIID binding to the core promoter.  In general, these cofactors are capable of repressing basal transcription when activators are absent and stimulating transcription in the presence of activators.  Here the authors review the roles of these cofactors and GTFs, as well as TBP-related factors (TRFs), TAF-contg. complexes (TFTC, SAGA, SLIK/SALSA, STAGA, and PRC1) and TAF variants, in pol II-mediated transcription, with emphasis on the events occurring after the chromatin has been remodeled but prior to the formation of the first phosphodiester bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWFhQkI2LzYbVg90H21EOLACvtfcHk0li25H1F2jAozA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvV2rtr8%253D&md5=6c6e557887a24ff4e15abb8ad50cfecb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F10409230600648736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10409230600648736%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%2BC.%26aulast%3DChiang%26aufirst%3DC.%2BM.%26atitle%3DThe%2520general%2520transcription%2520machinery%2520and%2520general%2520cofactors%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D41%26spage%3D105%26epage%3D178%26doi%3D10.1080%2F10409230600648736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varadarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poornima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, G. M.</span></span> <span> </span><span class="NLM_article-title">Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12668</span>– <span class="NLM_lpage">12681</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.18632%2Foncotarget.3706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=26059440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbit1eiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=12668-12681&author=S.+Varadarajanauthor=P.+Poornimaauthor=M.+Milaniauthor=K.+Gowdaauthor=S.+Aminauthor=H.+G.+Wangauthor=G.+M.+Cohen&title=Maritoclax+and+dinaciclib+inhibit+MCL-1+activity+and+induce+apoptosis+in+both+a+MCL-1-dependent+and+-independent+manner&doi=10.18632%2Foncotarget.3706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner</span></div><div class="casAuthors">Varadarajan Shankar; Poornima Paramasivan; Milani Mateus; Cohen Gerald M; Gowda Krishne; Amin Shantu; Wang Hong-Gang; Wang Hong-Gang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">12668-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The anti-apoptotic BCL-2 family proteins are important targets for cancer chemotherapy.  Specific and potent inhibitors of the BCL-2 family, such as ABT-263 (navitoclax) and ABT-199, are only effective against some members of the BCL-2 family but do not target MCL-1, which is commonly amplified in tumors and associated with chemoresistance.  In this report, the selectivity and potency of two putative MCL-1 inhibitors, dinaciclib and maritoclax, were assessed.  Although both compounds induced Bax/Bak- and caspase-9-dependent apoptosis, dinaciclib was more potent than maritoclax in downregulating MCL-1 and also in inducing apoptosis.  However, the compounds induced apoptosis, even in cells lacking MCL-1, suggesting multiple mechanisms of cell death.  Furthermore, maritoclax induced extensive mitochondrial fragmentation, and a Bax/Bak- but MCL-1-independent accumulation of mitochondrial reactive oxygen species (ROS), with an accompanying loss of complexes I and III of the electron transport chain.  ROS scavengers, such as MitoQ, could not salvage maritoclax-mediated effects on mitochondrial structure and function.  Taken together, our data demonstrate that neither dinaciclib nor maritoclax exclusively target MCL-1.  Although dinaciclib is clearly not a specific MCL-1 inhibitor, its ability to rapidly downregulate MCL-1 may be beneficial in many clinical settings, where it may reverse chemoresistance or sensitize to other chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpx_DiGIJ5y_EeosoOnpOLfW6udTcc2eZWl1VrmNqewbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbit1eiuw%253D%253D&md5=ca7166806754f153cf39c1ec30f2741d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3706%26sid%3Dliteratum%253Aachs%26aulast%3DVaradarajan%26aufirst%3DS.%26aulast%3DPoornima%26aufirst%3DP.%26aulast%3DMilani%26aufirst%3DM.%26aulast%3DGowda%26aufirst%3DK.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DMaritoclax%2520and%2520dinaciclib%2520inhibit%2520MCL-1%2520activity%2520and%2520induce%2520apoptosis%2520in%2520both%2520a%2520MCL-1-dependent%2520and%2520-independent%2520manner%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D12668%26epage%3D12681%26doi%3D10.18632%2Foncotarget.3706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booher, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolinski, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmonay, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Assaad, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebozhyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loboda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkel, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angagaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennon, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miselis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monahan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondic, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, P.</span></span> <span> </span><span class="NLM_article-title">MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e108371</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0108371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1371%2Fjournal.pone.0108371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=25289887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e108371&author=R.+N.+Booherauthor=H.+Hatchauthor=B.+M.+Dolinskiauthor=T.+Nguyenauthor=L.+Harmonayauthor=A.-S.+Al-Assaadauthor=M.+Ayersauthor=M.+Nebozhynauthor=A.+Lobodaauthor=H.+A.+Hirschauthor=T.+Zhangauthor=B.+Shiauthor=C.+E.+Merkelauthor=M.+H.+Angagawauthor=Y.+Wangauthor=B.+J.+Longauthor=X.+Q.+Lennonauthor=N.+Miselisauthor=V.+Pucciauthor=J.+W.+Monahanauthor=J.+Leeauthor=A.+G.+Kondicauthor=E.+K.+Imauthor=D.+Mauroauthor=R.+Blanchardauthor=G.+Gillilandauthor=S.+E.+Fawellauthor=L.+Zawelauthor=A.+G.+Schullerauthor=P.+Strack&title=MCL1+and+BCL-xL+levels+in+solid+tumors+are+predictive+of+dinaciclib-induced+apoptosis&doi=10.1371%2Fjournal.pone.0108371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis</span></div><div class="casAuthors">Booher, Robert N.; Hatch, Harold; Dolinski, Brian M.; Nguyen, Thi; Harmonay, Lauren; Al-Assaad, Ali-Samer; Ayers, Mark; Nebozhyn, Michael; Loboda, Andrey; Hirsch, Heather A.; Zhang, Theresa; Shi, Bin; Merkel, Carrie E.; Angagaw, Minilik H.; Wang, Yaolin; Long, Brian J.; Lennon, Xianlu Q.; Miselis, Nathan; Pucci, Vincenzo; Monahan, James W.; Lee, Junghoon; Kondic, Anna Georgieva; Im, Eun Kyung; Mauro, David; Blanchard, Rebecca; Gilliland, Gary; Fawell, Stephen E.; Zawel, Leigh; Schuller, Alwin G.; Strack, Peter</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e108371/1-e108371/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Dinaciclib is a potent CDK1, 2, 5 and 9 inhibitor being developed for the treatment of cancer.  Addnl. understanding of antitumor mechanisms and identification of predictive biomarkers are important for its clin. development.  Here we demonstrate that while dinaciclib can effectively block cell cycle progression, in vitro and in vivo studies, coupled with mouse and human pharmacokinetics, support a model whereby induction of apoptosis is a main mechanism of dinaciclib's antitumor effect and relevant to the clin. duration of exposure.  This was further underscored by kinetics of dinaciclib-induced downregulation of the antiapoptotic BCL2 family member MCL1 and correlation of sensitivity with the MCL1-to-BCL-xL mRNA ratio or MCL1 amplification in solid tumor models in vitro and in vivo.  This MCL1-dependent apoptotic mechanism was addnl. supported by synergy with the BCL2, BCL-xL and BCL-w inhibitor navitoclax (ABT-263).  These results provide the rationale for investigating MCL1 and BCL-xL as predictive biomarkers for dinaciclib antitumor response and testing combinations with BCL2 family member inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMdJOAK4lxgrVg90H21EOLACvtfcHk0li25H1F2jAozA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjs73L&md5=f1402fd17dd19279cf81ad5d94b3c9df</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0108371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0108371%26sid%3Dliteratum%253Aachs%26aulast%3DBooher%26aufirst%3DR.%2BN.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DDolinski%26aufirst%3DB.%2BM.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DHarmonay%26aufirst%3DL.%26aulast%3DAl-Assaad%26aufirst%3DA.-S.%26aulast%3DAyers%26aufirst%3DM.%26aulast%3DNebozhyn%26aufirst%3DM.%26aulast%3DLoboda%26aufirst%3DA.%26aulast%3DHirsch%26aufirst%3DH.%2BA.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DB.%26aulast%3DMerkel%26aufirst%3DC.%2BE.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DB.%2BJ.%26aulast%3DLennon%26aufirst%3DX.%2BQ.%26aulast%3DMiselis%26aufirst%3DN.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DMonahan%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DKondic%26aufirst%3DA.%2BG.%26aulast%3DIm%26aufirst%3DE.%2BK.%26aulast%3DMauro%26aufirst%3DD.%26aulast%3DBlanchard%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DSchuller%26aufirst%3DA.%2BG.%26aulast%3DStrack%26aufirst%3DP.%26atitle%3DMCL1%2520and%2520BCL-xL%2520levels%2520in%2520solid%2520tumors%2520are%2520predictive%2520of%2520dinaciclib-induced%2520apoptosis%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De108371%26doi%3D10.1371%2Fjournal.pone.0108371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bywater, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannan, R. D.</span></span> <span> </span><span class="NLM_article-title">Dysregulation of the basal RNA polymerase transcription apparatus in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1038/nrc3496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrc3496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=23612459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVeiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=299-314&author=M.+J.+Bywaterauthor=R.+B.+Pearsonauthor=G.+McArthurauthor=R.+D.+Hannan&title=Dysregulation+of+the+basal+RNA+polymerase+transcription+apparatus+in+cancer&doi=10.1038%2Fnrc3496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dysregulation of the basal RNA polymerase transcription apparatus in cancer</span></div><div class="casAuthors">Bywater, Megan J.; Pearson, Richard B.; McArthur, Grant A.; Hannan, Ross D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">299-314</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mutations that directly affect transcription by RNA polymerases rank among the most central mediators of malignant transformation, but the frequency of new anticancer drugs that selectively target defective transcription app. entering the clinic has been limited.  This is because targeting the large protein-protein and protein-DNA interfaces that control both generic and selective aspects of RNA polymerase transcription has proved extremely difficult.  However, recent technol. advances have led to a 'quantum leap' in our comprehension of the structure and function of the core RNA polymerase components, how they are dysregulated in a broad range of cancers and how they may be targeted for 'transcription therapy'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTjDkz-NvNvLVg90H21EOLACvtfcHk0lgx734ejChzpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVeiur0%253D&md5=09acaa7f20d40936b8f45903deb4e3f0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrc3496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3496%26sid%3Dliteratum%253Aachs%26aulast%3DBywater%26aufirst%3DM.%2BJ.%26aulast%3DPearson%26aufirst%3DR.%2BB.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DHannan%26aufirst%3DR.%2BD.%26atitle%3DDysregulation%2520of%2520the%2520basal%2520RNA%2520polymerase%2520transcription%2520apparatus%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D299%26epage%3D314%26doi%3D10.1038%2Fnrc3496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adelman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lis, J. T.</span></span> <span> </span><span class="NLM_article-title">Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">720</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1038/nrg3293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrg3293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=22986266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGnsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=720-731&author=K.+Adelmanauthor=J.+T.+Lis&title=Promoter-proximal+pausing+of+RNA+polymerase+II%3A+emerging+roles+in+metazoans&doi=10.1038%2Fnrg3293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans</span></div><div class="casAuthors">Adelman, Karen; Lis, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">720-731</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent years have witnessed a sea change in our understanding of transcription regulation: whereas traditional models focused solely on the events that brought RNA polymerase II (Pol II) to a gene promoter to initiate RNA synthesis, emerging evidence points to the pausing of Pol II during early elongation as a widespread regulatory mechanism in higher eukaryotes.  Current data indicate that pausing is particularly enriched at genes in signal-responsive pathways.  Here the evidence for pausing of Pol II from recent high-throughput studies will be discussed, as well as the potential interconnected functions of promoter-proximally paused Pol II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX1oOoJ6isLrVg90H21EOLACvtfcHk0lgx734ejChzpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGnsL7M&md5=8717dd13ced084695e8f6bc011566164</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrg3293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg3293%26sid%3Dliteratum%253Aachs%26aulast%3DAdelman%26aufirst%3DK.%26aulast%3DLis%26aufirst%3DJ.%2BT.%26atitle%3DPromoter-proximal%2520pausing%2520of%2520RNA%2520polymerase%2520II%253A%2520emerging%2520roles%2520in%2520metazoans%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2012%26volume%3D13%26spage%3D720%26epage%3D731%26doi%3D10.1038%2Fnrg3293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilchrist, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelman, K.</span></span> <span> </span><span class="NLM_article-title">Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.cell.2010.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=21074046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2010&pages=540-551&author=D.+A.+Gilchristauthor=G.+Dos+Santosauthor=D.+C.+Fargoauthor=B.+Xieauthor=Y.+Gaoauthor=L.+Liauthor=K.+Adelman&title=Pausing+of+RNA+polymerase+II+disrupts+DNA-specified+nucleosome+organization+to+enable+precise+gene+regulation&doi=10.1016%2Fj.cell.2010.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation</span></div><div class="casAuthors">Gilchrist, Daniel A.; Dos Santos, Gilberto; Fargo, David C.; Xie, Bin; Gao, Yuan; Li, Leping; Adelman, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">540-551</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Metazoan transcription is controlled through either coordinated recruitment of transcription machinery to the gene promoter or regulated pausing of RNA polymerase II (Pol II) in early elongation.  The authors report that a striking difference between genes that use these distinct regulatory strategies lies in the "default" chromatin architecture specified by their DNA sequences.  Pol II pausing is prominent at highly regulated genes whose sequences inherently disfavor nucleosome formation within the gene but favor occlusion of the promoter by nucleosomes.  In contrast, housekeeping genes that lack pronounced Pol II pausing show higher nucleosome occupancy downstream, but their promoters are deprived of nucleosomes regardless of polymerase binding.  These results indicate that a key role of paused Pol II is to compete with nucleosomes for occupancy of highly regulated promoters, thereby preventing the formation of repressive chromatin architecture to facilitate further or future gene activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2kU07Y9s-H7Vg90H21EOLACvtfcHk0lgx734ejChzpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahtbrF&md5=4df1ccb5962df23bcbfbe8e9c1b38b74</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DGilchrist%26aufirst%3DD.%2BA.%26aulast%3DDos%2BSantos%26aufirst%3DG.%26aulast%3DFargo%26aufirst%3DD.%2BC.%26aulast%3DXie%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DAdelman%26aufirst%3DK.%26atitle%3DPausing%2520of%2520RNA%2520polymerase%2520II%2520disrupts%2520DNA-specified%2520nucleosome%2520organization%2520to%2520enable%2520precise%2520gene%2520regulation%26jtitle%3DCell%26date%3D2010%26volume%3D143%26spage%3D540%26epage%3D551%26doi%3D10.1016%2Fj.cell.2010.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sansó, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Pause, play, repeat: CDKs push RNAP II’s buttons</span>. <i>Transcription</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.4161/trns.25146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.4161%2Ftrns.25146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=23756342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A280%3ADC%252BC3sjit1Kgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=146-152&author=M.+Sans%C3%B3author=R.+P.+Fisher&title=Pause%2C+play%2C+repeat%3A+CDKs+push+RNAP+II%E2%80%99s+buttons&doi=10.4161%2Ftrns.25146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pause, play, repeat: CDKs push RNAP II's buttons</span></div><div class="casAuthors">Sanso Miriam; Fisher Robert P</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">146-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) play a central role in governing eukaryotic cell division.  It is becoming clear that the transcription cycle of RNA polymerase II (RNAP II) is also regulated by CDKs; in metazoans, the cell cycle and transcriptional CDK networks even share an upstream activating kinase, which is itself a CDK.  From recent chemical-genetic analyses we know that CDKs and their substrates control events both early in transcription (the transition from initiation to elongation) and late (3' end formation and transcription termination).  Moreover, mutual dependence on CDK activity might couple the "beginning" and "end" of the cycle, to ensure the fidelity of mRNA maturation and the efficient recycling of RNAP II from sites of termination to the transcription start site (TSS).  As is the case for CDKs involved in cell cycle regulation, different transcriptional CDKs act in defined sequence on multiple substrates.  These phosphorylations are likely to influence gene expression by several mechanisms, including direct, allosteric effects on the transcription machinery, co-transcriptional recruitment of proteins needed for mRNA-capping, splicing and 3' end maturation, dependent on multisite phosphorylation of the RNAP II C-terminal domain (CTD) and, perhaps, direct regulation of RNA-processing or histone-modifying machinery.  Here we review these recent advances, and preview the emerging challenges for transcription-cycle research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVCXjX-6gFVbjnyZkbE8yXfW6udTcc2eZbxLrDU1J3HLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjit1Kgug%253D%253D&md5=4e774056e5b96f6d44504b2f5695f636</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.4161%2Ftrns.25146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Ftrns.25146%26sid%3Dliteratum%253Aachs%26aulast%3DSans%25C3%25B3%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DPause%252C%2520play%252C%2520repeat%253A%2520CDKs%2520push%2520RNAP%2520II%25E2%2580%2599s%2520buttons%26jtitle%3DTranscription%26date%3D2013%26volume%3D4%26spage%3D146%26epage%3D152%26doi%3D10.4161%2Ftrns.25146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napoleon, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin dependent kinase 9 inhibitors for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8667</span>– <span class="NLM_lpage">8684</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00150</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00150" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslGjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8667-8684&author=Y.+A.+Sonawaneauthor=M.+A.+Taylorauthor=J.+V.+Napoleonauthor=S.+Ranaauthor=J.+I.+Contrerasauthor=A.+Natarajan&title=Cyclin+dependent+kinase+9+inhibitors+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.6b00150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy</span></div><div class="casAuthors">Sonawane, Yogesh A.; Taylor, Margaret A.; Napoleon, John Victor; Rana, Sandeep; Contreras, Jacob I.; Natarajan, Amarnath</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8667-8684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and crit. functions within the cell.  Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics.  CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is crit. for the survival of transformed cells.  Focused chem. libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors.  Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOIqU9uSujdrVg90H21EOLACvtfcHk0lhRIlXaygswxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslGjsLo%253D&md5=0910a61f9c915002ff1073b22b5e20d6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00150%26sid%3Dliteratum%253Aachs%26aulast%3DSonawane%26aufirst%3DY.%2BA.%26aulast%3DTaylor%26aufirst%3DM.%2BA.%26aulast%3DNapoleon%26aufirst%3DJ.%2BV.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DContreras%26aufirst%3DJ.%2BI.%26aulast%3DNatarajan%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%25209%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8667%26epage%3D8684%26doi%3D10.1021%2Facs.jmedchem.6b00150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Midgley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabarek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontopidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClue, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLachlan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meades, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheleva, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1111</span>– <span class="NLM_lpage">1121</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.chembiol.2010.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=21035734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1111-1121&author=S.+Wangauthor=G.+Griffithsauthor=C.+A.+Midgleyauthor=A.+L.+Barnettauthor=M.+Cooperauthor=J.+Grabarekauthor=L.+Ingramauthor=W.+Jacksonauthor=G.+Kontopidisauthor=S.+J.+McClueauthor=C.+McInnesauthor=J.+McLachlanauthor=C.+Meadesauthor=M.+Meznaauthor=I.+Stuartauthor=M.+P.+Thomasauthor=D.+I.+Zhelevaauthor=D.+P.+Laneauthor=R.+C.+Jacksonauthor=D.+M.+Gloverauthor=D.+G.+Blakeauthor=P.+M.+Fischer&title=Discovery+and+characterization+of+2-anilino-4-+%28thiazol-5-yl%29pyrimidine+transcriptional+CDK+inhibitors+as+anticancer+agents&doi=10.1016%2Fj.chembiol.2010.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Wang, Shu-Dong; Griffiths, Gary; Midgley, Carol A.; Barnett, Anna L.; Cooper, Michael; Grabarek, Joanna; Ingram, Laura; Jackson, Wayne; Kontopidis, George; McClue, Steven J.; McInnes, Campbell; McLachlan, Janice; Meades, Christopher; Mezna, Mokdad; Stuart, Iain; Thomas, Mark P.; Zheleva, Daniella I.; Lane, David P.; Jackson, Robert C.; Glover, David M.; Blake, David G.; Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1111-1121</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The main difficulty in the development of ATP antagonist kinase inhibitors is target specificity, since the ATP-binding motif is present in many proteins.  We introduce a strategy that has allowed us to identify compds. from a kinase inhibitor library that block the cyclin-dependent kinases responsible for regulating transcription, i.e., CDK7 and esp. CDK9.  The screening cascade employs cellular phenotypic assays based on mitotic index and nuclear p53 protein accumulation.  This permitted us to classify compds. into transcriptional, cell cycle, and mitotic inhibitor groups.  We describe the characterization of the transcriptional inhibitor class in terms of kinase inhibition profile, cellular mode of action, and selectivity for transformed cells.  A structural selectivity rationale was used to optimize potency and biopharmaceutical properties and led to the development of a transcriptional inhibitor, 3,4-dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one, with anticancer activity in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryOG4LTevHibVg90H21EOLACvtfcHk0lhRIlXaygswxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL&md5=08aff2706f6eda4ba1038327267a361e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DMidgley%26aufirst%3DC.%2BA.%26aulast%3DBarnett%26aufirst%3DA.%2BL.%26aulast%3DCooper%26aufirst%3DM.%26aulast%3DGrabarek%26aufirst%3DJ.%26aulast%3DIngram%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DMcLachlan%26aufirst%3DJ.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DZheleva%26aufirst%3DD.%2BI.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DGlover%26aufirst%3DD.%2BM.%26aulast%3DBlake%26aufirst%3DD.%2BG.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDiscovery%2520and%2520characterization%2520of%25202-anilino-4-%2520%2528thiazol-5-yl%2529pyrimidine%2520transcriptional%2520CDK%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D1111%26epage%3D1121%26doi%3D10.1016%2Fj.chembiol.2010.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassington, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byth, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMiken, H. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcombe, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauptit, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanway, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, H. M.</span></span> <span> </span><span class="NLM_article-title">Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5487</span>– <span class="NLM_lpage">5492</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.bmcl.2008.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=18815031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5487-5492&author=M.+Andersonauthor=D.+M.+Andrewsauthor=A.+J.+Barkerauthor=C.+A.+Brassingtonauthor=J.+Breedauthor=K.+F.+Bythauthor=J.+D.+Culshawauthor=M.+R.+V.+Finlayauthor=E.+Fisherauthor=H.+H.+J.+McMikenauthor=C.+P.+Greenauthor=D.+W.+Heatonauthor=I.+A.+Nashauthor=N.+J.+Newcombeauthor=S.+E.+Oakesauthor=R.+A.+Pauptitauthor=A.+Robertsauthor=J.+J.+Stanwayauthor=A.+P.+Thomasauthor=J.+A.+Tuckerauthor=M.+Walkerauthor=H.+M.+Weir&title=Imidazoles%3A+SAR+and+development+of+a+potent+class+of+cyclin-dependent+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2008.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors</span></div><div class="casAuthors">Anderson, Malcolm; Andrews, David M.; Barker, Andy J.; Brassington, Claire A.; Breed, Jason; Byth, Kate F.; Culshaw, Janet D.; Finlay, M. Raymond V.; Fisher, Eric; McMiken, Helen H. J.; Green, Clive P.; Heaton, Dave W.; Nash, Ian A.; Newcombe, Nicholas J.; Oakes, Sandra E.; Pauptit, Richard A.; Roberts, Andrew; Stanway, Judith J.; Thomas, Andrew P.; Tucker, Julie A.; Walker, Mike; Weir, Hazel M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5487-5492</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed.  Protein inhibitor structure detn. has provided an understanding of the emerging structure activity trends for the imidazole series.  The introduction of a Me sulfone at the aniline terminus led to a more orally bioavailable CDK inhibitor that was progressed into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSg0heaJEiurVg90H21EOLACvtfcHk0liw4LaMq3hcqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs7zM&md5=c2967070f2ab5480c2fddb111a18687b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DBrassington%26aufirst%3DC.%2BA.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DByth%26aufirst%3DK.%2BF.%26aulast%3DCulshaw%26aufirst%3DJ.%2BD.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DFisher%26aufirst%3DE.%26aulast%3DMcMiken%26aufirst%3DH.%2BH.%2BJ.%26aulast%3DGreen%26aufirst%3DC.%2BP.%26aulast%3DHeaton%26aufirst%3DD.%2BW.%26aulast%3DNash%26aufirst%3DI.%2BA.%26aulast%3DNewcombe%26aufirst%3DN.%2BJ.%26aulast%3DOakes%26aufirst%3DS.%2BE.%26aulast%3DPauptit%26aufirst%3DR.%2BA.%26aulast%3DRoberts%26aufirst%3DA.%26aulast%3DStanway%26aufirst%3DJ.%2BJ.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26atitle%3DImidazoles%253A%2520SAR%2520and%2520development%2520of%2520a%2520potent%2520class%2520of%2520cyclin-dependent%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5487%26epage%3D5492%26doi%3D10.1016%2Fj.bmcl.2008.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapenna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle kinases as therapeutic targets for cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nrd2907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fnrd2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=19568282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+cycle+kinases+as+therapeutic+targets+for+cancer&doi=10.1038%2Fnrd2907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Lapenna, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-566</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells.  Although several mols. that inhibit cell cycle kinases have been developed and clin. screened as potential anticancer agents, none of these has been approved for com. use and an effective strategy to specifically control malignant cell proliferation has yet to be established.  However, recent genetic and biochem. studies have provided information about the requirement for certain cell cycle kinases by specific tumors and specialized tissue types.  Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7YptkwzjgrVg90H21EOLACvtfcHk0liw4LaMq3hcqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D&md5=7acb71b7aaf0ab644227103f7c14b892</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2907%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520cycle%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566%26doi%3D10.1038%2Fnrd2907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span>; <span class="NLM_string-name">Shen, M.</span>; <span class="NLM_string-name">Grondine, M.</span>; <span class="NLM_string-name">Boiko, S.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Borodovsky, A.</span>; <span class="NLM_string-name">Mazzola, A. M.</span>; <span class="NLM_string-name">Wu, A.</span>; <span class="NLM_string-name">Lawson, D.</span>; <span class="NLM_string-name">Ferguson, F.</span>; <span class="NLM_string-name">Gao, B.</span>; <span class="NLM_string-name">Cui, A.</span>; <span class="NLM_string-name">D’Cruz, C.</span>; <span class="NLM_string-name">Drew, L.</span></span> <span> </span><span class="NLM_article-title">AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, April 16–20, 2016</span>.  <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">76</span> (<span class="NLM_issue">14 Suppl.</span>), Abstract  <span class="NLM_fpage">3572</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=27197168" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3572&issue=14+Suppl.&author=J.+Cidado&author=M.+Shen&author=M.+Grondine&author=S.+Boiko&author=H.+Wang&author=A.+Borodovsky&author=A.+M.+Mazzola&author=A.+Wu&author=D.+Lawson&author=F.+Ferguson&author=B.+Gao&author=A.+Cui&author=C.+D%E2%80%99Cruz&author=L.+Drew&title=AZ5576%2C+a+novel+potent+and+selective+CDK9+inhibitor%2C+induces+rapid+cell+death+and+achieves+efficacy+in+multiple+preclinical+hematological+models.+Proceedings+of+the+107th+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+New+Orleans%2C+April+16%E2%80%9320%2C+2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCidado%26aufirst%3DJ.%26atitle%3DAZ5576%252C%2520a%2520novel%2520potent%2520and%2520selective%2520CDK9%2520inhibitor%252C%2520induces%2520rapid%2520cell%2520death%2520and%2520achieves%2520efficacy%2520in%2520multiple%2520preclinical%2520hematological%2520models.%2520Proceedings%2520of%2520the%2520107th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520New%2520Orleans%252C%2520April%252016%25E2%2580%259320%252C%25202016%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D14%2520Suppl%26spage%3D3572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span> AZ5576 is also
known
as PC585:<span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Cuellar, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Füller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäthner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetzner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeitlmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slany, R. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1435</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1038%2Fleu.2014.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=24445865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlSitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=1427-1435&author=M.+P.+Garcia-Cuellarauthor=E.+F%C3%BCllerauthor=E.+M%C3%A4thnerauthor=C.+Breitingerauthor=K.+Hetznerauthor=L.+Zeitlmannauthor=A.+Borkhardtauthor=R.+K.+Slany&title=Efficacy+of+cyclin-dependent-kinase+9+inhibitors+in+a+murine+model+of+mixed-lineage+leukemia&doi=10.1038%2Fleu.2014.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia</span></div><div class="casAuthors">Garcia-Cuellar, M.-P.; Fueller, E.; Maethner, E.; Breitinger, C.; Hetzner, K.; Zeitlmann, L.; Borkhardt, A.; Slany, R. K.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1427-1435</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mixed-lineage leukemia fusion proteins activate their target genes predominantly by stimulating transcriptional elongation.  A core component necessary for this activity is cyclin-dependent kinase 9.  Here we explored the effectiveness of small mols. targeting this enzyme as potential therapeutics.  A screen of seven compds. with anti-CDK9 activity applied to a panel of leukemia cell lines identified flavopiridol and the exptl. inhibitor PC585 as superior in efficacy with inhibitory concns. in the submicromolar range.  Both substances induced rapid dephosphorylation of the RNA polymerase II C-terminal domain, accompanied by downregulation of CDK9-dependent transcripts for MYC and HOXA9.  Global gene expression anal. indicated the induction of a general stress response program, culminating in widespread apoptosis.  Importantly, colony-forming activity in leukemia lines and primary patient samples could be completely inhibited under conditions that did not affect native precursors from bone marrow.  In vivo application in a mouse transplant model significantly delayed disease with PC585 showing also oral activity.  These results suggest CDK9 inhibition as novel treatment option for mixed-lineage leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpw5z9XGY1zbVg90H21EOLACvtfcHk0ljUpv9j6q9MOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlSitLk%253D&md5=d0160dbc9e168218924e55501cf7b375</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.40%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Cuellar%26aufirst%3DM.%2BP.%26aulast%3DF%25C3%25BCller%26aufirst%3DE.%26aulast%3DM%25C3%25A4thner%26aufirst%3DE.%26aulast%3DBreitinger%26aufirst%3DC.%26aulast%3DHetzner%26aufirst%3DK.%26aulast%3DZeitlmann%26aufirst%3DL.%26aulast%3DBorkhardt%26aufirst%3DA.%26aulast%3DSlany%26aufirst%3DR.%2BK.%26atitle%3DEfficacy%2520of%2520cyclin-dependent-kinase%25209%2520inhibitors%2520in%2520a%2520murine%2520model%2520of%2520mixed-lineage%2520leukemia%26jtitle%3DLeukemia%26date%3D2014%26volume%3D28%26spage%3D1427%26epage%3D1435%26doi%3D10.1038%2Fleu.2014.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span>AZ5576
was described in patent literature: <span class="NLM_contrib-group"><span class="NLM_string-name">Heiser, U.</span>; <span class="NLM_string-name">Niestroj, A. J.</span>; <span class="NLM_string-name">Zeitlmann, L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Protein Kinases</span>. PCT Int. Appl., WO 2011110612, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=U.+Heiser&author=A.+J.+Niestroj&author=L.+Zeitlmann&title=Inhibitors+of+Protein+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeiser%26aufirst%3DU.%26atitle%3DInhibitors%2520of%2520Protein%2520Kinases%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albert, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisterernst, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1111/bph.12408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1111%2Fbph.12408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=24102143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2mtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=55-68&author=T.+K.+Albertauthor=C.+Rigaultauthor=J.+Eickhoffauthor=K.+Baumgartauthor=C.+Antrechtauthor=B.+Kleblauthor=G.+Mittlerauthor=M.+Meisterernst&title=Characterization+of+molecular+and+cellular+functions+of+the+cyclin-dependent+kinase+CDK9+using+a+novel+specific+inhibitor&doi=10.1111%2Fbph.12408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor</span></div><div class="casAuthors">Albert, T. K.; Rigault, C.; Eickhoff, J.; Baumgart, K.; Antrecht, C.; Klebl, B.; Mittler, G.; Meisterernst, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The cyclin-dependent kinase CDK9 is an important therapeutic target but currently available inhibitors exhibit low specificity and/or narrow therapeutic windows.  Here we have used a new highly specific CDK9 inhibitor, LDC000067 to interrogate gene control mechanisms mediated by CDK9.  Exptl. Approach : The selectivity of LDC000067 was established in functional kinase assays.  Functions of CDK9 in gene expression were assessed with in vitro transcription expts., single gene analyses and genome-wide expression profiling.  Cultures of mouse embryonic stem cells, HeLa cells, several cancer cell lines, along with cells from patients with acute myelogenous leukemia were also used to investigate cellular responses to LDC000067.  Key Results : The selectivity of LDC000067 for CDK9 over other CDKs exceeded that of the known inhibitors flavopiridol and DRB.  LDC000067 inhibited in vitro transcription in an ATP-competitive and dose-dependent manner.  Gene expression profiling of cells treated with LDC000067 demonstrated a selective redn. of short-lived mRNAs, including important regulators of proliferation and apoptosis.  Anal. of de novo RNA synthesis suggested a wide ranging pos. role of CDK9.  At the mol. and cellular level, LDC000067 reproduced effects characteristic of CDK9 inhibition such as enhanced pausing of RNA polymerase II on genes and, most importantly, induction of apoptosis in cancer cells.  Conclusions and Implications : Our study provides a framework for the mechanistic understanding of cellular responses to CDK9 inhibition.  LDC000067 represents a promising lead for the development of clin. useful, highly specific CDK9 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphlq2wB8J8BbVg90H21EOLACvtfcHk0ljUpv9j6q9MOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2mtLbF&md5=61dccacb940578e746fb5f3962ccd87e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fbph.12408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12408%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DT.%2BK.%26aulast%3DRigault%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBaumgart%26aufirst%3DK.%26aulast%3DAntrecht%26aufirst%3DC.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMittler%26aufirst%3DG.%26aulast%3DMeisterernst%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520molecular%2520and%2520cellular%2520functions%2520of%2520the%2520cyclin-dependent%2520kinase%2520CDK9%2520using%2520a%2520novel%2520specific%2520inhibitor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D55%26epage%3D68%26doi%3D10.1111%2Fbph.12408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreklau, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fales, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carballares, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajamie, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronier, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foreman, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeckner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sissons, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halstead, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoho, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaynor, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span> <span> </span><span class="NLM_article-title">A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1442</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1158%2F1535-7163.MCT-13-0849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=24688048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Kqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1442-1456&author=T.+Yinauthor=M.+J.+Lallenaauthor=E.+L.+Kreklauauthor=K.+R.+Falesauthor=S.+Carballaresauthor=R.+Torresauthor=G.+N.+Wishartauthor=R.+T.+Ajamieauthor=D.+M.+Cronierauthor=P.+W.+Iversenauthor=T.+I.+Meierauthor=R.+T.+Foremanauthor=D.+Zecknerauthor=S.+E.+Sissonsauthor=B.+W.+Halsteadauthor=A.+B.+Linauthor=G.+P.+Donohoauthor=Y.+Qianauthor=S.+Liauthor=S.+Wuauthor=A.+Aggarwalauthor=X.+S.+Yeauthor=J.+J.+Starlingauthor=R.+B.+Gaynorauthor=A.+de+Diosauthor=J.+Du&title=A+novel+CDK9+inhibitor+shows+potent+antitumor+efficacy+in+preclinical+hematologic+tumor+models&doi=10.1158%2F1535-7163.MCT-13-0849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models</span></div><div class="casAuthors">Yin, Tinggui; Lallena, Maria J.; Kreklau, Emiko L.; Fales, Kevin R.; Carballares, Santiago; Torrres, Raquel; Wishart, Graham N.; Ajamie, Rose T.; Cronier, Damien M.; Iversen, Phillip W.; Meier, Timothy I.; Foreman, Robert T.; Zeckner, Douglas; Sissons, Sean E.; Halstead, Bart W.; Lin, Aimee B.; Donoho, Gregory P.; Qian, Yuewei; Li, Shuyu; Wu, Song; Aggarwal, Amit; Ye, Xiang S.; Starling, James J.; Gaynor, Richard B.; de Dios, Alfonso; Du, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1442-1456</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">DNA-dependent RNA polymerase II (RNAP II) largest subunit RPB1 C-terminal domain (CTD) kinases, including CDK9, are serine/threonine kinases known to regulate transcriptional initiation and elongation by phosphorylating Ser 2, 5, and 7 residues on CTD.  Given the reported dysregulation of these kinases in some cancers, we asked whether inhibiting CDK9 may induce stress response and preferentially kill tumor cells.  Herein, we describe a potent CDK9 inhibitor, LY2857785, that significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.  This mol. inhibits the growth of a broad panel of cancer cell lines, and is particularly efficacious in leukemia cells, including orthotopic leukemia preclin. models as well as in ex vivo acute myeloid leukemia and chronic lymphocytic leukemia patient tumor samples.  Thus, inhibition of CDK9 may represent an interesting approach as a cancer therapeutic target, esp. in hematol. malignancies.  Mol Cancer Ther; 13(6); 1442-56. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAbH82lPOkSbVg90H21EOLACvtfcHk0ljUpv9j6q9MOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Kqu7c%253D&md5=1e8a21ce9aed0a08012e9b58d8d668b9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0849%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DT.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3DKreklau%26aufirst%3DE.%2BL.%26aulast%3DFales%26aufirst%3DK.%2BR.%26aulast%3DCarballares%26aufirst%3DS.%26aulast%3DTorres%26aufirst%3DR.%26aulast%3DWishart%26aufirst%3DG.%2BN.%26aulast%3DAjamie%26aufirst%3DR.%2BT.%26aulast%3DCronier%26aufirst%3DD.%2BM.%26aulast%3DIversen%26aufirst%3DP.%2BW.%26aulast%3DMeier%26aufirst%3DT.%2BI.%26aulast%3DForeman%26aufirst%3DR.%2BT.%26aulast%3DZeckner%26aufirst%3DD.%26aulast%3DSissons%26aufirst%3DS.%2BE.%26aulast%3DHalstead%26aufirst%3DB.%2BW.%26aulast%3DLin%26aufirst%3DA.%2BB.%26aulast%3DDonoho%26aufirst%3DG.%2BP.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DAggarwal%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DX.%2BS.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DGaynor%26aufirst%3DR.%2BB.%26aulast%3Dde%2BDios%26aufirst%3DA.%26aulast%3DDu%26aufirst%3DJ.%26atitle%3DA%2520novel%2520CDK9%2520inhibitor%2520shows%2520potent%2520antitumor%2520efficacy%2520in%2520preclinical%2520hematologic%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1442%26epage%3D1456%26doi%3D10.1158%2F1535-7163.MCT-13-0849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Luecking, U.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Boemer, U.</span>; <span class="NLM_string-name">Ellinghaus, P.</span>; <span class="NLM_string-name">Walter, A. O.</span>; <span class="NLM_string-name">Valencia, R.</span>; <span class="NLM_string-name">Ince, S.</span>; <span class="NLM_string-name">von
Nussbaum, F.</span>; <span class="NLM_string-name">Mumberg, D.</span>; <span class="NLM_string-name">Brands, M.</span>; <span class="NLM_string-name">Karl Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia, April 18–22, 2015</span>.  <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume">75</span> (<span class="NLM_issue">15 Suppl.</span>), Abstract  <span class="NLM_fpage">DDT02</span>– <span class="NLM_lpage">02</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=DDT02-02&issue=15+Suppl.&author=A.+Scholz&author=U.+Luecking&author=G.+Siemeister&author=P.+Lienau&author=U.+Boemer&author=P.+Ellinghaus&author=A.+O.+Walter&author=R.+Valencia&author=S.+Ince&author=F.+von%0ANussbaum&author=D.+Mumberg&author=M.+Brands&author=K.+Karl+Ziegelbauer&title=BAY+1143572%3A+A+first-in-class%2C+highly+selective%2C+potent+and+orally+available+inhibitor+of+PTEFb%2FCDK9+currently+in+phase+I%2C+inhibits+MYC+and+shows+convincing+anti-tumor+activity+in+multiple+xenograft+models+by+the+induction+of+apoptosis.+Proceedings+of+the+106th+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Philadelphia%2C+April+18%E2%80%9322%2C+2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScholz%26aufirst%3DA.%26atitle%3DBAY%25201143572%253A%2520A%2520first-in-class%252C%2520highly%2520selective%252C%2520potent%2520and%2520orally%2520available%2520inhibitor%2520of%2520PTEFb%252FCDK9%2520currently%2520in%2520phase%2520I%252C%2520inhibits%2520MYC%2520and%2520shows%2520convincing%2520anti-tumor%2520activity%2520in%2520multiple%2520xenograft%2520models%2520by%2520the%2520induction%2520of%2520apoptosis.%2520Proceedings%2520of%2520the%2520106th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520Philadelphia%252C%2520April%252018%25E2%2580%259322%252C%25202015%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D15%2520Suppl%26spage%3DDDT02%26epage%3D02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terebesi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boemer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ince, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choidas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruehter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span> <span> </span><span class="NLM_article-title">Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1776</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1002%2Fcmdc.201700447" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=28961375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1776-1793&author=U.+Lueckingauthor=A.+Scholzauthor=P.+Lienauauthor=G.+Siemeisterauthor=D.+Kosemundauthor=R.+Bohlmannauthor=H.+Briemauthor=I.+Terebesiauthor=K.+Meyerauthor=K.+Prelleauthor=K.+Dennerauthor=U.+Boemerauthor=M.+Schaeferauthor=K.+Eisauthor=R.+Valenciaauthor=S.+Inceauthor=F.+von+Nussbaumauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=B.+Kleblauthor=A.+Choidasauthor=P.+Nussbaumerauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=G.+Ruehterauthor=J.+Eickhoffauthor=M.+Brands&title=Identification+of+atuveciclib+%28BAY+1143572%29%2C+the+first+highly+selective%2C+clinical+PTEFb%2FCDK9+inhibitor+for+the+treatment+of+cancer&doi=10.1002%2Fcmdc.201700447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Luecking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Boemer, Ulf; Schaefer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbauer, Karl; Klebl, Bert; Choidas, Axel; Nussbaumer, Peter; Baumann, Matthias; Schultz-Fademrecht, Carsten; Ruehter, Gerd; Eickhoff, Jan; Brands, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1776-1793</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective inhibition of exclusively transcription-regulating PTEFb/CDK9 is a promising new approach in cancer therapy.  Starting from lead compd. BAY-958, lead optimization efforts strictly focusing on kinase selectivity, physicochem. and DMPK properties finally led to the identification of the orally available clin. candidate atuveciclib (BAY 1143572).  Structurally characterized by an unusual benzyl sulfoximine group, BAY 1143572 exhibited the best overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats.  BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqypgkxBuypa7Vg90H21EOLACvtfcHk0ljRJZX73v3tag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltLvJ&md5=04fb5dae9956246889e1313c87339990</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700447%26sid%3Dliteratum%253Aachs%26aulast%3DLuecking%26aufirst%3DU.%26aulast%3DScholz%26aufirst%3DA.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DBohlmann%26aufirst%3DR.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DTerebesi%26aufirst%3DI.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DPrelle%26aufirst%3DK.%26aulast%3DDenner%26aufirst%3DK.%26aulast%3DBoemer%26aufirst%3DU.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DEis%26aufirst%3DK.%26aulast%3DValencia%26aufirst%3DR.%26aulast%3DInce%26aufirst%3DS.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DRuehter%26aufirst%3DG.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBrands%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520atuveciclib%2520%2528BAY%25201143572%2529%252C%2520the%2520first%2520highly%2520selective%252C%2520clinical%2520PTEFb%252FCDK9%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1776%26epage%3D1793%26doi%3D10.1002%2Fcmdc.201700447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U. T. R.</span>; <span class="NLM_string-name">Scholz, A.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Bohlmann, R.</span>; <span class="NLM_string-name">Briem, H.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Terebesi, I.</span>; <span class="NLM_string-name">Meyer, K.</span>; <span class="NLM_string-name">Prelle, K.</span>; <span class="NLM_string-name">Valencia, R.</span>; <span class="NLM_string-name">Ince, S.</span>; <span class="NLM_string-name">von Nussbaum, F.</span>; <span class="NLM_string-name">Mumberg, D.</span>; <span class="NLM_string-name">Ziegelbauer, K.</span>; <span class="NLM_string-name">Brands, M.</span></span>. <span> </span><span class="NLM_article-title">Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops. Proceedings of the 2017 Annual Meeting of the American Association for Cancer Research (AACR), Washington D.C., April 1–5, 2017</span>,  <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">77</span> (<span class="NLM_issue">13 Suppl.</span>), Abstract  <span class="NLM_fpage">984</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=984&issue=13+Suppl.&author=U.+T.+R.+Luecking&author=A.+Scholz&author=D.+Kosemund&author=R.+Bohlmann&author=H.+Briem&author=P.+Lienau&author=G.+Siemeister&author=I.+Terebesi&author=K.+Meyer&author=K.+Prelle&author=R.+Valencia&author=S.+Ince&author=F.+von+Nussbaum&author=D.+Mumberg&author=K.+Ziegelbauer&author=M.+Brands&title=Identification+of+potent+and+highly+selective+PTEFb+inhibitor+BAY+1251152+for+the+treatment+of+cancer%3A+from+p.o.+to+i.v.+application+via+scaffold+hops.+Proceedings+of+the+2017+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29%2C+Washington+D.C.%2C+April+1%E2%80%935%2C+2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuecking%26aufirst%3DU.%2BT.%2BR.%26atitle%3DIdentification%2520of%2520potent%2520and%2520highly%2520selective%2520PTEFb%2520inhibitor%2520BAY%25201251152%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520from%2520p.o.%2520to%2520i.v.%2520application%2520via%2520scaffold%2520hops.%2520Proceedings%2520of%2520the%25202017%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%252C%2520Washington%2520D.C.%252C%2520April%25201%25E2%2580%25935%252C%25202017%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D13%2520Suppl%26spage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span> <span> </span><span class="NLM_article-title">Novel Parham-type cycloacylations of 1<i>H</i>-pyrazole-1-alkanoic acids</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>1997</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1055/s-1997-955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1055%2Fs-1997-955" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1997&publication_year=1997&pages=1013-1014&author=S.+D.+Larsen&title=Novel+Parham-type+cycloacylations+of+1H-pyrazole-1-alkanoic+acids&doi=10.1055%2Fs-1997-955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1055%2Fs-1997-955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1997-955%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26atitle%3DNovel%2520Parham-type%2520cycloacylations%2520of%25201H-pyrazole-1-alkanoic%2520acids%26jtitle%3DSynlett%26date%3D1997%26volume%3D1997%26spage%3D1013%26epage%3D1014%26doi%3D10.1055%2Fs-1997-955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galeta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenora, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potacek, M.</span></span> <span> </span><span class="NLM_article-title">Dihydropyrrolo[1,2-b]pyrazoles: withasomnine and related compounds</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">7139</span>– <span class="NLM_lpage">7146</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2013.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.tet.2013.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCru7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=7139-7146&author=J.+Galetaauthor=L.+Tenoraauthor=S.+Manauthor=M.+Potacek&title=Dihydropyrrolo%5B1%2C2-b%5Dpyrazoles%3A+withasomnine+and+related+compounds&doi=10.1016%2Fj.tet.2013.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydropyrrolo[1,2-b]pyrazoles: withasomnine and related compounds</span></div><div class="casAuthors">Galeta, Juraj; Tenora, Lukas; Man, Stanislav; Potacek, Milan</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">7139-7146</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A methodol. involving the prepn. of substituted dihydropyrrolo[1,2-b]pyrazoles, e.g., I, focuses on withasomnine and the synthesis of several structurally related compds, is reported.  The developed reaction protocols enable the prepn. of the mentioned bicyclic system with broadly diverse substitution.  The reaction protocol, consisting of two multi-step synthetic pathways, includes Sonogashira and Suzuki-Miyaura cross-coupling reactions, allenyl synthon formation, Kulinkovich cyclopropanation, ring transformations, and nonsym. homoallenyl azines cycloaddns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ6qZtfek5lrVg90H21EOLACvtfcHk0lgxmR0xHLMEXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCru7rI&md5=ae731d6c6d5c3902a6348b7d6eb02e00</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2013.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2013.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DGaleta%26aufirst%3DJ.%26aulast%3DTenora%26aufirst%3DL.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DPotacek%26aufirst%3DM.%26atitle%3DDihydropyrrolo%255B1%252C2-b%255Dpyrazoles%253A%2520withasomnine%2520and%2520related%2520compounds%26jtitle%3DTetrahedron%26date%3D2013%26volume%3D69%26spage%3D7139%26epage%3D7146%26doi%3D10.1016%2Fj.tet.2013.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">660</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1021/jm301495v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+structural+and+functional+studies+of+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+inhibitors+suggest+the+basis+for+isotype+selectivity&doi=10.1021%2Fjm301495v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span></div><div class="casAuthors">Hole, Alison J.; Baumli, Sonja; Shao, Hao; Shi, Shenhua; Huang, Shiliang; Pepper, Chris; Fischer, Peter M.; Wang, Shudong; Endicott, Jane A.; Noble, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer that constitutes pos. transcription elongation factor b, is a well-validated target for treatment of several diseases, including cancer and cardiac hypertrophy.  In order to aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T and CDK2/cyclin A.  We find that for a given CDK, the melting temp. of a CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that differential scanning fluorometry (DSF) is a useful orthogonal measure of inhibitory activity for this series.  We have used DSF to demonstrate that the binding of these compds. is independent of the presence or absence of the C-terminal tail region of CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimidazone-1-β-D-ribofuranoside (DRB).  Finally, on the basis of 11 cocrystal structures bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather than from the formation of specific polar contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGJy-t5isJBbVg90H21EOLACvtfcHk0lgxmR0xHLMEXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE&md5=8c09b13b5f828b7a013607cab64b0b80</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520structural%2520and%2520functional%2520studies%2520of%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520inhibitors%2520suggest%2520the%2520basis%2520for%2520isotype%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670%26doi%3D10.1021%2Fjm301495v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daunt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loddick, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M.</span></span> <span> </span><span class="NLM_article-title">The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6369</span>– <span class="NLM_lpage">6373</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1016%2Fj.bmcl.2008.10.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=18996007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWjs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6369-6373&author=C.+D.+Jonesauthor=D.+M.+Andrewsauthor=A.+J.+Barkerauthor=K.+Bladesauthor=P.+Dauntauthor=S.+Eastauthor=C.+Gehauthor=M.+A.+Grahamauthor=K.+M.+Johnsonauthor=S.+A.+Loddickauthor=H.+M.+McFarlandauthor=A.+McGregorauthor=L.+Mossauthor=D.+A.+Rudgeauthor=P.+B.+Simpsonauthor=M.+L.+Swainauthor=K.+Y.+Tamauthor=J.+A.+Tuckerauthor=M.+Walker&title=The+discovery+of+AZD5597%2C+a+potent+imidazole+pyrimidine+amide+CDK+inhibitor+suitable+for+intravenous+dosing&doi=10.1016%2Fj.bmcl.2008.10.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing</span></div><div class="casAuthors">Jones, Clifford D.; Andrews, David M.; Barker, Andrew J.; Blades, Kevin; Daunt, Paula; East, Simon; Geh, Catherine; Graham, Mark A.; Johnson, Keith M.; Loddick, Sarah A.; McFarland, Heather M.; McGregor, Alexandra; Moss, Louise; Rudge, David A.; Simpson, Peter B.; Swain, Michael L.; Tam, Kin Y.; Tucker, Julie A.; Walker, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6369-6373</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described.  Optimization of inhibitory potency against multiple CDK's (1, 2 and 9) resulted in imidazole pyrimidine amides with potent in vitro anti-proliferative effects against a range of cancer cell lines.  Excellent physiochem. properties and large margins against inhibition of CYP isoforms and the hERG ion channel were achieved by modification of lipophilicity and amine basicity.  A candidate with disease model activity in human cancer cell line xenografts and with suitable physiochem. and pharmacokinetic profiles for i.v. (iv) dosing was selected for further development as AZD5597 (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnX9-GP03dzbVg90H21EOLACvtfcHk0lgxmR0xHLMEXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWjs7bP&md5=084ed54076134c7173953ebbdb23fd86</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.102%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DDaunt%26aufirst%3DP.%26aulast%3DEast%26aufirst%3DS.%26aulast%3DGeh%26aufirst%3DC.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMcFarland%26aufirst%3DH.%2BM.%26aulast%3DMcGregor%26aufirst%3DA.%26aulast%3DMoss%26aufirst%3DL.%26aulast%3DRudge%26aufirst%3DD.%2BA.%26aulast%3DSimpson%26aufirst%3DP.%2BB.%26aulast%3DSwain%26aufirst%3DM.%2BL.%26aulast%3DTam%26aufirst%3DK.%2BY.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWalker%26aufirst%3DM.%26atitle%3DThe%2520discovery%2520of%2520AZD5597%252C%2520a%2520potent%2520imidazole%2520pyrimidine%2520amide%2520CDK%2520inhibitor%2520suitable%2520for%2520intravenous%2520dosing%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6369%26epage%3D6373%26doi%3D10.1016%2Fj.bmcl.2008.10.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span>Compounds <b>6</b>, <b>23</b>, and <b>24</b> have been disclosed
in <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span>; <span class="NLM_string-name">Barlaam, B. C.</span>; <span class="NLM_string-name">Hawkins, J.</span>; <span class="NLM_string-name">De Savi, C.</span>; <span class="NLM_string-name">Vasbinder, M. M.</span>; <span class="NLM_string-name">Hird, A.</span>; <span class="NLM_string-name">Lamb, M.</span></span> <span> </span><span class="NLM_article-title">Polycyclic Amide Derivatives as CDK9 Inhibitors</span>. PCT Int. Appl., WO2017001354, <span class="NLM_year">2017</span>. Preparation and characterization of crystalline forms (e.g. Form B of <b>6</b>, Form B of <b>23</b> and Form A of <b>24</b>) are described herein.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+G.+Pike&author=B.+C.+Barlaam&author=J.+Hawkins&author=C.+De+Savi&author=M.+M.+Vasbinder&author=A.+Hird&author=M.+Lamb&title=Polycyclic+Amide+Derivatives+as+CDK9+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26atitle%3DPolycyclic%2520Amide%2520Derivatives%2520as%2520CDK9%2520Inhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of distribution in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+distribution+in+drug+design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0lgGeq-keqUIWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520distribution%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cidado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boiko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criscione, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pop-Damkov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roamio Franklin, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekhar Reddy Chilamakuri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Santos, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, L.</span></span> <span> </span><span class="NLM_article-title">AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-1853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=10.1158%2F1078-0432.CCR-19-1853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=31699827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslylsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=922-934&author=J.+Cidadoauthor=S.+Boikoauthor=T.+Proiaauthor=D.+Fergusonauthor=S.+W.+Criscioneauthor=M.+San+Martinauthor=P.+Pop-Damkovauthor=N.+Suauthor=V.+N.+Roamio+Franklinauthor=C.+Sekhar+Reddy+Chilamakuriauthor=C.+S.+D%E2%80%99Santosauthor=W.+Shaoauthor=J.+C.+Saehauthor=R.+Kochauthor=D.+M.+Weinstockauthor=M.+Zindaauthor=S.+E.+Fawellauthor=L.+Drew&title=AZD4573+is+a+highly+selective+CDK9+inhibitor+that+suppresses+Mcl-1+and+induces+apoptosis+in+hematological+cancer+cells&doi=10.1158%2F1078-0432.CCR-19-1853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells</span></div><div class="casAuthors">Cidado, Justin; Boiko, Scott; Proia, Theresa; Ferguson, Douglas; Criscione, Steven W.; Martin, Maryann San; Pop-Damkov, Petar; Su, Nancy; Franklin, Valar Nila Roamio; Chilamakuri, Chandra Sekhar Reddy; D'Santos, Clive S.; Shao, Wenlin; Saeh, Jamal C.; Koch, Raphael; Weinstock, David M.; Zinda, Michael; Fawell, Stephen E.; Drew, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">922-934</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CDK9 is a transcriptional regulator and potential therapeutic target for many cancers.  Multiple nonselective CDK9 inhibitors have progressed clin. but were limited by a narrow therapeutic window.  This work describes a novel, potent, and highly selective CDK9 inhibitor, AZD4573.  The antitumor activity of AZD4573 was detd. across broad cancer cell line panels in vitro as well as cell line- and patient-derived xenograft models in vivo.  Multiple approaches, including integrated transcriptomic and proteomic analyses, loss-of-function pathway interrogation, and pharmacol. comparisons, were employed to further understand the major mechanism driving AZD4573 activity and to establish an exposure/effect relationship.  AZD4573 is a highly selective and potent CDK9 inhibitor.  It demonstrated rapid induction of apoptosis and subsequent cell death broadly across hematol. cancer models in vitro, and MCL-1 depletion in a dose- and time-dependent manner was identified as a major mechanism through which AZD4573 induces cell death in tumor cells.  This understanding of the mechanism, exposure, and antitumor activity of AZD4573 facilitated development of a robust pharmacokinetic/PD/efficacy model used to inform the clin. trial design.  Selective targeting of CDK9 enables the indirect inhibition of MCL-1, providing a therapeutic option for MCL-1-dependent diseases.  Accordingly, AZD4573 is currently being evaluated in a phase I clin. trial for patients with hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp213MDHb0Y7rVg90H21EOLACvtfcHk0lgGeq-keqUIWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslylsLrK&md5=18be82de651b9be77a95f3d7c423b6aa</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-1853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-1853%26sid%3Dliteratum%253Aachs%26aulast%3DCidado%26aufirst%3DJ.%26aulast%3DBoiko%26aufirst%3DS.%26aulast%3DProia%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DCriscione%26aufirst%3DS.%2BW.%26aulast%3DSan%2BMartin%26aufirst%3DM.%26aulast%3DPop-Damkov%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DN.%26aulast%3DRoamio%2BFranklin%26aufirst%3DV.%2BN.%26aulast%3DSekhar%2BReddy%2BChilamakuri%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Santos%26aufirst%3DC.%2BS.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DKoch%26aufirst%3DR.%26aulast%3DWeinstock%26aufirst%3DD.%2BM.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DFawell%26aufirst%3DS.%2BE.%26aulast%3DDrew%26aufirst%3DL.%26atitle%3DAZD4573%2520is%2520a%2520highly%2520selective%2520CDK9%2520inhibitor%2520that%2520suppresses%2520Mcl-1%2520and%2520induces%2520apoptosis%2520in%2520hematological%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D922%26epage%3D934%26doi%3D10.1158%2F1078-0432.CCR-19-1853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF','PDB','4BCF'); return false;">PDB: 4BCF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Z45" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Z45','PDB','6Z45'); return false;">PDB: 6Z45</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i43"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01754">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_28843"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01754?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01754</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures for the synthesis and characterization of intermediates and metabolites <b>6-M1</b>, <b>6-M2</b>, <b>24-M1</b>, and <b>24-M2</b>; crystal structure of compound <b>24</b> bound to CDK9 in complex with cyclin T1; ligand docking protocol; procedures for determination of DMPK properties; protocol for human PK predictions and clinical dose projections; biological testing protocol, data, and associated errors (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_001.pdf">jm0c01754_si_001.pdf (1.36 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01754/suppl_file/jm0c01754_si_002.csv">jm0c01754_si_002.csv (3.28 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates of the crystal structure of compound <b>24</b> bound to CDK9 in complex with cyclin T1 have been deposited under the following code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Z45">6Z45</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01754&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01754" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01754" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991a61dd4b248d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
